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ABSTRACT 
 
 
Rationale:  Physiological functions of mitochondria in contractile arterial smooth muscle 
cells are poorly understood.  Mitochondria can uptake calcium (Ca2+), but intracellular 
Ca2+ signals that regulate mitochondrial Ca2+ concentration ([Ca2+]mito) and physiological 
functions of changes in [Ca2+]mito in arterial smooth muscle cells are unclear. 
 
Objective:  Identify Ca2+ signals that regulate [Ca2+]mito, examine the significance of 
changes in [Ca2+]mito, and test the hypothesis that [Ca2+]mito controls functional ion 
channel transcription in smooth muscle cells of resistance-size cerebral arteries.   
 
Methods and Results:  Endothelin-1 (ET-1) activated Ca2+ waves and elevated global 
Ca2+ concentration ([Ca2+]i) via inositol 1,4,5-triphosphate receptor (IP3R) activation.  
IP3R-mediated sarcoplasmic reticulum (SR) Ca2+ release increased [Ca2+]mito and induced 
mitochondrial depolarization, which stimulated mitochondrial reactive oxygen species 
(mitoROS) generation that elevated cytosolic ROS.  In contrast, a global [Ca2+]i elevation 
did not alter [Ca2+]mito, mitochondrial potential, or mitoROS generation.  ET-1 stimulated 
nuclear translocation of nuclear factor kappa B (NF-κB) p50 subunit and ET-1-induced 
IP3R-mediated mitoROS elevated NF-κB-dependent transcriptional activity.  ET-1 
elevated voltage-dependent Ca2+ (CaV1.2) channel expression, leading to an increase in 
both pressure (myogenic tone)- and depolarization-induced vasoconstriction.  Baseline 
CaV1.2 expression and the ET-1-induced elevation in CaV1.2 expression were both 
reduced by IP3R inhibition, mitochondrial electron transport chain block, antioxidant 
treatment, and NF-κB subunit knockdown, leading to vasodilation.  
 
Conclusions:  IP3R-mediated SR Ca2+ release elevates [Ca2+]mito, which induces 
mitoROS generation.  MitoROS activate NF-κB, which stimulates CaV1.2 channel 
transcription.  Thus, mitochondria sense IP3R-mediated SR Ca2+ release to control NF-
κB-dependent CaV1.2 channel expression in arterial smooth muscle cells, thereby 
modulating arterial contractility. 
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CHAPTER 1. INTRODUCTION* 
 
 
1.1. Ca2+ Signaling in Vascular Smooth Muscle Cells 
 
Calcium (Ca2+) is a highly versatile signal transduction element in almost every 
cell type, controlling a wide variety of functions (Berridge, 2001; Bootman et al., 2001; 
Berridge, 2004).  Ca2+ translates an array of extracellular stimuli, including hormones, 
neurotransmitters, and growth factors into distinct intracellular functions, varying from 
contraction to secretion, and from survival to differentiation.  Under resting conditions, 
cytosolic Ca2+ concentration ([Ca2+]i) is maintained at ~100 nM, whereas the extracellular 
medium and intracellular stores contain more than 1 mM (Rizzuto & Pozzan, 2006).  The 
difference in concentrations permits stimulation of rapid Ca2+ signals, to regulate various 
cellular responses.  Under resting conditions, [Ca2+]i is influenced by the regulation of 
several processes, which either introduce Ca2+ into or remove Ca2+ from the entire 
cytosol or a localized region of the cytosol (Bootman et al., 2001).  Stimuli that elevate 
[Ca2+]i cause Ca2+ influx from extracellular space and/or Ca2+ release from internal 
sources.  Most of this Ca2+ is bound to buffers, whereas a small proportion of the Ca2+ 
binds to effector elements, leading to stimulation of numerous Ca2+-dependent processes 
(Berridge et al., 1998).  Removal of Ca2+ from the cytosol occurs via various plasma 
membrane exchangers, which extrude Ca2+ into the extracellular space, or intracellular 
pumps, which recycle Ca2+ back into organelles (Berridge et al., 1998).  Interplay 
between these opposing processes is responsible for the maintenance of [Ca2+]i and 
modulation of Ca2+-dependent functions (Bootman et al., 2001). 
 
To influence different cellular functions, Ca2+ signals are flexibly and precisely 
regulated with regard to space, time, and amplitude (Berridge et al., 1998).  Spatial 
distribution of Ca2+ signals occur due to differences in Ca2+sources, including Ca2+ entry 
from extracellular medium through plasma membrane ion channels, and Ca2+ release 
from internal stores (Berridge et al., 2003).  Diffusion of Ca2+ from one cellular 
compartment to another, and localization of a Ca2+ signal to a specific cellular region also 
contribute to spatial heterogeneity.  Temporal organization of Ca2+ signals occurs by 
modulation of the frequency of Ca2+ signals, leading to variations in intensity and nature 
of cellular process (Berridge et al., 2003).  Changes in amplitude or concentration of Ca2+ 
also serve to differentially influence specific functions.  The spatiotemporal organization 
of Ca2+ signals influences the diversity of Ca2+ signals, controls recruitment of different 
intracellular components, and regulation of specific cellular functions (Berridge, 2001; 
Bootman et al., 2001; Berridge, 2004). 
 
 
 
 
 
* Portions of this chapter adapted with permission. Narayanan D, Xi Q, Pfeffer LM, & 
Jaggar JH (2010). Mitochondria control functional CaV1.2 expression in smooth muscle 
cells of cerebral arteries. Circ Res 107, 631-641. 
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1.2. Ca2+ Transport Mechanisms across Plasma Membrane  
 
Ca2+ entry from the extracellular medium occurs through plasma membrane ion 
channels in response to a wide variety of stimuli, including membrane depolarization, 
stretch, noxious stimuli, extracellular agonists, intracellular messengers, and the depletion 
of intracellular stores (Berridge et al., 2003).  Under physiological conditions, the 
membrane potential of smooth muscle cells from resistance-size arteries is ~45 mV (Knot 
& Nelson, 1998).  The negative membrane potential, coupled with a high extracellular 
Ca2+ concentration creates a considerable electrochemical gradient across the plasma 
membrane, which drives Ca2+ entry through ion channels on the plasma membrane.  
Based on the mechanism of activation, several different types of Ca2+ influx channels 
have been found in vascular smooth muscle cells – voltage-dependent Ca2+ channels 
(VDCCs), receptor-operated Ca2+ channels (ROCCs), and store-operated Ca2+ channels 
(SOCCs) (Bootman et al., 2001).  Two Ca2+ efflux mechanisms that exist are the plasma 
membrane Ca2+-adenosine 5’-triphosphatase (ATPase) (PMCA) and sodium (Na+)/Ca2+ 
exchanger (NCX). 
 
 
1.2.1. Voltage-dependent Ca2+ channels 
 
VDCCs open in response to membrane depolarization, permitting rapid Ca2+ entry 
to regulate numerous physiological functions, including excitation–contraction coupling, 
excitation-secretion coupling, neurotransmitter release, gene expression, and hormone 
secretion (Halling et al., 2005;  Liao et al., 2005).  VDCCs are hetero-oligomeric protein 
complexes, composed of an α1 subunit in association with auxiliary β, α2δ, and γ subunits 
(Liao et al., 2005).  The 190-250 kilodalton (kDa) α1 subunit is the autonomous pore-
forming subunit, comprising four membrane-spanning domains, with each domain 
consisting of six transmembrane segments (S1–S6) (Liao et al., 2005).  The S4 segment 
contains three to five positively charged amino acids and serves as the voltage sensor of 
the channel (Liao et al., 2005).  The α1 subunit also contains binding sites for 
dihydropyridines.  An intracellular β subunit, a transmembrane, disulfide-linked α2δ 
subunit, and a γ subunit interact with the α1 subunit to regulate its expression and 
characteristics, such as activity and membrane trafficking of the channel (Liao et al., 
2005).  Based on the homology of their sequences, VDCCs are classified into three 
families - CaV1 (L-type), CaV2 (P/Q-, N-, and R-type), and CaV3 (T-type) (Catterall, 
2000;  Ertel et al., 2000).  VDCC α1 subunits are encoded by ten genes.  Based on the α1 
subunit, there are four types of CaV1 channels.  CaV1.1 (α1S) expressed in skeletal muscle 
cells, CaV1.2 (α1C) expressed in heart, vascular, and visceral smooth muscle cells, CaV1.3 
(α1D) expressed in brain, and CaV1.4 (α1F) expressed in the retina (Ertel et al., 2000).   
 
CaV1.2 channel is the major VDCC isoform and the primary Ca2+ entry pathway 
expressed in vascular smooth muscle cells (Gollasch & Nelson, 1997).  Molecular 
diversity of CaV1.2 channels is achieved by alternative gene splicing and transcriptional 
regulation by different promoters in the 5’ flanking regions of α1C gene.  This has given 
rise to exon 1a, exon 1b, and exon 1c in the N-terminus of α1C subunit of CaV1.2 in 
vascular smooth muscle cells (Cheng et al., 2007).  The α1C subunit of CaV1.2 is 
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synthesized as a ~240 kDa protein which is proteolytically cleaved in its C-terminal 
domain by enzymes, including calpain to yield ~190 and 50 kDa products (Gerhardstein 
et al., 2000).  The 50 kDa C-terminal product reassociates with the 190 kDa channel to 
form the fully functional CaV1.2 channel.   
 
Activation of CaV1.2 channels by membrane depolarization, leads to Ca2+ influx, 
[Ca2+]i elevation, and vasoconstriction (Berridge, 2001;  Cheng et al., 2007).  Ca2+ influx 
also stimulates Ca2+ release from intracellular stores.  In small, resistance-sized arteries 
and arterioles, CaV1.2 channels are essential for myogenic tone development and blood 
pressure regulation (Cheng et al., 2007).  Hypertension is associated with an elevation in 
arterial smooth muscle cell CaV1.2 expression, which leads to increased Ca2+ influx, 
[Ca2+]i elevation, and vasoconstriction (Wang et al., 2006).  L-type Ca2+ channel blockers 
are widely used to treat hypertension because of their ability to reduce arterial smooth 
muscle cell contractility (Triggle, 2006). 
 
Vascular smooth muscle cells also express CaV1.3, CaV2.1, CaV3.1, and CaV3.2 
channels.  Ca2+ influx through these channels make a minor contribution to [Ca2+]i in 
vascular smooth muscle cells. 
 
 
1.2.2. Store-operated Ca2+ channels 
 
SOCCs are plasma membrane, non-selective, cation channels that are activated in 
response to depletion of intracellular Ca2+ stores (Bootman et al., 2001).  Although, the 
precise mechanisms are presently unclear, there exist two major theories which attempt to 
elucidate the activation mechanism of SOCCs.  According to these schemes, SOCCs are 
activated by either a conformational coupling between Ca2+ channels on the SR and those 
on the plasma membrane, or SR Ca2+ depletion stimulates a second messenger, which 
activates plasma membrane Ca2+ channels (Bootman et al., 2001). 
 
The molecular identities of SOCCs are presently unclear.  Many of the SOCCs are 
speculated to belong to the large transient receptor potential (TRP) channel family, which 
were first identified in Drosophila (Beech et al., 2004).  The mammalian TRP channel 
superfamily that is subdivided into 7 families, is encoded by at least 28 different genes 
(Beech et al., 2004).  Vascular smooth muscle cells express at least members of three 
TRP families, including TRPC (1, 3, 4, 5, 6, and 7), TRPM (2, 4, 7, and 8), and TRPV (2 
and 4) (Earley & Brayden, 2010).  TRP channels, which are permeable to Ca2+, Na+, 
potassium (K+), and magnesium (Mg2+), regulate multiple functions in arterial smooth 
muscle cells, including membrane potential, [Ca2+]i, contractility, and proliferation 
(Beech et al., 2004;  Adebiyi et al., 2010).  Recent studies have identified two other 
proteins, including Orai1 and stromal interaction molecule (STIM)1 which regulate store-
operated Ca2+ entry in smooth muscle cells (Guibert et al., 2008).  Orai1 is a plasma 
membrane protein which has been suggested to be the pore subunit of store-operated 
current (Guibert et al., 2008).  STIM1 is primarily an endoplasmic reticulum (ER) 
membrane protein but it is also present in the plasma membrane (Guibert et al., 2008).  
Few studies have suggested that SOCCs comprise an assembly of proteins, including 
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TRPC, STIM1 and Orai1 present in the plasma membrane (Guibert et al., 2008). 
 
In smooth muscle cells, the regulation, ion selectivity, and conductance of store-
operated cation currents differ in anatomically diverse blood vessels (Xi et al., 2008).  In 
rat cerebral artery smooth muscle cells, the preparation used in this study, there is very 
little evidence for SOCCs.  Ca2+ depletion of sarcoplasmic reticulum (SR) by 
thapsigargin, an SR Ca2+ ATPase inhibitor (Lytton et al., 1991) resulted in 
vasoconstriction at 60 mm Hg but not at 20 mm Hg of intravascular pressure, indicating 
that SR Ca2+ depletion-induced current is pressure-dependent (Xi et al., 2008).  SR Ca2+ 
depletion has been suggested to constrict cerebral arteries by inhibiting Ca2+ sparks and 
large conductance Ca2+-activated K+ (KCa) channels, which are activated by an elevation 
in intravascular pressure (Xi et al., 2008).   
 
 
1.2.3. Receptor-operated Ca2+ channels 
 
ROCCs comprise a range of structurally and functionally diverse channels that 
exist in many cells, including vascular smooth muscle cells (Bootman et al., 2001).  They 
are Ca2+-permeable, non-selective, cation channels activated by the binding of an agonist 
to the extracellular domain (Bootman et al., 2001).  In vascular smooth muscle cells, a 
wide variety of agonists, including adenosine 5’-triphosphate (ATP), serotonin, 
norepinephrine (NE), acetylcholine, endothelin-1 (ET-1), vasopressin, glutamate, and 
angiotensin II (Ang II) activate ROCCs, and induce Ca2+ entry (Large, 2002).  Apart 
from the P2X1 receptor, an ATP-gated cation channel, other receptor-operated currents 
are likely to be mediated via G-protein-coupled receptors, and some through tyrosine 
kinases (Large, 2002).  In guinea pig aorta, NE-induced Ca2+ influx was only partially 
blocked by Ca2+ channel blockers (Gouw et al., 1990).  In rat cultured aortic smooth 
muscle cells, ATP, Ang II, and vasopressin cause 45Ca2+ influx that is independent of 
membrane depolarization and unaffected by Ca2+ channel antagonists, but reduced by 
phospholipase C (PLC) inhibitors (Ruegg et al., 1989).   
 
Several TRP channels, including TRPC4, TRPC5, and heteromultimeric complex 
of TRPC6 and TRPC7 can be activated by various stimuli, such as vasopressin (Plant & 
Schaefer, 2003;  Earley, 2006;  Maruyama et al., 2006) suggesting that TRP channels 
could also act as ROCCs. 
 
 
1.2.4. Other Ca2+ entry channels 
 
Apart from VDCCs, SOCCs, and ROCCs, Ca2+ influx could occur through other 
pathways.  One example is the stretch-activated cation channels which allow Ca2+ entry 
and regulate cell contractility (Bootman et al., 2001;  Hill et al., 2001).  In isolated 
vascular smooth muscle cells, longitudinal stretch activates a non-selective, inward cation 
conductance (Hill et al., 2001).  Therefore, it is accepted that stretch activation 
contributes to membrane depolarization, leading to activation of VDCCs (Hill et al., 
2001).  Mechanical disturbance of cell membranes also releases factors that modulate the 
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activity of stretch-activated channels (Hill et al., 2001).  Second messengers, including 
fatty acids, arachidonic acid metabolites, diacylglycerol (DAG), and cyclic nucleotides 
have been suggested to activate channels by regulating ion channel gating (Hill et al., 
2001). 
 
 
1.2.5. Plasma membrane Ca2+-ATPases 
 
PMCA extrude Ca2+ from cytosol to the extracellular compartment using energy 
derived from ATP hydrolysis to pump Ca2+ against the steep electrochemical gradient 
(Berridge, 2001).  The C-terminus contains a calmodulin (CaM)-binding domain, which 
acts as an autoinhibitory domain and maintains the pump in an inactive state (Sanders, 
2001).  Binding of CaM removes the inhibition and stimulates pump activity (Sanders, 
2001).  Phosphorylation by protein kinases, including protein kinase A (PKA) and G 
(PKG) also reduces autoinhibition and facilitates Ca2+ transport (Sanders, 2001).  
 
Four isoforms of PMCAs (1-4) are widely expressed (Bootman et al., 2001).  
Vascular smooth muscle cells express PMCA1 and PMCA4 (Abramowitz et al., 2000).  
PMCA4b inhibits neuronal nitric oxide synthase (nNOS), by binding of its C-terminus to 
the PDZ domain of nNOS (Schuh et al., 2001).  Transgenic mice overexpressing 
PMCA4b in vascular smooth muscle cells are associated with elevated peripheral blood 
pressure due to inhibition of nNOS activity (Gros et al., 2003).  Mesenteric arteries from 
these transgenic mice display more prominent myogenic response and elevated responses 
to vasoconstrictors, including phenylephrine and prostaglandin F2α (Gros et al., 2003).  
PMCAs localize in caveolae of visceral smooth muscle cells, endothelial cells, and rat 
cardiomyocytes, but whether similar localization occurs in vascular smooth muscle cells 
is unclear. 
 
 
1.2.6. Plasma membrane Na+/Ca2+ exchanger 
 
NCX is an integral plasma membrane protein which counter-transports Ca2+ in 
exchange for Na+, utilizing the Na+ gradient across the plasma membrane, generated by 
the Na+/K+-ATPase (NKA), as an energy source (Bootman et al., 2001).  The mammalian 
NCX family comprises three isoforms NCX (1-3) with numerous splice variants.  
Vascular smooth muscle cells predominantly expresses NCX1.3 and NCX1.7 (Quednau 
et al., 1997).  NCXs function either to pump one molecule of Ca2+ out (forward mode) of 
cells, or into cells (reverse mode) in exchange for three molecules of Na+.  NCX activity 
is regulated by membrane potential, ATP, and transmembrane gradients of Na+ and Ca2+ 
(Iwamoto et al., 2005).  In vascular smooth muscle cells, NCXs are colocalized with 
NKA on the plasma membrane near the SR, suggesting that NCX/NKA can functionally 
operate with SERCA (Ishida & Paul, 2005).  Under physiological conditions, high 
extracellular Na+ concentration stimulates NCX to pump Ca2+ out of cells.  
Cardiovascular diseases, including hypertension are associated with improper functioning 
of NCX.  High salt diet inhibits NKA, leading to elevated submembrane Na+ levels, 
resulting in NCX functioning in the reverse mode.  Ca2+ influx through NCX increases 
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[Ca2+]i and may contribute to salt-sensitive hypertension (Iwamoto et al., 2005).  Aortic 
smooth muscle cells from spontaneously hypertensive rats are associated with elevated 
NCX1 expression and enhanced Ang II-induced Ca2+ efflux via NCX (Ishida & Paul, 
2005). 
 
 
1.3. Intracellular Ca2+ Stores 
 
Cytosol of smooth muscle cell is packed with myofilaments and intermediate 
filaments, occupying up to 90% of the cell volume with the intracellular organelles 
sharing the remaining space (Wray & Burdyga, 2010).  Intracellular stores contain a high 
Ca2+ concentration, and release Ca2+ into the cytosol upon stimulation and opening of 
Ca2+ channels on their membrane.  SR, a rich reticular network, which occupies ~5% of 
cell volume, is the major intracellular Ca2+ source (Wray & Burdyga, 2010).  Apart from 
the SR, mitochondria can store and release Ca2+. 
 
 
1.3.1. Sarcoplasmic reticulum 
 
In vascular smooth muscle cells, Ca2+ release from the SR occurs through inositol 
1,4,5-triphosphate (IP3) receptors (IP3R) and ryanodine-sensitive Ca2+ release (RyR) 
channels.  Ca2+ release from these channels are regulated by a collection of messengers, 
including Ca2+, IP3, cyclic ADP ribose (cADPR), nicotinic acid adenine dinucleotide 
phosphate (NAADP), and sphingosine-1-phosphate (S1P), that operate on both the 
luminal and cytosolic surfaces of the channel (Berridge et al., 2003).  
Sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), which is located on the SR 
membrane pumps Ca2+ from the cytosol into the SR (Inesi, 1987). 
 
 
1.3.1.1. Ryanodine-sensitive Ca2+ release channels 
 
RyR channels specifically bind the plant alkaloid ryanodine, which is the reason 
for its name (Jaggar et al., 2000).  Three molecularly distinct RyR isoforms (1-3), 
encoded by distinct genes, are present in a variety of tissues (Jaggar et al., 2000).  RyR1 
is expressed primarily in skeletal muscle, whereas RyR2 and RyR3 are found in cardiac 
muscle and brain, respectively (Jaggar et al., 2000).  All three RyR isoforms are 
expressed in smooth muscles of pulmonary and systemic vessels, with variations in the 
type and the relative proportion of each being tissue- and species-dependent (Wray & 
Burdyga, 2010).  In rat cerebral artery smooth muscle cells, RyR2 is the predominant 
isoform (Vaithianathan et al., 2010). 
 
Each of these isoforms exists as a homotetramer with the subunits surrounding a 
central Ca2+ pore (Jaggar et al., 2000;  Wray & Burdyga, 2010).  The subunits are 
associated with FK-506-binding protein (FKBP), a regulatory protein.  The pore-forming, 
membrane-spanning regions are localized to the C-terminus (Wray & Burdyga, 2010).  
The cytosolic N-terminus, which is the modulatory region, contains phosphorylation sites 
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and binding sites for Ca2+, adenine nucleotides, CaM, and FKBP.  RyRs are 
approximately twice as large as IP3R (Wray & Burdyga, 2010).  Because of their massive 
size, RyR is suitable for sudden and large release of SR Ca2+ (Wray & Burdyga, 2010). 
 
The principal endogenous modulator of RyR activity is Ca2+, which upon binding  
can activate or inhibit the channels.  Low cytosolic Ca2+ concentrations (nM to µM) 
activate RyR, whereas high cytosolic Ca2+ concentrations (µM to mM) inhibit RyRs 
(Bootman et al., 2001).  Similarly, ryanodine at low concentrations (1-10 µM) locks 
RyRs into a long-lived subconductance state, leading to Ca2+ release over a prolonged 
period of time and eventually SR Ca2+ depletion.  At high concentrations (~100 µM), 
ryanodine irreversibly inhibits RyR channel opening.  RyR channels have to be activated 
for ryanodine to bind to them (Bootman et al., 2001).  Millimolar concentrations of 
caffeine activate RyRs by increasing the sensitivity of RyRs to Ca2+, resulting in basal 
Ca2+ concentrations to become activatory and stimulate further Ca2+ release (Bootman et 
al., 2001).  Changes in the SR luminal Ca2+ concentration, which is ~1 mM can activate 
RyRs (Bootman et al., 2001).  Activation of SERCA, which is responsible for 
maintaining SR Ca2+ load, activates RyR by increasing luminal Ca2+ concentration 
(Bootman et al., 2001).  cADPR is an endogenous cellular messenger that causes RyR-
mediated SR Ca2+ release.  The precise mechanism by which cADPR activates RyR is 
unclear.  It has been suggested that cADPR binds to the inhibitory protein FKBP, 
resulting in increasing the open probability of RyR (Bootman et al., 2001).  cADPR 
could also activate SERCA, leading to an increase in SR Ca2+ load, resulting in RyR 
activation (Lukyanenko et al., 2001).  RyR channels can also be regulated by several 
protein kinases and phosphatases, including PKA, protein kinase C (PKC), PKG, CaM 
kinase II, and protein phosphatase 1 (Jaggar et al., 2000;  Bootman et al., 2001;  Wray & 
Burdyga, 2010). 
 
 
1.3.1.2. Inositol 1,4,5-triphosphate receptors 
 
Binding of ligands, including hormones, and growth factors to plasma membrane 
Gq protein-coupled receptors activates PLC, leading to hydrolysis of phosphatidylinositol 
4,5-biphosphate (PIP2) to produce IP3 and DAG (Bootman et al., 2001).  IP3 binds to 
IP3R-gated Ca2+ channels on the SR, leading to Ca2+ release.  DAG serves as an 
intracellular messenger to activate PKC (Bootman et al., 2001). 
 
Distinct genes encode each of the three IP3R isoforms (1-3) (Wray & Burdyga, 
2010).  IP3R isoforms, which are structurally and functionally related, differ in their 
sensitivities to destruction by intracellular proteases, with IP3R1 and IP3R3 being more 
susceptible to breakdown than IP3R2 (Wray & Burdyga, 2010).  IP3Rs are extensively 
expressed in brain and other tissues including vascular smooth muscles.  In vascular 
smooth muscles, IP3R density is ~100 times less than that in the brain, and the 
stoichiometric ratio of IP3Rs to RyRs is 3-4:1 (Wray & Burdyga, 2010).  Smooth muscle 
cells express multiple IP3R isoforms (Zhao et al., 2008;  Wray & Burdyga, 2010).  IP3R1 
has been found in rat aorta, basilar, and mesenteric arteries, whereas IP3R2 and IP3R3 
have been detected in basilar artery and a cell line derived from rat aorta, respectively 
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(Wray & Burdyga, 2010).  IP3R1 is the predominant isoform expressed in smooth muscle 
cells of resistance-size cerebral arteries (Zhao et al., 2008). 
 
IP3Rs are tetrameric, with a monomeric mass of ~300 kDa, containing ~2700 
amino acids (Wray & Burdyga, 2010).  IP3Rs can form either homo- or hetero-tetramer, 
although reports suggesting IP3R as a heterotetramer complex have been derived from 
cell lines (Patterson et al., 2004).  The IP3R structure can be divided to two regions.  The 
C-terminal end of IP3R contains the Ca2+ channel region, which shares sequence 
homology with that of the RyR (Patterson et al., 2004).  The C-terminal region consists 
of six membrane-spanning helices with the C-terminus projecting into the cytosol 
(Patterson et al., 2004).  The N-terminal region which also extends to the cytosol, 
contains the IP3-binding site (Patterson et al., 2004).  The modulatory domain, which 
contains binding sites for Ca2+, nucleotides, CaM, and protein kinases is located between 
the ligand-binding domain and the channel pore (Patterson et al., 2004). 
 
The principal mechanism which results in IP3R-mediated SR Ca2+ release, is the 
interaction of IP3 with IP3R (Bootman et al., 2001).  IP3 produced at the plasma 
membrane is highly mobile and diffuses in the cytosol to bind IP3R on the SR membrane 
(Bootman et al., 2001).  Binding of IP3 induces a conformational change in IP3R, 
resulting in channel opening and release of Ca2+, which is stored at high concentrations in 
the SR (Patterson et al., 2004).  Although binding of IP3 is essential for IP3R activation, 
Ca2+ concentration at their cytosolic side also regulate IP3R activity, thereby permitting 
IP3R-mediated Ca2+ release to regulate further Ca2+ release (Patterson et al., 2004).  
Binding of IP3 increases the IP3R sensitivity to Ca2+, which has a biphasic action 
(Patterson et al., 2004).  At low IP3 levels (<100 nM), IP3Rs are stimulated by Ca2+ 
concentrations between 100 and 300 nM, whereas inhibited by cytosolic Ca2+ 
concentrations >1 µM (Worley et al., 1987;  Bootman et al., 2001).  At high IP3 levels 
(>100 nM), very high Ca2+ concentration is required to induce inhibition of IP3R 
(Berridge, 2001).  Ca2+-dependence of IP3R activity is important for the generation of 
complex patterns of Ca2+ signals seen.  SR luminal Ca2+ can also regulate IP3R activity, 
whereby a reduced SR Ca2+ load, leads to a decrease in IP3-induced Ca2+ release 
(Patterson et al., 2004).  In permeabilized hepatocytes, IP3R is inactivated by IP3, and this 
effect is enhanced by cytosolic Ca2+, suggesting that IP3 and Ca2+ inhibit IP3R, resulting 
in limiting the IP3R-mediated SR Ca2+ release (Hajnoczky & Thomas, 1994).  Certain SR 
luminal proteins, including calreticulin and calnexin, which are Ca2+-binding proteins are 
also known to interact with IP3R and regulate their activity (Berridge, 2001).  IP3R 
activity can also be modulated by other signaling pathways, including phosphorylation by 
PKA, PKC, PKG, and CaM kinase II (Bootman et al., 2001).   
 
In smooth muscle cells of resistance-size cerebral arteries, IP3R1 activation also 
induces physical coupling of the N-terminus of IP3R1 and the C-terminus of plasma 
membrane TRPC3 channel, leading to non-selective cation current (ICat) activation.  IP3R-
dependent ICat activation produces membrane depolarization, CaV1.2 channel activation, 
and global [Ca2+]i elevation (Xi et al., 2008;  Zhao et al., 2008;  Adebiyi et al., 2010).  
This is an additional mechanism by which IP3R activation contributes to global [Ca2+]i 
elevation in arterial smooth muscle cells.  
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1.3.1.3. Sarcoplasmic/endoplasmic reticulum Ca2+ATPases 
 
Three mammalian isoforms of SERCA (1-3) exist and splice variants have been 
reported in each of the isoforms (Rizzuto et al., 1993).  SERCA2a, 2b, and 3 are the 
isoforms expressed in vascular smooth muscle cells, with SERCA2b being the major 
isoform (Wu et al., 2001;  Ishida & Paul, 2005). 
 
SERCA transports two molecules of Ca2+ into the SR using the energy from the 
hydrolysis of one molecule of ATP (Inesi, 1987).  Counter-transport of two or three 
hydrogen (H+) ions into the cytosol ensures partial charge balancing (Levy et al., 1990).  
In smooth muscle cells, the locations of Ca2+ release and re-uptake by the SERCA on the 
SR membrane are spatially separated (Floyd & Wray, 2007).  Ca2+-binding proteins in 
the SR lumen regulate SERCA activity to attain a free Ca2+ concentration of ~500 µM.  
In uterine smooth muscle cells, overloading the SR with Ca2+ did not alter, whereas 
reducing SR Ca2+ load, inhibited IP3-induced Ca2+ signals, suggesting that the ability of 
SR to store Ca2+ is finite (Floyd & Wray, 2007). 
 
Phospholamban (PLN) endogenously inhibits SERCA through direct protein-
protein interactions by lowering its apparent Ca2+ affinity (Wray & Burdyga, 2010).  PLN 
is phosphorylated by PKA or CaM kinase, leading to removal of the inhibition, resulting 
in an increase in SERCA activity (Ishida & Paul, 2005; Wray & Burdyga, 2010).  
Sarcolipin, a PLN homolog, which inhibits SERCA by lowering its apparent Ca2+ 
affinity, is expressed in skeletal and cardiac muscles, but not in smooth muscle cells 
(Vangheluwe et al., 2005).  SERCA activity is also controlled by regulators such as 
insulin-receptor substrate 1/2, the Ca2+-binding protein S100A1, acylphosphatase, and the 
antiapoptotic protein Bc1-2 (Wray & Burdyga, 2010). 
 
 
1.3.2. Mitochondria 
 
Intracellular Ca2+ signaling is also regulated by mitochondria which accumulate 
and retain Ca2+.  Electron transport chain (ETC) complexes present on the inner 
mitochondrial membrane transfer electrons to molecular oxygen during oxidative 
phosphorylation.  The electron transfer is coupled with translocation of protons into the 
intermembrane space, which creates and sustains the mitochondrial membrane potential 
(ψm) which is ~150-200 mV more negative than the cytosol (McCarron et al., 2006).  
This difference in potential between the cytosol and mitochondrial matrix, drives Ca2+ 
transport into the mitochondria (McCarron et al., 2006).  Mitochondria act as a local, 
spatial buffering system, by regulating Ca2+ signals which arise from the SR or plasma 
membrane in many cells, including smooth muscle cells.  Mitochondrial Ca2+ uptake 
occurs via the voltage-dependent anion channel (VDAC), mitochondrial Ca2+ uniporter 
(MCU), and rapid uptake mode (RaM) (Gunter et al., 2000).  The mitochondrial 
permeability transition pore (mPTP) and the mitochondrial Na+/Ca2+ exchanger (mNCX) 
extrude Ca2+ from the mitochondrial matrix to the cytosol (Gunter et al., 2000). 
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1.3.2.1. Voltage-dependent anion channel 
 
Ca2+ transit through the outer mitochondrial membrane occurs through VDAC, 
the most abundant protein on the outer mitochondrial membrane.  Mammals have three 
distinct VDAC isoforms (1-3).  VDAC is an anion-selective channel, fully opened at low 
potential (<20–30 mV), but switches to cation selectivity at higher potentials (“closed” 
state) (Colombini, 2004).  In the resting condition, VDAC is closed and exhibits higher 
permeability to Ca2+, rather than in the opened state (Tan & Colombini, 2007).  In HeLa 
cells and skeletal myotubes, VDAC overexpression enhanced Ca2+ transport from SR into 
the mitochondrial matrix (Rapizzi et al., 2002).  VDAC activity is regulated by several 
factors, including nicotinamide adenine dinucleotide (NADH), Bcl-2 proteins, 
chaperones, and cytoskeletal elements (Rizzuto et al., 2009). 
 
 
1.3.2.2. Mitochondrial Ca2+ uniporter 
 
MCU is a highly selective ion channel located on the inner mitochondrial 
membrane that transports Ca2+ from the cytosol into the mitochondrial matrix (Rizzuto et 
al., 2000).  MCU has both an activation site as well as a transport site (Gunter & Pfeiffer, 
1990).  MCU activation stimulates Ca2+ influx into the mitochondrial matrix due to the 
negative ψm (Rizzuto et al., 2000).  MCU has low sensitivity to Ca2+ and is activated by 
Ca2+ concentrations >3 μM (Km ~10 μM) in the inter membrane space (Poburko et al., 
2004).  The velocity of Ca2+ uptake is near zero for external [Ca2+]i <200-300 nM 
(Poburko et al., 2004).  [Ca2+]i regulates MCU activity in a biphasic manner (Montero et 
al., 2004; Moreau et al., 2006).  Studies in HeLa cells suggested that MCU activation by 
Ca2+ is mediated by the activation of Ca2+-dependent CaM and subsequently, CaM kinase 
II (Montero et al., 2004).  Following activation, cytosolic Ca2+ elevation inactivates the 
MCU and limits mitochondrial Ca2+ uptake.  This biphasic regulation of MCU activity by 
cytosolic Ca2+ occurs with MCU activation and Ca2+ uptake occurring with a time 
constant of ~6 seconds, while the Ca2+-dependent MCU inactivation occurs with a time 
constant of ~17 seconds.  This mechanism permits oscillations in mitochondrial Ca2+ 
concentrations ([Ca2+]mito), but prevents excessive Ca2+ uptake when [Ca2+]i elevation is 
prolonged (Moreau et al., 2006).  Different PKC isoforms have been suggested to 
participate in the cytosolic Ca2+-mediated regulation of MCU activity (Rizzuto et al., 
2009).  Overexpression of uncoupling proteins, including UCP2 and UCP3 in an 
endothelial cell line enhanced mitochondrial Ca2+ uptake, and small interfering RNA 
(siRNA)-mediated knockdown decreased MCU activity and mitochondrial Ca2+ 
sequestration, suggesting that uncoupling proteins could be essential components of 
MCU (Trenker et al., 2007).  MCU activity is inhibited by ruthenium red and its related 
compound Ru360, and adenine nucleotides (ATP>ADP>AMP) (Rizzuto et al., 2009). 
 
 
1.3.2.3. Rapid uptake mode 
 
Ca2+ pulses of physiological concentration (~400 nM) more effectively induce 
mitochondrial Ca2+ uptake compared to a steady [Ca2+]i for the same overall time 
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(Rizzuto et al., 2000; Rizzuto et al., 2009).  RaM is a mechanism by which large amounts 
of Ca2+ are transported in short pulses at least 300 times faster than through the MCU 
(Rizzuto et al., 2000).  The activity, identity, and regulation of RaM remains poorly 
understood.  It is speculated that RaM transports Ca2+ only for a brief period during the 
initial part of the pulse, followed by inactivation induced by binding of Ca2+ to an 
external site (Rizzuto et al., 2009).  RaM exhibits a high initial Ca2+ uptake velocity, and 
its steady-state uptake is inhibited at [Ca2+]i >150-180 nM (Gunter & Gunter, 2001), 
suggesting that RaM functions in resting conditions to maintain basal [Ca2+]mito (Poburko 
et al., 2004). 
 
 
1.3.2.4. Mitochondrial permeability transition pore 
 
Mitochondria accumulate Ca2+ in the presence of adenine nucleotides.  Depletion 
of adenine nucleotides in the presence of oxidants stimulates Ca2+ overload in the 
mitochondrial matrix.  Ca2+ overload triggers opening of mPTP, a high conductance, non-
selective channel located in the inner-outer contact sites of the mitochondrial membranes 
(Rizzuto et al., 2000; Rizzuto et al., 2009).  Several factors, including high [Ca2+]mito, 
mitochondrial depolarization, oxidative stress, adenine nucleotide depletion, and a high 
concentration of inorganic phosphate (Pi) stimulate mPTP opening (Duchen, 2000a; 
Rizzuto et al., 2009).  mPTP opening is stimulated by Ca2+ influx into the mitochondrial 
matrix which binds to a site on the mPTP (Rizzuto et al., 2009).  In the presence of high 
Ca2+ concentrations, cyclophilin D (CypD) binds to the inner mitochondrial membrane 
and to adenine nucleotide translocase (ANT), thus inhibiting ATP/adenosine 5’-
diphosphate (ADP) binding and inducing mPTP opening (Rizzuto et al., 2009).  mPTP 
opening is inhibited by cyclosporine A, and ions such as Mg2+, strontium (Sr2+), and 
manganese (Mn2+) (Rizzuto et al., 2009).  The molecular identity of mPTP is unclear 
with studies speculating it to be a multi-protein complex comprising VDAC, ANT, and 
CypD, while others indicate that inhibiting one or more of these components does not 
affect mPTP activity (Duchen, 2000a; Rizzuto et al., 2009).  Apoptosis which causes loss 
of mitochondrial components is associated with mPTP opening (Chang & Yang, 2000; 
Rizzuto et al., 2009).  Reversible mPTP openings have been observed both in individual 
isolated mitochondria (Huser et al., 1998) and in intact cells (Petronilli et al., 1999).  
However, it is unclear whether mPTP can function as a physiological mitochondrial Ca2+ 
release channel (Bernardi & Petronilli, 1996). 
 
 
1.3.2.5. Mitochondrial Na+/Ca2+ exchanger 
 
mNCX mediates physiological Ca2+ cycling out of the mitochondrial matrix 
(Rizzuto et al., 2000).  One molecule of Ca2+ is transported out of the mitochondria for 
every three molecules of Na+ transported in (Rizzuto et al., 2000).  Difference in Na+ 
concentration between the cytosol and mitochondria causes Na+ influx into the 
mitochondrial matrix.  Na+ influx drives Ca2+ efflux out of the mitochondria into the 
cytosol.  mNCX is inhibited by ions such as Sr2+, barium (Ba2+), Mg2+ or Mn2+, 
ruthenium red, and drugs, including antimycin A, amiloride, trifluoperazine, diltiazem, 
12 
 
verapamil, clonazepam, bepridil and CGP37157 (Rizzuto et al., 2009).  mNCX is 
inhibited by protonophores which disrupt ψm, indicating that mNCX activity is regulated 
by the difference in potential between the cytosol and mitochondria (Rizzuto et al., 
2000).  Studies done in cultured vascular smooth muscle cells have found that CGP-
37157, a selective mNCX inhibitor, increased resting [Ca2+]mito indicating that mNCX 
contributes to mitochondrial Ca2+ efflux in smooth muscle cells (Poburko et al., 2004). 
 
 
1.3.3. Other intracellular stores 
 
NAADP is formed from β-NADP+ and β-NAD+ by ADP ribosyl cyclases which 
also produce cADPR (Berridge, 2001).  Unlike cADPR, NAADP does not activate RyR, 
but stimulates Ca2+ release from an internal store, which is distinct from the SR because 
Ca2+ depletion of SR does not affect NAADP-mediated Ca2+ release (Bootman et al., 
2001).  The mechanism(s) behind NAADP-mediated Ca2+ release and the channel 
identity remains unclear (Clapham, 1995). 
 
Sphingolipids, including sphingosylphosphorylcholine and S1P stimulate Ca2+ 
release in several different cell types (Bootman et al., 2001).  Sphingolipid-derived 
messengers are believed to be responsible for agonist-induced SR Ca2+ signals that are 
generated independently of IP3R or RyR (Berridge et al., 2003).  The exact mechanism 
for S1P-mediated Ca2+ release is unclear.  The identity of the S1P receptor is believed to 
be the sphingolipid Ca2+-release-mediating protein of ER (SCaMPER), a 20 kDa protein 
with a transmembrane domain (Bootman et al., 2001).  In rat cerebral artery smooth 
muscle cells, plasma membrane S1P receptors activate PLC, leading to IP3R and RyR 
activation, resulting in Ca2+ release (Yatomi, 2006). 
 
 
1.4. Cytosolic Ca2+ Signals 
 
In arterial smooth muscle cells, four principal Ca2+ signaling modalities have been 
described: “Global intracellular Ca2+”, “Ca2+ sparks”, “Ca2+ sparklets”, and “Ca2+ 
waves”.  These Ca2+ signals differ with respect to spatial localization, temporal kinetics, 
and amplitude properties (Jaggar et al., 2000; Lee et al., 2002; Wray et al., 2005).  
Several factors, including Ca2+ sensitivity and proximity to the source of a Ca2+ signal, 
influence whether proteins detect local or global Ca2+ signals (Jaggar, 2007).  
 
 
1.4.1. Global intracellular Ca2+ 
 
Global [Ca2+]i is the spatially averaged cytosolic [Ca2+]i.  In arterial smooth 
muscle cells, an elevation in global [Ca2+]i occurs because of Ca2+ influx through plasma 
membrane Ca2+ channels and Ca2+ release from the SR through IP3R channels (Jaggar et 
al., 2000; Zhao et al., 2008).  Either of these events which produce an initial rise in global 
[Ca2+]i can be further enhanced by RyR-mediated Ca2+ release via a Ca2+-induced Ca2+ 
release mechanism (Bolton et al., 2004).  In addition to these mechanisms, IP3R 
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activation induces Ca2+ influx through plasma membrane TRPC3 channels, resulting in a 
further elevation in global [Ca2+]i (Adebiyi et al., 2010).  A nanomolar elevation in global 
[Ca2+]i regulates cell contractility by modulating Ca2+/CaM-dependent myosin light chain 
(MLC) kinase activity (Nelson et al., 1988; Brayden & Nelson, 1992; Endo, 2006).  Ca2+ 
binds CaM and the Ca2+-CaM complex activates MLC kinase which phosphorylates 
MLC20.  MLC20 is bound to the myosin head near the neck, and prevents it from 
interacting with actin.  MLC20 phosphorylation by MLC kinase activates the myosin 
head, initiating contraction.  A reduction in global [Ca2+]i leads to MLC20 
dephosphorylation by MLC phosphatase, resulting in vasodilation (Jaggar, 2001; Endo, 
2006). 
 
Ca2+ influx through CaV1.2 channels is the major contributor to global [Ca2+]i in 
arterial smooth muscle cells.  Therefore, membrane potential, a key regulator of CaV1.2 
channel activation, influences global [Ca2+]i (Knot & Nelson, 1998).  In cerebral artery 
smooth muscle cells under physiological conditions, the membrane potential is ~-45 mV, 
and global [Ca2+]i is ~193 nM (Knot & Nelson, 1998; Cheranov & Jaggar, 2004; Zhao et 
al., 2008).  Small changes in membrane potential result in significant changes to Ca2+ 
influx through CaV1.2 channels, global [Ca2+]i, and arterial diameter.  Membrane 
depolarization from -45 mV by ∼9 mV elevates global [Ca2+]i by ∼45 nM and constricts 
the artery by about 25%.  In arterial smooth muscle cells, the entire range of global 
[Ca2+]i which is from ~120 to 350 nM, and arterial diameter from fully dilated to 
maximally constricted state, is associated with membrane potentials from -65 to -25 mV 
(Knot & Nelson, 1998).   
 
 
1.4.2. Ca2+ sparks 
 
Ca2+ sparks are localized, intracellular Ca2+ transients that occur due to the 
activation of RyR channels on the SR (Cheng et al., 1993; Nelson et al., 1995; Jaggar et 
al., 2000).  In resting arterial smooth muscle cells, the Ca2+ spark frequency is very low 
(~1 Hz in rat cerebral artery), and the spatial spread (full width at half maximal 
amplitude) is only ~2-3 µm (Jaggar et al., 2000).  A single Ca2+ spark does not alter 
global [Ca2+]i significantly in arterial smooth muscle cells (Wellman & Nelson, 2003).  
However, Ca2+ sparks can produce a rapid, local elevation in [Ca2+]i and activate Ca2+-
sensitive proteins.  One of the targets for Ca2+ sparks is the plasma membrane KCa 
channel (Jaggar et al., 2000).  Ca2+ sparks generate a micromolar [Ca2+]i elevation near 
the release site, which activates many plasma membrane KCa channels, causing a transient 
KCa current (Jaggar et al., 2000; Perez et al., 2001; Zhuge et al., 2002).  KCa channel, 
which has a low Ca2+ affinity would not be activated by global [Ca2+]i changes (Perez et 
al., 2001).  Ca2+ spark-activated KCa current induces membrane hyperpolarization, which 
reduces CaV1.2 activity, causing global [Ca2+]i reduction and vasodilation (Nelson et al., 
1995; Jaggar et al., 2000).  Therefore, in small resistance-size arteries, RyR, KCa, and 
CaV1.2 channels form a functional unit that provides a negative feedback mechanism for 
the regulation of vascular tone and blood pressure (Jaggar et al., 2000). 
 
RyR channels also form signaling complex with TRPV4 and KCa channels in rat 
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cerebral artery smooth muscle cells, and produce membrane hyperpolarization and 
vasodilation (Earley et al., 2005).  In smooth muscle cells of pulmonary arteries and 
portal vein, Ca2+ sparks activate Ca2+-activated chloride (ClCa) channels, leading to 
chloride (Cl-) efflux and membrane depolarization (Wang et al., 1992; Hogg et al., 1993).  
Rat pulmonary artery smooth muscle cells express both KCa and ClCa channels, giving 
rise to mixed K+ and Cl- efflux. 
 
 
1.4.3. Ca2+ waves 
 
Ca2+ waves are intracellular Ca2+ transients that propagate across the whole cell 
along the longitudinal axis (Jaggar et al., 2000; Jaggar & Nelson, 2000).  Ca2+ wave 
generation requires: 1) a stimulus that activates Ca2+ channels, initiating Ca2+ release; 2) 
regenerative Ca2+ release propagating across the cell; 3) Ca2+ clearance from the cytosol; 
4) refilling of intracellular Ca2+ stores; and 5) reactivation of Ca2+ release channels (Lee 
et al., 2005). 
 
In resting arterial smooth muscle cells, Ca2+ wave frequency is low (Jaggar & 
Nelson, 2000).  Vasoconstrictors, including ET-1, NE, phenylephrine, uridine 5’-
triphosphate (UTP), and vasopressin stimulate Ca2+ waves in smooth muscle cells of rat 
tail artery, portal vein, mesenteric and cerebral arteries (Boittin et al., 1999; Jaggar & 
Nelson, 2000; Mauban et al., 2001; Lamont & Wier, 2004; Dai et al., 2007).  Elevating 
the agonist concentration increases the frequency but not the amplitude of Ca2+ waves 
(Shimamura et al., 1999; Lee et al., 2002).  Intravascular pressure elevation increases 
Ca2+ wave frequency via increasing IP3 synthesis and activating RyR channels (Jaggar, 
2001).  Blocking SERCA abolishes Ca2+ waves, suggesting the requirement of Ca2+ 
release from intracellular Ca2+ stores (Lee et al., 2002).  Ca2+ waves could occur by 
activation of both RyR and IP3Rs, with the relative involvement of each varying in 
different smooth muscle cells.  In rat portal vein smooth muscle cells, an anti-IP3R 
antibody blocked NE-induced Ca2+ waves (Boittin et al., 1999).  Vasoconstrictor-induced 
Ca2+ waves are also abolished by ryanodine (Blatter & Wier, 1992; Lamont & Wier, 
2004).  In rat pulmonary artery smooth muscle cells, NAADP initiated Ca2+ waves, which 
were blocked by ryanodine but not by xestospongin C (XeC), an IP3R inhibitor (Gafni et 
al., 1997), suggesting that NAADP-mediated RyR activation results in Ca2+ waves 
(Boittin et al., 2002).  During a Ca2+ wave, intracellular stores release Ca2+ and need to be 
refilled by extracellular Ca2+ influx to maintain the ongoing wave (Lee et al., 2005).  In 
rat cerebral arteries, diltiazem, a CaV1.2 channel inhibitor blocked Ca2+ influx and 
reduced Ca2+ waves (Jaggar, 2001).  The oscillatory feature of Ca2+ waves implicates 
repetitive [Ca2+]i increase due to Ca2+ release from intracellular stores, and [Ca2+]i 
decrease due to both a reduction in Ca2+ release and removal of cytosolic Ca2+ (Aalkjaer 
& Nilsson, 2005).   
 
Presently, the physiological function of Ca2+ waves is poorly understood.  In rat 
mesenteric arteries, adrenergic stimulation using vasoconstrictors, including 
phenylephrine and NE elevated asynchronous propagating wave-like Ca2+ transients 
which induced vasoconstriction (Miriel et al., 1999; Mauban et al., 2001; Lamont & 
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Wier, 2004) and synchronous spatially uniform Ca2+ transients which caused oscillatory 
vasomotion (Mauban et al., 2001; Lamont & Wier, 2004).  In rat cerebral arteries, 
alkalinizing external pH (Heppner et al., 2002) or increasing intravascular pressure from 
10 to 60 mm Hg (Jaggar, 2001) elevated Ca2+ wave frequency, but Ca2+ waves do not 
appear to significantly contribute to the global [Ca2+]i elevation required for 
vasoconstriction (Jaggar, 2001; Heppner et al., 2002).  Therefore, it is unclear if Ca2+ 
waves influence vascular contractility with reports suggesting that activation of a large 
Ca2+ wave frequency can induce constriction, while others indicate that Ca2+ waves and 
oscillations do not contribute to contractile Ca2+ (Jaggar, 2007).  Apart from contractility, 
Ca2+ waves have been suggested to regulate gene expression in cultured mouse cerebral 
artery segments (Wilkerson et al., 2006).  IP3R-mediated Ca2+ waves induced nuclear 
translocation of proliferating cell nuclear antigen, a transcriptional regulator resulting in 
smooth muscle cell proliferation (Wilkerson et al., 2006).   
 
 
1.4.4. Ca2+ sparklets 
 
Ca2+ sparklets are intracellular subsarcolemmal Ca2+ transients generated by Ca2+ 
influx through one or several tightly clustered VDCCs, causing a local high [Ca2+]i 
elevation near the Ca2+ channel (Amberg et al., 2007).  In cerebral artery smooth muscle 
cells, Ca2+ sparklets occur due to the activation of CaV1.2 channels (Navedo et al., 2005; 
Navedo et al., 2006).  There are two modes of Ca2+ sparklet activity in arterial smooth 
muscle cells.  Low activity Ca2+ sparklets occure due to random, brief openings of L-type 
Ca2+ channels (Navedo et al., 2006).  Persistent Ca2+ sparklets occur due to small clusters 
of L-type Ca2+ channels operating in a high activity mode, generating sites of constant 
Ca2+ influx (Navedo et al., 2006).  Persistent Ca2+ sparklets occur as a result of 
AKAP150, a scaffolding protein, which targets PKC alpha (PKCα) to specific regions of 
the plasma membrane, leading to Ca2+ channel activation, Ca2+ influx, and global [Ca2+]i 
elevation (Navedo et al., 2008).  Calcineurin, which is associated with AKAP150, 
inhibits PKCα and Ca2+ sparklets (Navedo et al., 2008).  Membrane depolarization 
increases the occurrence of both modes of Ca2+ sparklets, resulting in an elevation in 
local and global [Ca2+]i (Santana & Navedo, 2009).  Ca2+ sparklet activity is increased in 
arterial smooth muscle cells during hypertension, resulting in activation of the 
transcription factor nuclear factor of activated T cell (NFAT) c3 (Nieves-Cintron et al., 
2008).  Ca2+ sparklet activity is also elevated via a PKA-dependent pathway in cerebral 
artery smooth muscle cells during hyperglycemia (Navedo et al., 2010). 
 
 
1.5. Mitochondria in Vascular Smooth Muscle Cells 
 
 
1.5.1. Electron transport chain and ATP synthesis 
 
Mitochondrial ETC consists of four proteins called Complexes I (NADH-
ubiquinone oxidoreductase), II (succinate dehydrogenase), III (cytochrome bc1), and IV 
(cytochrome c oxidase) (Fernie et al., 2004).  Electrons are transferred from the strongly 
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reducing products (NADH, succinate) of the citric acid cycle through the ETC complexes 
to molecular oxygen (O2) (Fernie et al., 2004).  Coenzymes ubiquinone (UQ), which is in 
the lipid membrane and cytochrome c, which is in the intermembrane space regulate the 
electron transfer between the ETC complexes (Fernie et al., 2004).  Complex I transfers 
electrons from the Kreb’s cycle product NADH to UQ, which also receives electrons 
from complex II (Fernie et al., 2004).  UQ transfers electrons from Complexes I and II to 
III, and cytochrome c transfers electrons from Complex III to IV (Fernie et al., 2004).  
Complex IV uses the electrons to reduce O2 to water.  Energy obtained as a result of 
electron transfer through the ETC complexes is coupled to pump protons from the 
mitochondrial matrix to the intermembrane space by complexes I and IV, and by UQ at 
complexes I, II, and III (Fernie et al., 2004).  Proton pumping creates an electrochemical 
proton gradient across the inner mitochondrial membrane (Fernie et al., 2004).  ATP 
synthase uses the H+ flow down the gradient back into the matrix to stimulate ATP 
production from ADP and Pi (Fernie et al., 2004). 
 
 
1.5.2. Mitochondrial membrane potential 
 
The proton gradient that is physiologically generated across the inner 
mitochondrial membrane by the respiratory chain activity is responsible for the 
maintenance of ψm (Gunter et al., 2000).  ψm is ~150-180 mV more negative compared to 
the cytosol (Gunter et al., 2000).  Kinetics of ATP synthase follows a sigmoidal pattern in 
response to increase in ψm, reaching a plateau phase when ψm ~50 mV more negative 
compared to the cytosol, suggesting that ATP synthesis is regulated primarily by the 
availability of the substrates ADP and Pi and not by ψm in the physiological range 
(Brookes, 2005).  ψm maintenance is essential for the normal functioning of 
mitochondria.  Transport of ions and metabolites into and out of the mitochondria is 
regulated predominantly by ψm (Brookes, 2005).  According to Nernst equation, 
equilibrium would be reached only if [Ca2+]mito is 106 times that of [Ca2+]i (Graier et al., 
2007).  Uncouplers, including carbonyl cyanide 3-chlorophenylhydrazone (CCCP), 
which disrupt the proton gradient across the inner mitochondrial membrane, reduce the 
driving force for Ca2+, resulting in strongly diminishing mitochondrial Ca2+ uptake 
(Graier et al., 2007). 
 
 
1.5.3. Spatial proximity between SR and mitochondria 
 
To reconcile the low mitochondrial affinity for Ca2+ at physiological [Ca2+]i, 
mitochondria may be exposed to Ca2+ microdomains, such as intracellular Ca2+ stores, 
permitting localized mitochondrial Ca2+ uptake to occur (Rizzuto et al., 2009).  In HeLa 
cells, imaging green fluorescent protein (GFP) constructs targeted to the SR and 
mitochondria has revealed that ~5-20 % of the mitochondrial surface is in close 
apposition to the SR (Rizzuto et al., 2009).  Conventional thin section transmission 
electron microscopy studies indicate that mitochondria are located in close proximity 
(~10-25 nm) to the SR in many cell types, including arterial smooth muscle cells 
(Rizzuto et al., 1999; Duchen, 2000b; Szado et al., 2003; Rizzuto et al., 2009).   
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To achieve effective local Ca2+ signaling between the SR and mitochondria, the 
SR Ca2+ release sites and the mitochondrial Ca2+ uptake channels should be present at the 
interface area (Hajnoczky et al., 2000).  Distribution of the IP3Rs and RyRs is not 
homogenous on the SR membrane (Hajnoczky et al., 2000).  In cardiac muscle cells, 
~90% of the SR Ca2+ release channels are located very close to mitochondria (Sharma et 
al., 2000).  A high density of IP3R1 and IP3R2 exist on regions of the SR which face the 
mitochondria (Takei et al., 1992; Simpson et al., 1997).  MCU is exclusively localized in 
the regions of contact between the mitochondria and ER (Hajnoczky et al., 2000). 
 
In addition to being in close proximity to each other, SR and mitochondria may be 
physically tethered to one another to sustain local communication during continuous 
organelle movement and reorganization (Hajnoczky et al., 2000; Csordas & Hajnoczky, 
2009).  The SR-mitochondria physical coupling is established via several anchoring 
proteins, including dynamin-like protein-1 (Pitts et al., 1999), glucose-regulated protein 
75 (Szabadkai et al., 2006), sigma-1 receptor (Hayashi & Su, 2007), and mitofusin-2 (De 
Brito & Scorrano, 2008).  Since both SR and mitochondria bind to microtubules/actin 
filaments, cytoskeletal proteins may also offer additional physical support to the SR-
mitochondria associations (Spat et al., 2008).  Therefore, the spatial distribution of SR 
and mitochondria, and the physical coupling between them may provide a strong 
platform for efficient local communication. 
 
Not all the mitochondria are in close proximity to the SR.  Some mitochondria 
may be isolated or relatively far from the SR, resulting in them either not or poorly 
responding to SR Ca2+ release (Hajnoczky et al., 2000).  There may also exist substantial 
heterogeneity among different mitochondria in the efficacy of Ca2+ uptake with 
differences in MCU activation, driving force, rate, and peak of Ca2+ uptake (Rizzuto et 
al., 2004).  Therefore, a sub-population of mitochondria may be exposed to [Ca2+]i much 
higher than other mitochondria in the same cell (McCarron et al., 2006). 
 
 
1.5.4. Interplay between mitochondria and cytosolic Ca2+ signals 
 
Ca2+ transport pathways of the mitochondria consist of high velocity, ψm-driven 
uptake mechanisms which are activated by local [Ca2+]i elevations, and slow, easily 
saturable, concentration-dependent efflux systems, which are only mildly stimulated by 
[Ca2+]mito elevations.  Therefore, mitochondria accumulate Ca2+ during rapid, local [Ca2+]i 
elevations and slowly release it back into the cytosol (Rizzuto et al., 2000).  This permits 
the mitochondria to alter spatio-temporal patterns of global and local Ca2+ signaling 
(Rizzuto et al., 2000; Xi et al., 2005).  The physiological range of arterial smooth muscle 
cell global [Ca2+]i is ~100-300 nM.  Local Ca2+ signals elevate Ca2+ into the micromolar 
concentration range, which is sufficient for mitochondrial Ca2+ uptake because in vitro Kd 
for Ca2+ of MCU is ~10-20 µM (Gunter & Pfeiffer, 1990; Perez et al., 2001).  SR Ca2+ 
release due to the activation of IP3R-gated Ca2+-release channels caused a micromolar 
increase in the local cytosolic [Ca2+]i and Ca2+ uptake by localized mitochondria (Rizzuto 
et al., 1993; Duchen et al., 1998; Hajnoczky et al., 2002).  In rat pulmonary artery 
smooth muscle cells, cytosolic Ca2+ oscillations due to SR Ca2+ release resulted in 
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[Ca2+]mito oscillations (Drummond & Tuft, 1999).  In cardiac smooth muscle cells, local 
SR Ca2+ release via RyR channels elicited miniature [Ca2+]mito elevations termed “Ca2+ 
marks”, and transient mitochondrial depolarizations termed “flickers” (Duchen et al., 
1998; Pacher et al., 2002). 
 
Vascular smooth muscle cell mitochondria can in turn feedback to alter the 
activity of Ca2+ channels which produce the local Ca2+ signals (Cheranov & Jaggar, 2004; 
Poburko et al., 2004; Chalmers et al., 2007).  In particular, mitochondria regulate IP3R 
and RyR channel activity, and in turn influence the propagation of Ca2+ waves and 
generation of Ca2+ sparks, respectively (Lee et al., 2002; Wellman & Nelson, 2003).  
Mitochondria can regulate these SR Ca2+ release channels by buffering local [Ca2+]i, 
controlling ATP synthesis, via reactive oxygen species (ROS) signaling, and cADPr 
metabolism (Poburko et al., 2004; Xi et al., 2005; Chalmers et al., 2007).  RyR and IP3R 
are sensitive to cADPr and ATP, respectively (Bezprozvanny & Ehrlich, 1995; 
Sitsapesan et al., 1995), and both channels have distinct Ca2+-sensitive stimulating and 
inhibiting sites.  By influencing channel modulators and by buffering [Ca2+]i, 
mitochondria can regulate both the Ca2+ sensitivity and the duration of opening of RyR 
and IP3R.  In various cell types, including vascular smooth muscle cells, mitochondria 
affect RyR channel activity and influence the frequency and amplitude of Ca2+ sparks 
(Pacher et al., 2002; Xi et al., 2005).  In cerebral artery smooth muscle cells, 
mitochondrial depolarization-induced ROS elevation activated Ca2+ sparks, leading to 
KCa channel stimulation, resulting in vasodilation (Xi et al., 2005).  In pulmonary and 
mesenteric artery smooth muscle cells, mitochondria increased both Ca2+ spark frequency 
and amplitude, resulting in increased ClCa current (Wang et al., 2003).  Mitochondrial 
regulation of IP3R activity has been reported in colonic and arterial smooth muscle cells 
(McCarron & Muir, 1999; Sward et al., 2002).  In rat tail artery smooth muscle cells, 
mitochondrial inhibitors increased the frequency and decreased the amplitude of IP3R-
mediated [Ca2+]i oscillations (Sward et al., 2002).  Mitochondria can also regulate SR 
Ca2+ refilling by controlling ATP synthesis and modulating Ca2+ efflux via mNCX 
(Landolfi et al., 1998; Arnaudeau et al., 2001).  In vascular smooth muscle cells, 
mitochondria regulate the activity of several plasma membrane ion channels, including 
SOCCs, VDCCs, KCa, and ClCa channels (Poburko et al., 2004).  Mitochondria influence 
plasma membrane channel activity by buffering local subplasmalemmal Ca2+ gradients, 
which activate or inhibit channels and also through regulation of SR Ca2+ refilling, which 
dictates the activity of SOCCs (Poburko et al., 2004).  Therefore, the activity of 
mitochondria may regulate and be influenced by Ca2+ signals in smooth muscle cells. 
 
 
1.5.5. Role of mitochondria in vascular smooth muscle cells 
 
In vascular smooth muscle cells, the physiological role of mitochondria apart 
from their energy-generating function is unclear.  Mitochondria provide an efficient 
system for buffering cytosolic Ca2+ changes, thereby controlling a variety of 
mitochondrial events, including ATP synthesis, mPTP opening, and mitochondrial ROS 
(mitoROS) generation.  However, the physiological consequences of these [Ca2+]mito 
elevation-mediated events are poorly understood. 
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Mitochondrial dysfunction is associated with several pathological conditions of 
the vasculature, including apoptosis, migration, remodeling, and glycation (Lee et al., 
2008; Birukov, 2009; Wang et al., 2009; Ahn et al., 2010).  Few studies have examined 
the role of mitochondria in regulating physiological functions of vascular smooth muscle 
cells.  In cerebral artery smooth muscle cells, mitoROS activate Ca2+ sparks and stimulate 
KCa channels, resulting in vasodilation (Xi et al., 2005).  Cold-induced constriction of 
cutaneous arteries is mediated through mitoROS generation (Bailey et al., 2005).  During 
hypoxia, mitochondria in pulmonary artery smooth muscle cells act as oxygen sensors 
and stimulate redox-sensitive transcription factors (Schumacker, 2003; Sato et al., 2005).  
Therefore, there is very minimal information available about the role of mitochondria in 
mediating normal physiological processes other than ATP synthesis in vascular smooth 
muscle cells. 
 
 
1.6. Reactive Oxygen Species in Vascular Smooth Muscle Cells 
 
In physiological or pathological conditions, O2 is converted into highly reactive 
oxygen-derived molecules and free radicals, called reactive oxygen species (ROS) that 
interact with reducible compounds.  There are different species of ROS, including 
hydrogen peroxide (H2O2), superoxide anion (O2-·), hydroxyl radical (OH·). nitric oxide 
(NO), peroxynitrite (ONOO·), hypochlorous acid (HOCl), and singlet oxygen (1O2) 
(Mueller et al., 2005; Gloire et al., 2006).  O2-· and H2O2 are the two major species of 
ROS produced in cells.  O2-· through reaction with NO generates ONOO·.  OH· is 
produced from H2O2 in a Fenton reaction (Turrens, 2003). 
 
 
1.6.1. Cellular sources of ROS 
 
Multiple sources generate ROS, including mitochondrial ETC complexes, 
NAD(P)H oxidase, cytochrome P450 (CYP450), xanthine oxidoreductase, NO synthase 
(NOS), cyclooxygenases, and lipoxygenases (Irani, 2000; Turrens, 2003; Wong et al., 
2003; Mueller et al., 2005; Clempus & Griendling, 2006).  The major sources of ROS in 
vascular smooth muscle cells are mitochondrial ETC and NAD(P)H oxidase (Mueller et 
al., 2005). 
 
 
1.6.1.1. Mitochondrial ETC complexes 
 
Mitochondrial ETC is a major source of O2-· and H2O2 in most tissues, including 
vascular smooth muscle cells (Mueller et al., 2005; Clempus & Griendling, 2006).  Under 
normal metabolic conditions, electron leakage occurs during transfer between complexes, 
resulting in the incomplete reduction of ~1–5% of total O2 consumed, to produce O2-· 
(Mueller et al., 2005).  Mitochondrial O2-· production occurs primarily at ETC complexes 
I and III (Mueller et al., 2005).  The main source of O2-· in mitochondria is the 
ubisemiquinone radical intermediate (QH·), which is formed from UQ at complex III 
(Brookes et al., 2004).  QH· formation occurs under two conditions: 1) an increase in 
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QH· concentration when ETC is inhibited distally, and 2) an increased rate of QH· 
production when ETC functions faster (Brookes et al., 2004).  Therefore, both 
stimulation and inhibition of mitochondrial ETC elevate mitochondrial O2-· generation. 
 
Mitochondrial superoxide dismutase converts O2-· to H2O2 (Clempus & 
Griendling, 2006).  Since O2-· generation is non-enzymatic, the rate of mitoROS 
production is directly proportional to the rate of metabolism (Brookes, 2005).  MitoROS 
generation is regulated primarily by the redox state of the ETC complexes, which is 
controlled by the ψm and the proton gradient (Brookes, 2005; Xi et al., 2005).  Several 
other stimuli, including mitochondrial Ca2+ uptake (Wolin et al., 2005), and mPTP 
opening (Wang et al., 2008a) stimulate mitoROS production in cell types, including 
vascular smooth muscle cells.  MitoROS regulates several physiological and pathological 
signaling pathways, including cell cycle, cell proliferation, apoptosis, metalloproteinase 
function, protein phosphorylation, dephosphorylation, Ca2+ signaling, vascular 
contractility, and transcription factors (Brookes et al., 2004; Xi et al., 2005). 
 
 
1.6.1.2. NAD(P)H oxidase 
 
NAD(P)H oxidases are multiprotein complexes consisting of the p22phox subunit 
bound to the catalytic subunit Nox (known as gp91phox in phagocytes) (Touyz et al., 
2002; Mueller et al., 2005; Paravicini & Touyz, 2006; Parfenova & Leffler, 2008; 
Basuroy et al., 2009).  In addition to the membrane-bound Nox/p22phox complex, there 
are three cytosolic subunits, including Rac1, p47phox and p67phox, which are recruited to 
the membrane upon activation (Abo et al., 1991; Ambasta et al., 2004; Basuroy et al., 
2009).  The catalytic subunit in vascular smooth muscle cells is either Nox1, Nox2, or 
Nox4 (Mueller et al., 2005; Paravicini & Touyz, 2006).  Nox1 expression levels, which 
are low in vascular smooth muscle cells, can be induced by stimuli such as platelet-
derived growth factor (PDGF), Ang II, and serum (Lassegue & Clempus, 2003).  Nox2 is 
expressed in endothelial and adventitial cells of large arteries and in vascular smooth 
muscle cells of smaller resistance-size arteries (Wang et al., 1998; Gorlach et al., 2000; 
Touyz et al., 2002; Parfenova & Leffler, 2008; Basuroy et al., 2009).  Nox4 is 
constitutively expressed and active in vascular smooth muscle and endothelial cells (Ago 
et al., 2004; Hilenski et al., 2004; Basuroy et al., 2009). 
 
Activation of NAD(P)H oxidase results in the assembly of the cytosolic  and 
membrane-bound subunits to form an enzyme complex (Lassegue & Clempus, 2003; 
Mueller et al., 2005).  NAD(P)H oxidase produces O2-· by the transfer of two electrons 
from NAD(P)H to O2 (Paravicini & Touyz, 2006).  Vasoactive hormones (Ang II), 
growth factors (PDGF), and mechanical stimuli (shear stress) activate NAD(P)H oxidase 
in vascular smooth muscle cells (Mueller et al., 2005). 
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1.6.1.3. Cytochrome P450 
 
Membrane-bound microsomal monooxygenase system is present in the SR of 
most tissues, including vascular smooth muscle cells (Zangar et al., 2004).  It contains 
CYP450 enzymes which oxygenate exogenous and endogenous compounds.  NAD(P)H-
CYP450 reductase transfers two electrons to CYP450 resulting in activation of O2, 
leading to monooxygenation of substrates (Zangar et al., 2004).  The efficiency with 
which electrons are transferred from NAD(P)H to CYP450 for substrate oxygenation is 
not tightly regulated, resulting in ROS production (Gorsky et al., 1984; Blanck et al., 
1991).  Therefore, continuous generation of O2-· and H2O2 by CYP450, as a result of 
NAD(P)H consumption occurs both in the presence and absence of substrates (Kuthan & 
Ullrich, 1982; Zangar et al., 2004).   
 
 
1.6.1.4. Xanthine oxidoreductase 
 
The xanthine oxidoreductase system exists as xanthine dehydrogenase (XDH) and 
xanthine oxidase (XO) (Mueller et al., 2005).  XDH transfers electrons from 
hypoxanthine and xanthine to NAD+ to produce NADH and uric acid (Harrison, 2002).  
XO forms O2-· and H2O2 by transferring electron from NADH and uric acid to O2 
(Harrison, 2002).  Therefore, the relative cellular amounts of XDH and XO determine the 
ROS produced (Mueller et al., 2005).  Several stimuli, including tumor necrosis factor 
alpha (TNF-α), and ONOO· convert XDH to XO, and thereby increase ROS production 
in vascular smooth muscle cells (Friedl et al., 1989; Sakuma et al., 1997). 
 
 
1.6.1.5. Nitric oxide synthases 
 
There are three NOS isoforms, namely endothelial NOS (eNOS) and nNOS, 
which are constituvely expressed, and inducible NOS (iNOS) (Kibbe et al., 1999).  Under 
normal conditions, NOS transfers electrons to L-arginine in the presence of cofactor 
tetrahydrobiopterin (BH4) to yield NO (Mueller et al., 2005).   
 
eNOS activity is regulated by [Ca2+]i between ~100 and 500 nM, which permits 
CaM binding and its activation (Forstermann et al., 1994).  In pathological conditions, 
including hypertension, elevated levels of O2-· oxidize BH4 , thereby uncoupling eNOS, 
which transfers electron to O2 instead of L-arginine to produce additional O2-· (Mueller et 
al., 2005).  
 
In addition to eNOS-derived NO production in endothelial cells, NO generation in 
vascular smooth muscle cells occurs via iNOS (Griendling & FitzGerald, 2003).  iNOS 
generates 100-1000-fold more NO than eNOS and nNOS (Kibbe et al., 1999).  iNOS is 
expressed in conditions where smooth muscle cells change from a contractile to a 
proliferative phenotype in response to cellular stress, inflammatory states, and arterial 
injury (Kibbe et al., 1999; Griendling & FitzGerald, 2003). 
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1.6.1.6. Cyclooxygenases and lipoxygenases 
 
Cyclooxygenases and lipoxygenases metabolize arachidonic acid.  O2-· 
production occurs due to the hydroperoxidase activity of the enzymes via side-chain 
reactions that are dependent upon the presence of a suitable reducing substrate, either 
NADH or NAD(P)H (Wong et al., 2003).  Like cyclooxygenases, lipoxygenases can 
produce O2-· in the presence of either NADH or NAD(P)H (Lotzer et al., 2005). 
 
 
1.6.2. Antioxidant mechanisms 
 
Cells have developed defensive antioxidant mechanisms to eliminate excess ROS 
from cell compartments and extracellularly.  The antioxidant mechanisms include 
superoxide dismutase (SOD), catalase, thioredoxin, glutathione peroxidases and 
peroxiredoxins (Karihtala & Soini, 2007).  In human cells, three different types of SODs 
are expressed, including cytosolic copper-zinc SOD, mitochondrial manganese SOD and 
extracellular SOD (Karihtala & Soini, 2007).  All three SODs dismutate two O2-· anions 
to H2O2 and O2 (Karihtala & Soini, 2007).  Catalase, thioredoxin, glutathione 
peroxidases, and peroxiredoxins reduce H2O2 to water and O2 (Karihtala & Soini, 2007).  
When cellular production of ROS overwhelms its antioxidant capacity, a state of 
oxidative stress is reached leading to serious cellular injuries and contributing to the 
pathogenesis of several diseases. 
 
 
1.6.3. ROS regulation of vascular smooth muscle cell functions 
 
When generated in optimal concentrations, ROS can act as second messengers in 
regulating signal transduction pathways, leading to regulation of cellular responses in a 
variety of cell types and conditions, including cytokine, growth factor and hormone 
treatments, ion transport, transcription, neuromodulation, and apoptosis (Lander, 1997; 
Hensley et al., 2000).  Distinct properties of different species of ROS determine their 
capability of stimulating diverse signaling pathways, which may then lead to convergent 
or divergent consequences.  O2-· and OH· are very reactive, have short half-lives and 
therefore, are unlikely to mediate effects distant from where they are produced 
(Paravicini & Touyz, 2006).  The negative charge on O2-· prevents it from crossing 
cellular membranes, except through ion channels (Paravicini & Touyz, 2006).  H2O2 is 
comparatively more stable, has a greater diffusion radius than O2-· and OH·, and is able 
to diffuse across membranes and between cells (Paravicini & Touyz, 2006).  Therefore, 
different species of ROS are capable of regulating multiple signaling pathways, 
depending on their reactivity and stability (Paravicini & Touyz, 2006). 
 
In arterial smooth muscle cells, several ligands, including Ang II, ET-1, and 
PDGF, mechanical stress, and hypoxia increase ROS production (Griendling et al., 1994; 
Nishio & Watanabe, 1997; Xi et al., 2005; Clempus & Griendling, 2006; Paravicini & 
Touyz, 2006).  ROS exert their effects through interaction with and regulating the 
functions of multiple cellular components, including ion channels, protein kinases and 
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phosphatases, transcription factors, and cell cycle proteins (Clempus & Griendling, 2006; 
Paravicini & Touyz, 2006). 
 
In vascular smooth muscle cells, ROS regulate several processes, including 
contractility, hypertrophy, hyperplasia, migration, differentiation, secretion of 
inflammatory cytokines, gene expression, extracellular matrix protein deposition, 
activation of matrix metalloproteinases, and inflammation (Clempus & Griendling, 2006; 
Paravicini & Touyz, 2006).  ROS stimulate smooth muscle cell hypertrophy and 
hyperplasia by regulating the activity of redox-sensitive kinases and phosphatases, which 
lead to c-Src activation (Clempus & Griendling, 2006).  Several vasoactive ligands, 
including PDGF, insulin-like growth factor-1, thrombin, vascular endothelial growth 
factor (VEGF), and monocyte chemoattractant protein-1 (MCP-1) induce redox-
dependent migration of vascular smooth muscle cells (Clempus & Griendling, 2006).  
ROS mediate smooth muscle cell differentiation from a native, contractile to an invasive, 
proliferative phenotype in response to arterial injury (Clempus & Griendling, 2006).  
Arterial contractility is controlled by ROS by regulating functions of ion channels, 
including KCa channels (Xi et al., 2005; Clempus & Griendling, 2006; Paravicini & 
Touyz, 2006).  In addition, ROS also influence gene expression by activating redox-
sensitive transcription factors. 
 
ROS modulate the activity of redox-sensitive transcription factors, including 
activator protein (AP)-1, nuclear factor kappa B (NF-κB), cyclic AMP response element-
binding protein (CREB), hypoxia-inducible factor-1 alpha (HIF-1α), peroxisome 
proliferator-activated receptors, NF-E2-related factor-2 (Nrf2), Gax, and gut-enriched 
kruppel-like factor in vascular smooth muscle cells (Clempus & Griendling, 2006; Gloire 
et al., 2006).  ROS regulation of transcription factor activity occurs via direct and indirect 
mechanisms (Kunsch & Medford, 1999).  Direct mechanism involves oxidation of the 
transcription factor, leading to alteration of its activity (Kunsch & Medford, 1999).  ROS 
can also indirectly control transcription factor function by regulating its post-translational 
modifications (phosphorylation or dephosphorylation) via redox-sensitive kinases and 
phosphatases (Kunsch & Medford, 1999).  Both mechanisms alter several properties of 
transcription factors, including cellular localization, DNA binding, and recruitment of 
activators and/or repressors (Kunsch & Medford, 1999).  Vasoconstrictors, including Ang 
II induce expression of genes, including MCP-1 and interleukin (IL)-6 through ROS-
dependent NF-κB activation (Chen et al., 1998; Han et al., 1999).  Therefore, ROS 
regulate both physiological and pathological functions in vascular smooth muscle cells. 
 
 
1.7. NF-κB in Vascular Smooth Muscle Cells  
 
 
1.7.1. NF-κB family of proteins 
 
NF-κB proteins comprise structurally-related eukaryotic transcription factors that 
regulate gene expression and control a large number of cellular processes, including 
immune and inflammatory responses, cellular growth, and apoptosis.  NF-κB proteins 
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regulate gene expression by binding to cis-acting κB sites in the promoter regions.  In 
mammals, there are five NF-κB/REL genes, NF-κB1, NF-κB2, RELA, c-REL and RELB 
(Chen & Greene, 2004; Hayden & Ghosh, 2008).  The NF-κB family of transcription 
factors contains five members: NF-κB1 (p105/p50), NF-κB2 (p100/p52), RelA (p65), 
RelB, and c-Rel (Chen & Greene, 2004; Hayden & Ghosh, 2008).  NF-κB proteins are 
related through the presence of a highly conserved Rel homology domain in their N-
terminal region (Chen & Greene, 2004; Hayden & Ghosh, 2008).  The Rel homology 
domain which contains a nuclear localization sequence is involved in DNA binding, 
dimerization with other NF-κB proteins, and interaction with the inhibitory I kappa B 
(IκB) proteins (Chen & Greene, 2004; Hayden & Ghosh, 2008).  p105 and p100 are 
processed to generate the DNA binding subunits p50 and p52, respectively.  p105 and 
p100 proteins contain ankyrin repeats, as well as glycine-rich regions in their C-terminal 
regions.  The glycine-rich regions are essential for co-translational processing of p105 to 
p50 and post-translational processing of p100 to p52 by the ubiquitin-proteasome 
pathway (Chen & Greene, 2004; Hayden & Ghosh, 2008).  In addition to the Rel 
homology domain, p65, c-Rel, and RelB contain transactivation domains in their C-
teminal region.  Transactivation domains interact with various parts of the transcription 
apparatus to regulate gene expression (Chen & Greene, 2004; Hayden & Ghosh, 2008).  
p50 and p52 proteins contain the Rel homology domains but lack the transactivation 
domains.  NF-κB proteins are expressed in a cell- and tissue-specific manner (Chen & 
Greene, 2004; Hayden & Ghosh, 2008).  p50 and p65 are ubiquitously expressed, 
whereas NF-κB2, Rel-B, and c-Rel are specifically expressed in lymphoid tissues 
(Hayden & Ghosh, 2008). 
 
NF-κB proteins dimerize to form homo- or hetero-dimers, which produce specific 
responses to different stimuli and diverse effects on transcription.  The most often 
observed NF-κB complexes in cells are the p50-p65 and p52-RelB heterodimers (Sun & 
Andersson, 2002).  Homodimers of p50 and p52 act as transcriptional repressors (Sun & 
Andersson, 2002).  Presence of different NF-κB homo- and hetero-dimers determines 
which dimers control transcription.  Therefore, depending on the dimer, transcriptional 
activity is either stimulated or inhibited (Sun & Andersson, 2002). 
 
 
1.7.2. NF-κB activation pathways 
 
There are two modes of signaling pathways, including the “classical/canonical” 
pathway and the “alternative/non-canonical” pathway, each of which lead to the 
translocation of NF-κB dimers from the cytosol to the nucleus (Bonizzi & Karin, 2004).  
NF-κB activated by each of these pathways regulate the transcription of distinct target 
genes (Bonizzi & Karin, 2004; Chen & Greene, 2004; Hayden & Ghosh, 2008). 
 
 
1.7.2.1. Classical/Canonical pathway 
 
The prototypical NF-κB complex comprising the p50-p65 heterodimer is bound to 
IκB which masks the nuclear localization signal (NLS) of p65 and causes cytosolic 
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retention of NF-κB (Bonizzi & Karin, 2004).  Activation occurs when signalsome 
containing the IκB kinases (IKKs), including IKKα, IKKβ, and IKKγ phosphorylates IκB 
on serine residues 32 and 36 (Karin, 1999).  IκB phosphorylation leads to IκB 
dissociation from the inactive NF-κB/IκB complex (Karin, 1999).  Dissociated IκB is 
ubiquitinated and degraded by the 26S proteasome complex (Karin, 1999).  IκB 
degradation unmasks the NLS on p65, leading to nuclear translocation of activated NF-
κB and DNA binding (Karin, 1999). 
 
 
1.7.2.2. Alternative/Non-canonical pathway 
 
Certain stimuli, including B-cell activating factor and CD40 activate NF-κB-
inducing kinase and IKKα, leading to NF-κB2 (p100) phosphorylation (Senftleben et al., 
2001).  p100 phosphorylation leads to its ubiquitination, and is proteolytically processed 
by the 26S proteasome to yield p52 (Lin et al., 1998).  This pathway principally involves 
the p52-RelB heterodimer as opposed to the p50-p65 heterodimer produced by the 
canonical pathway (Senftleben et al., 2001; Chen & Greene, 2004).   
 
Upon nuclear translocation, NF-κB regulates gene expression by recruiting 
additional transcriptional activators and/or repressors, which contain κB consensus 
sequences (5'-GGGRNYYYCC-3', where R is a purine, Y is a pyrimidine, and N is any 
nucleic acid) (Chen & Greene, 2004).  One of the target genes that is always stimulated 
by NF-κB is IκBα, which is depleted during the events of NF-κB activation (Chen & 
Greene, 2004).  IκBα expression results in translocating the nuclear NF-κB back to the 
cytosol, thereby terminating the transcriptional regulation (Chen & Greene, 2004).  
 
 
1.7.3. Mechanisms of NF-κB activation 
 
NF-κB is activated by a range of stimuli, including various pro-inflammatory 
cytokines, growth factors, DNA-damaging agents, and viral proteins.  The cellular events 
underlying NF-κB activation consists of IKK activation and IκBα degradation (classical 
pathway) or the post-translational processing of p100 to p52 (alternative pathway) (Sun 
& Andersson, 2002).  With regard to vascular biology, various stimuli including TNF-α, 
IL-1, advanced glycation end products, hyperglycemia, mechanical stress, ROS, and 
hypoxia/reperfusion activate NF-κB (De Martin et al., 2000).  ROS activates NF-κB in 
vascular smooth muscle cells and other cell types (Asehnoune et al., 2004; Bubici et al., 
2006; Miller, Jr. et al., 2007).  In addition, mitoROS activate NF-κB in several cell types, 
including in cultured vascular smooth muscle cells, skeletal muscle myotubes, and 
cultured macrophages (Li et al., 1999; Chandel et al., 2000; Lee et al., 2008).  The 
mechanism through which ROS activate NF-κB appears to involve the activity of IKKs, 
including IKKα and IKKβ (Gloire et al., 2006). 
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1.7.4. Regulation of vascular function by NF-κB 
 
NF-κB is constitutively activated and inactivated in arterial smooth muscle cells 
and is essential for the regulation of a variety of vascular functions, including smooth 
muscle cell proliferation, angiogenesis, and induction of cytokines (Asehnoune et al., 
2004; Bubici et al., 2006; Clempus & Griendling, 2006; Miller, Jr. et al., 2007).  In 
arterial smooth muscle cells, NF-κB regulates expression of genes, including vascular 
cell adhesion molecule-1, IL-1, and c-myc (Bourcier et al., 1997; Detmer et al., 2001).  
NF-κB also induces expression of anti-apoptotic genes, leading to protection during 
abnormal proliferation (De Martin et al., 2000).  The physiological NF-κB-dependent 
gene expression may be exaggerated in pathological situations, resulting in damage to the 
vessel wall and impaired vascular cell function (De Martin et al., 2000).  High levels of 
NF-κB are present in arterial smooth muscle cells of arteriosclerotic intimal lesions (De 
Martin et al., 2000).   
 
Previous reports in cultured arterial smooth muscle cells have suggested that NF-
κB plays an important role in regulating gene expression and proliferation (Landry et al., 
1997).  NF-κB is also involved in regulating gene transcription of ion channels, including 
amiloride-sensitive Na+ channel, small conductance Ca2+-activated K+ channel, and 
TRPC1 channel (Baines et al., 2002; Paria et al., 2006; Kye et al., 2007) in several cell 
types, including cultured aortic smooth muscle cells.  In pathological states, NF-κB 
activation has been shown to upregulate ETB receptor expression in arterial smooth 
muscle cells, leading to enhanced contraction (Xu et al., 2008).  However, the 
physiological functions and mechanisms of regulation of NF-B in contractile arterial 
smooth muscle cells are poorly understood.  In this study, we have examined the 
physiological regulation of arterial contractility by NF-κB-dependent ion channel 
expression. 
 
 
1.8. Transcriptional Regulation of CaV1.2 Expression 
 
CaV1.2 channels are expressed in heart, vascular, and visceral smooth muscle 
cells (Ertel et al., 2000).  The α1C subunit of human CaV1.2 is encoded by the CACNA1C 
gene, which is located in the distal region of chromosome 12 (Tang et al., 2004).  
CACNA1C contains 55 exons, of which 15 are subjected to alternative splicing, 
generating 40 reported splice variations, expressed in different tissues (Tang et al., 2004).  
In smooth muscle cells, alternatively splicing has been reported in exons 1, 8, and 9 in 
smooth muscle cells, and in exons 1, 8, 31, and 32 in cardiac muscle (Liao et al., 2005).  
CACNA1C transcription is regulated by different promoters in cardiac muscle and 
smooth muscle cells (Dai et al., 2002; Saada et al., 2003).  CACNA1C transcription is 
driven by promoters upstream of exon 1a and 1b in cardiac muscle and smooth muscle 
cells, respectively (Dai et al., 2002; Saada et al., 2003).  The promoter driving α1C 
expression in cardiac muscle has binding sites for several transcription factors, including 
myocyte enhancer factor-2, Nkx2.5, NFAT, and CREB (Dai et al., 2002).  The promoter 
region of α1C in human colonic smooth muscle cells has 2 binding sites for CREB, which 
upregulates transcription, and 3 binding sites for NF-κB which represses transcription 
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(Shi et al., 2005; Shi et al., 2007).  The identity of the transcription factors which bind to 
the promoter region of α1C in vascular smooth muscle cells are unknown.  It is poorly 
understood if transcription factors regulating α1C gene expression in visceral and vascular 
smooth muscle cells are similar or different.  In rat renal arteries, global [Ca2+]i elevation 
increased CaV1.2 protein expression (Pesic et al., 2004).  In coronary artery smooth 
muscle cells, PKC delta (PKCδ) increased CaV1.2 protein levels (Maddali et al., 2005).  
Although these studies report an increase in CaV1.2 protein levels, little is known about 
the transcriptional regulation of CaV1.2 α1C gene in vascular smooth muscle cells.   
 
 
1.9. Unresolved Issues 
 
Smooth muscle cells from small, resistance-size arteries generate multiple types 
of local and global Ca2+ signals.  Physiological functions of vasoconstrictor-induced Ca2+ 
signals, specifically Ca2+ waves in smooth muscle cells of resistance-size arteries are 
poorly understood (Miriel et al., 1999; Jaggar, 2001; Mauban et al., 2001; Heppner et al., 
2002; Lamont & Wier, 2004; Jaggar, 2007).  Elevation in intracellular [Ca2+]i induces 
mitochondrial Ca2+ uptake (Poburko et al., 2004; Chalmers et al., 2007), but identity of 
the intracellular Ca2+ signal(s) that regulate [Ca2+]mito in arterial smooth muscle cells is 
unclear.  Physiological functions of changes in [Ca2+]mito and mitoROS in arterial smooth 
muscle cells are also poorly understood.  Similarly, stimuli that cause mitochondrial 
depolarization and generate mitoROS in arterial smooth muscle cells are unclear (Rizzuto 
et al., 1999; Duchen, 2000b; Szado et al., 2003; Poburko et al., 2004).  Also, little is 
known about the mechanisms that regulate NF-κB activity in contractile arterial smooth 
muscle cells.  CaV1.2 channels are the major Ca2+ entry pathway for smooth muscle cells 
of resistance-size arteries and are essential for myogenic tone development and blood 
pressure regulation (Cheng et al., 2007).  However, the transcriptional regulation of 
CaV1.2 gene expression in vascular smooth muscle cells is unclear.   
 
This study aimed to determine the Ca2+ signaling mechanisms that regulate 
[Ca2+]mito and to investigate the physiological functions of changes in [Ca2+]mito in smooth 
muscle cells of resistance-size cerebral arteries in their native, contractile phenotype. 
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CHAPTER 2. HYPOTHESIS 
 
 
2.1. Goal 
 
The unifying goal of this study was to test the hypothesis that ET-1-induced IP3R-
mediated SR Ca2+ release elevates [Ca2+]mito and mitoROS generation, which activates 
NF-κB, leading to transcription of CaV1.2 channels and vasoconstriction. 
 
 
2.2. Specific Aims 
 
 
2.2.1. Aim 1 
 
To test the hypothesis that ET-1-induced IP3R-mediated SR Ca2+ release elevates 
[Ca2+]mito leading to mitochondrial depolarization. 
 
Regulation of local and global Ca2+ signals by ET-1 was studied.  Mechanisms by 
which ET-1 regulate [Ca2+]mito and ψm were examined in arterial smooth muscle cells.  
ET-1 regulation of local and global Ca2+ signals was studied in intact arteries using fluo-
4, a Ca2+-sensitive fluorescent dye and rapid confocal imaging.  [Ca2+]mito was measured 
in smooth muscle cells of intact arteries using confocal imaging of 2mt8CG2, a 
mitochondria-targeted, genetically-encoded Ca2+ indicator.  ψm was studied by measuring 
TMRM fluorescence in isolated cerebral artery smooth muscle cells. 
 
 
2.2.2. Aim 2 
 
To investigate the hypothesis that ET-1-induced [Ca2+]mito elevation and 
mitochondrial depolarization elevate mitoROS production, which activates NF-κB.   
 
The importance of ET-1-induced [Ca2+]mito elevation and mitochondrial 
depolarization in the mitoROS elevation was examined.  The contributions of ET-1-
induced IP3R-mediated SR Ca2+ release and mitoROS elevation in mediating NF-κB 
activation in arterial smooth muscle cells were also studied.  MitoROS and cytosolic ROS 
were measured in smooth muscle cells of intact arteries using genetically-encoded 
fluorescent ROS indicators targeted to the mitochondria and cytosol, respectively.  ROS 
measurements obtained using genetically-encoded fluorescent ROS indicators were 
confirmed using 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, 
acetyl ester (CM-H2DCFDA) and laser-scanning confocal microscopy.  ET-1 regulation 
of endogenous NF-κB activity was evaluated by using immunofluorescence to study 
nuclear translocation of activated NF-κB in smooth muscle cells of intact arteries. 
Transcriptional activity of NF-κB was measured by using luciferase reporter gene assays, 
which was also used to support results obtained in immmunofluorescence experiments. 
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2.2.3. Aim 3  
 
To explore the hypothesis that NF-B, activated by ET-1-induced mitoROS 
elevation, stimulates Cav1.2 transcription, leading to vasoconstriction. 
 
Mechanisms by which ET-1 elevates CaV1.2 channel expression were 
investigated.  The importance of ET-1-induced mitoROS elevation and NF-κB activation 
in regulating CaV1.2 expression in smooth muscle cells of cerebral arteries was studied.  
CaV1.2 mRNA and protein levels were quantified by real-time polymerase chain reaction 
(RT-PCR) and Western blotting, respectively.  Pressurized artery diameter measurements 
were used to assess the functional effects of the ET-1-induced elevation in CaV1.2 
expression. 
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CHAPTER 3. MATERIALS AND METHODS* 
 
 
3.1. Vertebrate Animal Subjects 
 
 
3.1.1. Justification of animal use 
 
Male Sprague-Dawley rats (200–250 g body wt) (12-14 weeks of age) were 
purchased from Harlan-Teklad Laboratories (Ewing, IL).  Rats were chosen for this study 
because diameter regulation by intravascular pressure, physiological functions of CaV1.2 
channels, and vasoconstrictor-induced modulation of local and global Ca2+ signals are 
best described in rats.  Therefore, rats were the most appropriate species in which to 
conduct this study.  All experimental methodologies were carried out ex vivo on 
appropriate tissues collected from rats immediately following euthanasia.  The number of 
animals used for a given experiment varied based on specific experimental design, 
variability of the measurements of the parameter in question, and the absolute difference 
among groups.  For biochemical techniques such as Western blotting, it was usual for 
more than one rat to be used per experimental observation since the arteries used in this 
study gave smaller protein yields compared to other samples such as rat brain.  For non-
biochemical techniques used herein, one rat was typically used per experimental number.  
In functional studies, more than one drug was tested in a single experiment, either alone, 
or in combination with other modulators, which increased the experimental observations 
obtained per animal. 
 
 
3.1.2. Information on veterinary care  
 
Research was conducted in accordance with the Guide for Care and Use of 
Laboratory Animals, and the provisions of the Animal Welfare Act (USDA) and all other 
applicable federal and state laws and regulations.  Protocols were reviewed and approved 
by IACUC.  The University of Tennessee maintains an AAALAC-accredited facility that 
is staffed by three full-time veterinarians, two of whom are board-certified in laboratory 
animal care.  The Department of Comparative Medicine (DCM) was responsible for 
husbandry and veterinary care for all vertebrate animals on campus.  Animals were 
housed by species and health status to minimize infectious disease problems. 
 
 
 
 
 
 
 
* Portions of this chapter adapted with permission. Narayanan D, Xi Q, Pfeffer LM, & 
Jaggar JH (2010). Mitochondria control functional CaV1.2 expression in smooth muscle 
cells of cerebral arteries. Circ Res 107, 631-641. 
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3.1.3. Euthanasia 
 
 
3.1.3.1. Procedure for limiting animal discomfort, distress, pain, and injury  
 
All experiments were performed using cerebral arteries isolated from rat brain 
after euthanization.  Rats were rendered pliant (immobile but visibly breathing) with CO2 
introduced directly into a specially designed housing chamber, prior to euthanasia by 
sodium pentobarbital injection.  Care was taken at all times to minimize distress to rats 
during the euthanization process.  
 
 
3.1.3.2. Method of euthanasia 
 
Rats were euthanized by intraperitoneal injection of sodium pentobarbital solution 
(150 mg/kg) (Vortech Pharmaceuticals, Dearborn, MI).  This method induces euthanasia 
smoothly and it is consistent with the recommendations of the American Veterinary 
Medical Association Panel on Euthanasia (American Veterinary Medical Association 
Panel on Euthanasia, 2001).  Overdose of sodium pentobarbital causes rapid 
unconsciousness, followed by respiratory arrest through paralysis of the diaphragm and 
collapse of the lungs.  The drug then suppresses cardiac activity, thus causing death.  A 
new syringe and small needle was used with each animal to reduce injection trauma.  
Animal expiration was confirmed by cessation of spontaneous reflex movement to 
toe/skin pinch, absence of respiration, heartbeat, and corneal reflex.  After confirmation 
of expiration, the rats were euthanized by decapitation and the brain removed, for 
dissection/removal of cerebral arteries. 
 
 
3.2. Tissue Preparation 
 
The brain was removed and placed into ice-cold (4°C) HEPES-buffered 
physiological salt solution (PSS) containing (in mM): 134 NaCl, 6 KCl, 2 CaCl2, 1 
MgCl2, 10 HEPES, and 10 glucose (with pH adjusted to 7.4 with NaOH).  Posterior 
cerebral, middle cerebral, and cerebellar arteries (~50–200 µm diameter) were removed 
from the brain.  The arteries were cleaned of connective tissue.  Care was taken while 
cleaning to avoid stretching and damage to the arteries.  The cleaned arteries were placed 
in a petri dish containing 4°C HEPES-buffered PSS.  Intact artery segments and 
enzymatically isolated smooth muscle cells were harvested on the day of 
experimentation.  Enzymatically isolated smooth muscle cells were used for 
colocalization studies and ψm measurements.  For all other experiments, intact artery 
segments were used. 
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3.3. Endothelial Denudation 
 
When appropriate, endothelial layer of the arterial wall was removed.  Briefly, the 
artery segments (1–2 mm in length) were cannulated at one end in a perfusion chamber 
(Living Systems Instrumentation, Burlington, VT).  Following cannulation at one end, an 
air bubble was gently introduced into the arterial lumen for 2 minutes.  After 2 minutes, 
PSS was flushed through the lumen.  This approach of endothelial denudation has been 
shown to be effective in previous studies (Xi et al., 2005; Adebiyi et al., 2008; Zhao et 
al., 2008). 
 
 
3.4. Isolation of Arterial Smooth Muscle Cells   
 
 
3.4.1. Preparation of solutions used for smooth muscle cell isolation 
 
Isolated cerebral arteries were placed for 15 minutes in a Ca2+-free solution 
containing (in mM): 55 NaCl, 80 sodium glutamate, 5.6 KCl, 2 MgCl2, 10 HEPES, and 
10 glucose (with pH adjusted to 7.4 with NaOH).  3 glass vials were rinsed with KOH 
and washed thoroughly with distilled water.  Papain (0.7 mg/ml) and dithioerythreitol (1 
mg/ml) were dissolved in enzyme solution (Ca2+-free solution containing bovine serum 
albumin (BSA) (1 mg/ml)).  Collagenases F and H were added to enzyme solution 
supplemented with CaCl2 (100 µM) in a ratio of 2:1 (1 mg/ml total collagenase).  Vials 
containing papain and collagenase solutions were warmed to 37°C for 10 minutes prior to 
transferring arteries into them. 
 
 
3.4.2. Dissociation of smooth muscle cells 
 
 
3.4.2.1. Freshly dissociated cerebral arteries  
 
Cerebral arteries were placed into vial containing prewarmed papain solution and 
incubated for 12 minutes at 37°C.  Then, the arteries were immediately transferred to a 
vial containing prewarmed collagenase solution and incubated for 9 minutes at 37°C.  
Arteries were subsequently washed in three petri dishes containing ice-cold Ca2+-free 
solution for 10 min, to remove the enzymes from the arteries.  The rinsed arteries were 
transferred to a vial containing Ca2+-free solution and triturated gently using three 
polished glass pasteur pipettes of progressively decreasing diameter of their opening.  
The trituration process gently dissociates the smooth muscle cells from the arteries.  
Smooth muscle cells were used for experimentation within 8 hours of dissociation. 
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3.4.2.2. Reverse-permeabilized arteries 
 
To deliver expression vectors into smooth muscle cells of intact arteries, reverse 
permeabilization procedure (described in detail in section 3.8) was used.  Reverse-
permeabilized arteries were then placed in Dulbecco's Modified Eagle Medium 
(DMEM)/F-12 culture medium (Cellgro, Manassas, VA) supplemented with 
penicillin/streptomycin (1%) (Cellgro, Manassas, VA) and placed in a 74% N2/21% 
O2/5% CO2 incubator at 37°C for 4 days prior to use to allow expression of the genes of 
interest.  After 4 days, smooth muscle cells were isolated and used for colocalization 
experiments.  The protocol for dissociation of smooth muscle cells from reverse-
permeabilized arteries was similar to that used for dissociating smooth muscle cells from 
freshly isolated arteries.  The durations of papain and collagenase treatments were 
reduced to 9 and 7 minutes at 37°C, respectively.  
 
 
3.5. Laser-Scanning Confocal Ca2+ Imaging 
 
 
3.5.1. Fluo-4 AM loading 
 
Endothelium-denuded cerebral artery segments were cannulated on 10-15 mm 
length borosilicate rectangular tubing (external dimensions: 220 × 40 µm) (internal 
dimensions: 200 × 20 µm, wall thickness: 20 µm) (Friedrich & Dimmock Inc., Millville, 
NJ).  Branches were removed from cerebral artery segments to provide a flat surface for 
imaging.  Cannulated arteries were incubated in the dark in HEPES-buffered PSS 
containing fluo-4 AM (10 µM) (Molecular Probes, Invitrogen, Eugene, OR) and 0.05% 
Pluronic F-127 (Molecular Probes, Invitrogen, Eugene, OR) for 1 hour at room 
temperature.  To allow indicator de-esterification, the cannulated arteries were then 
placed for 30 minutes at room temperature in 30 mM K+ solution containing (in mM): 
110 NaCl, 30 KCl, 10 HEPES, 2 CaCl2, 1 MgCl2, and 10 glucose (with pH adjusted to 
7.4 with NaOH).  30 mM K+ solution depolarizes smooth muscle cells to ~-40 mV, which 
is similar to the membrane potential of cerebral arteries pressurized to 60 mmHg (Jaggar 
et al., 1998; Jaggar & Nelson, 2000; Jaggar, 2001).   
 
 
3.5.2. Imaging protocol 
 
Intracellular Ca2+ signals in cerebral artery smooth muscle cells were imaged 
using a Noran Oz laser-scanning confocal microscope (Noran Instruments, Middleton, 
WI) with a 60X water-immersion objective (numerical aperture=1.2) attached to a Nikon 
TE300 microscope by illuminating with a krypton-argon laser at 488 nm and collecting 
emitted light >500 nm.  Sequential planar images (256 × 240 pixels, 56.3 × 52.8 µm) of 
each region of the arterial wall containing ~8-10 smooth muscle cells were recorded 
every 16.6 ms (60 Hz) for 10 seconds.  In each artery, 2-3 different regions of smooth 
muscle cells were scanned for each condition.  The same area of artery was scanned only 
once to avoid any laser-induced changes in Ca2+ signaling.  Ca2+ spark frequency, Ca2+ 
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wave frequency and global [Ca2+]i were analyzed offline using custom software written 
with IDL 5.3 (Research Systems Inc., Boulder, CO) kindly provided by Dr. M. T. Nelson 
(University of Vermont, Burlington, VT).  The full 10-second acquisition period of each 
image stack was analyzed to measure Ca2+ sparks, Ca2+ waves, and global [Ca2+]i.   
 
 
3.5.3. Analysis of cytosolic Ca2+signals 
 
 
3.5.3.1. Detection of Ca2+ sparks and Ca2+ waves 
 
Ca2+ sparks were detected by dividing fluorescence (F) in an area 1.54 µm × 1.54 
µm (7 × 7 pixels, 2.37 µm2) in individual smooth muscle cells in each image by a 
baseline fluorescence (F0) that was determined by averaging 10 images without Ca2+ 
spark activity.  The entire area of each image was analysed to detect Ca2+ sparks.  A Ca2+ 
spark was defined as a localized rapid increase in F/F0>1.2 (Jaggar et al., 2000).  
 
Ca2+ waves were detected by placing 2.2 × 2.2 µm (10 × 10 pixel, 4.84 µm2) 
boxes in individual smooth muscle cells, and refer to an elevation in F/F0>1.3 that was 
monitored for >200 milliseconds and propagated for more than 20 µm. 
 
 
3.5.3.2. Calculation of Ca2+ spark and wave frequency, and global [Ca2+]i 
 
Changes in Ca2+ spark frequency, Ca2+ wave frequency, and global [Ca2+]i in 
response to pharmacological manipulation were determined in paired arteries.  For each 
condition, Ca2+ spark and wave frequency for a region was calculated by dividing the 
number of Ca2+ sparks or waves detected in that region by the time of acquisition.  Ca2+ 
spark and wave frequency per cell was calculated by dividing the frequency for each 
region by the number of smooth muscle cells in that region.  Ca2+ spark and Ca2+ wave 
frequency, and global [Ca2+]i that were obtained from smooth muscle cells of multiple 
regions of the same artery were averaged, giving data under each condition.  Global F/F0 
for a given condition was calculated as the mean pixel value of 100 different images 
acquired over 10 seconds.  Global [Ca2+]i was calculated using the following equation: 
[Ca2+]i = KR/{K/([Ca2+]rest + 1 – R)}, where K is the apparent affinity of fluo-4 AM for 
Ca2+ (770 nM) (Cheranov & Jaggar, 2004), R is the fractional fluorescence increase 
(F/F0), and [Ca2+]rest is [Ca2+]i at F0 (193 nM) (Cheranov & Jaggar, 2004).  Changes in 
global [Ca2+]i were calculated from a control value previously determined using fura-2 
(Cheranov & Jaggar, 2004).  Arterial Ca2+ signal values were then averaged generating 
mean data.  In results, n (experimental number) refers to the number of arteries from 
which data were obtained under each condition. 
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3.6. Genetically-Encoded Fluorescent Indicators 
 
 
3.6.1. 2mt8CG2 
 
pMITO-2mt8CG2 vector encoding 2mt8CG2, a genetically-encoded, 
mitochondria-targeted, fluorescent Ca2+ indicator (Griesbeck et al., 2001; Filippin et al., 
2005) was a kind gift from Dr. Tullio Pozzan (University of Padua, Italy).  pMITO-
2mt8CG2 was constructed as follows: firstly, CaM, the Ca2+ probe was inserted into the 
backbone of yellow fluorescent protein (YFP) in place of Tyr145 (Griesbeck et al., 2001).  
YFP-tagged CaM was then inserted in-frame with two copies of the first 36 amino acids 
of subunit VIII of human cytochrome c oxidase (ETC complex IV), a mitochondrial 
specific protein (Filippin et al., 2005).  2mt8CG2 targets to mitochondria via cytochrome 
c oxidase subunit expression (Filippin et al., 2005).  Upon mitochondrial localization, 
Ca2+ in the mitochondrial matrix binds to CaM and causes a conformational change in 
YFP, leading to a change in fluorescence (Filippin et al., 2005).  2mt8CG2 has a Kd for 
Ca2+ of ~5.3 µM (Griesbeck et al., 2001).  Therefore, 2mt8CG2 is not capable of 
detecting changes in global [Ca2+]i, which is usually in the nanomolar range (Rizzuto & 
Pozzan, 2006).   
 
 
3.6.2. mt-cpYFP 
 
pShuttle-CMV vector encoding mt-cpYFP, a genetically-encoded, mitochondria-
targeted, fluorescent O2-· indicator was a kind gift from Dr. Heping Cheng (Peking 
University, China).  mt-cpYFP comprises a circularly permuted YFP (cpYFP) that 
selectively detects O2-·, the major ROS generated by the mitochondrial ETC (Wang et al., 
2008a).  mt-cpYFP localizes to mitochondria using subunit IV of cytochrome C oxidase 
targeting sequence (Wang et al., 2008a).  In vitro experiments have suggested that 
fluorescence changes of cpYFP are highly selective to O2-· levels since its fluorescence is 
unchanged by H2O2 and ONOO·, and is decreased by OH· and NO (Wang et al., 2008a). 
 
 
3.6.3. HyPer-CYTO  
 
pHyPer-Cyto vector encoding HyPer-CYTO, a genetically-encoded cytosolic 
fluorescent H2O2 indicator  was purchased from Axxora, Evrogen (San Diego, CA).  
HyPer comprises a cpYFP inserted into the regulatory domain of Escherichia Coli OxyR, 
a prokaryotic H2O2-sensing protein (Belousov et al., 2006).  Upon exposure to H2O2, the 
regulatory domain of OxyR undergoes a dramatic conformational change leading to an 
increase in cpYFP fluorescence (Belousov et al., 2006).  HyPer demonstrates affinity to 
H2O2 but is insensitive to other oxidants including O2-·, reactive nitrogen species, NO, 
and ONOO· (Belousov et al., 2006). 
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3.7. Transformation of Bacteria 
 
 
3.7.1. Introduction of expression vectors 
 
Ultracompetent GC10 bacterial cells (Sigma-Aldrich, St.Louis, MO) 
(transformation efficiency is ~1 × 109 colony-forming units/μg of plasmid DNA) were 
used for transformation.  Vector (~10 ng) was added to GC10 cells (50 µl) and incubated 
at 4ºC for 30 minutes.  Cells were then heat shocked in a water bath at 42ºC for 45 
seconds.  This heat shock step permeabilizes the membrane of the competent cells so that 
the expression vector can enter the cells.  Following heat shock, GC10 cells were added 
to LB Broth (950 µl) and incubated for 60 minutes at 37ºC.  Incubation allows the cell 
membranes to recover from heat shock and permits cell replication to begin.  
Transformed bacteria were then plated onto LB agar plates.  Ampicillin (100 µg/ml)-
resistant plates were used for pMITO-2mt8CG2 vector.  Kanamycin (50 µg/ml)-resistant 
plates were used for pShuttle-CMV and pHyPer-Cyto vectors, respectively.  Agar plates 
were then incubated at 37°C for 16 to 20 hours.  Following incubation, bacterial colonies 
which have taken up the expression vector and therefore resistant to the antibiotic added 
to the agar plate, appear on agar plates.   
 
 
3.7.2. DNA Maxiprep 
 
LB Broth (3 ml) was supplemented with ampicillin (100 µg/ml) (for pMITO-
2mt8CG2) or kanamycin (50 µg/ml) (for pShuttle-CMV and pHyPer-Cyto).  LB Broth 
supplemented with antibodies was inoculated with a single bacterial colony and 
incubated at 37°C at 200 RPM for 6 to 8 hours.  This “starter culture” was then added to 
a large volume of LB Broth (150 ml) supplemented with antibodies and incubated at 
37°C for 16 to 20 hours or until the solution turns turbid.  Incubation allows amplification 
of the bacteria which have taken up the expression vector.  Plasmid cDNA was purified 
from the bacterial culture using Qiagen Maxiprep HiSpeed Plasmid Purification kit 
(Qiagen, Valencia, CA). 
 
 
3.7.3. Quantification of DNA 
 
Maxipreped DNA (1:80 dilution) was quantified by measuring the absorbance of 
UV light at 230 nm (A230), 260 nm (A260), and 280 nm (A280 nm) using a UV 
spectrophotometer.  DNA concentration was calculated using the equation: 
 
DNA concentration (µg/ml) = (A260 – A230) × dilution factor × 50 µg/ml 
 
Nucleic acid purity was estimated from A260/A280 and A260/A230 ratios.  
Ratios between 1.8 and 2.0 generally represent high-quality nucleic acid sample.  
Reduction of A260/A280 and A260/A230 ratios indicate contamination with protein and 
organic compounds, respectively. 
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3.8. Reverse Permeabilization 
 
 
3.8.1. Composition of solutions used 
 
To deliver expression vectors into smooth muscle cells of intact arteries, reverse 
permeabilization was used (Lesh et al., 1995; Welsh et al., 2002).  Compositions of the 
solutions used for reverse permeabilization are as follows.  Solution 1 (in mM): 10 
EGTA, 120 KCl, 5 ATP, 2 MgCl2, 20 TES (pH 6.8 at 4°C); solution 2 (in mM): 120 KCl, 
5 ATP, 2 MgCl2, 20 TES (pH 6.8 at 4°C); solution 3 (in mM): 120 KCl, 5 ATP, 10 
MgCl2, 20 TES (pH 6.8 at 4°C); solution 4 (in mM): 140 NaCl, 5 KCl, 10 MgCl2, 5.6 
glucose, 2 MOPS (pH 7.1 at 22°C). 
 
 
3.8.2. Procedure 
 
Freshly isolated and cleaned arteries were placed into the following solutions: 
solution 1 for 20 minutes at 4°C, solution 2 containing expression vector (10 µg/ml) for 
90 minutes at 4°C, solution 3 containing expression vector (10 µg/ml) for 30 minutes at 
4°C, and solution 4 containing expression vector (10 µg/ml) for 30 minutes at room 
temperature.  Ca2+ concentration in solution 4 was then increased incrementally to (in 
mM): 0.01, 0.1 and 1.8 at 15-minute intervals.  Arteries were then placed in DMEM/F-12 
culture medium supplemented with penicillin/streptomycin (1%) and placed in a 74% 
N2/21% O2/5% CO2 incubator at 37°C for 4 days prior to use.  Fig. 3-1 illustrates HyPer-
CYTO expression in smooth muscle cells of intact arteries. 
 
 
3.8.3. Principle 
 
The mechanism of reversible permeabilization has been suggested to involve 
binding of ATP4- to cell surface receptors and the removal of membrane-associated 
divalent cations when the arteries are in solutions 1, 2, and 3 (Lesh et al., 1995).  The 
resulting increase in membrane permeability is responsible for the delivery of the 
expression vectors into the smooth muscle cells.  The increase in membrane permeability 
is reversed in solution 4 by removal of extracellular ATP and addition of high [Mg2+] 
followed by graded restoration of the physiological concentrations of extracellular Ca2+.  
Arteries are then placed in DMEM/F-12 culture medium supplemented with 
penicillin/streptomycin (1%) for 4 days to allow expression of the genes of interest.  
Culture of arteries in serum-supplemented DMEM has been suggested to change the 
phenotype of smooth muscle cell from a contractile to an invasive proliferative one 
(Absher et al., 1989; Campbell et al., 1989; Eguchi et al., 1994).  To prevent the 
phenotypic change of smooth muscle cells, the arteries are incubated in serum-free 
DMEM.  Studies suggest that reverse permeabilization does not alter the ultrastructural 
features and contractile properties of smooth muscle cells (Lesh et al., 1995). 
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Figure 3-1. Reverse permeabilization of HyPer-CYTO in smooth muscle cells of 
intact arteries 
 
Notes:  Images comparing fluorescence in smooth muscle cells of intact arteries reverse 
permeabilized with either no vector or vectors encoding HyPer-CYTO.  Rectangular 
glass cannula inserted intralumenally to provide a flat surface for imaging can be seen 
within each artery.  Scale bar=20 µm. 
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3.9. Confocal Imaging of Genetically-Encoded Fluorescent Indicators 
 
 
3.9.1. Introduction of indicators into arterial smooth muscle cells 
 
pMITO-2mt8CG2, pShuttle-CMV, or pHyPer-Cyto vectors were inserted into 
smooth muscle cells of intact cerebral arteries using reverse permeabilization to express 
2mt8CG2, mt-cpYFP, or HyPer-CYTO, respectively.  Following incubation for 4 days in  
serum-free DMEM, cerebral artery segments were cannulated on borosilicate rectangular 
tubing for confocal imaging.   
 
 
3.9.2. Imaging protocol 
 
Cannulated artery segment was placed in a No. 0 glass coverslip bottom petri dish 
(MatTek Corporation, Ashland, MA).  2mt8CG2, mt-cpYFP, or HyPer-CYTO were 
excited with 488 nm light and emitted light >510 nm captured using a Zeiss LSM5 Pascal 
laser-scanning confocal microscope.  In experiments where indicated, fluorescence was 
measured in smooth muscle cells of intact arteries.  2mt8CG2 fluorescence was measured 
using a z-resolution of ~4.5 µm, and mt-cpYFP and HyPer-CYTO fluorescence were 
measured using a z-resolution of ~2.5 µm.  Adjusting the z-plane, the field for image 
acquisition was chosen in a region containing exclusively of smooth muscle cells.  Laser 
intensity was kept at a minimum while choosing the field to prevent laser-induced 
bleaching of the indicator fluorescence.  Once the imaging field was chosen, the laser 
intensity was restored to original values.  At the end of each experiment, smooth muscle 
cell viability was confirmed by application of CCCP, which uncouples the ETC and 
disrupts ψm, leading to decrease in 2mt8CG2 and mt-cpYFP fluorescence.  For 
experiments performed using HyPer-CYTO, cell viability at the end of each experiment 
was confirmed by an elevation in fluorescence to H2O2 application. 
 
 
3.9.3. Analysis of confocal images 
 
Mean intensity of smooth muscle cells in the imaging field was used as a measure 
of fluorescence.  Cerebral arteries reverse permeabilized with no vector were used as 
controls.  Background (autofluorescence) was measured from smooth muscle cells in 
these arteries with the same imaging parameters (laser intensity, detector gain, and z-
resolution) used to image smooth muscle cells of intact arteries expressing 2mt8CG2, mt-
cpYFP, or HyPer-CYTO.  Autofluorescence was then subtracted from all fluorescence 
measurements obtained from arteries expressing the fluorescent indicators.  Following 
autofluorescence subtraction, changes in indicator fluorescence induced by 
pharmacological agents were calculated as a % of the initial pre-exposure fluorescence.  
Time control measurements were also obtained in arteries expressing the fluorescent 
indicators.  Percentage changes in 2mt8CG2, mt-cpYFP, or HyPer-CYTO were corrected 
for indicator bleaching using time control measurements. 
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3.10. Localization of Mitochondria-Targeted Indicators 
 
 
3.10.1. Loading smooth muscle cells with MitoTracker 
 
To confirm targeting of 2mt8CG2 and mt-cpYFP to the mitochondria, 
colocalization experiments were performed with MitoTracker Orange CMTMRos 
(Molecular Probes, Invitrogen, Eugene, OR), an organic mitochondria-selective dye.  
MitoTracker Orange CMTMRos is a cell permeant dye which upon entering the cells is 
sequestered to the mitochondria because of its mildly thiol-reactive chloromethyl moiety 
(Poot et al., 1996) (Molecular Probes, Invitrogen, Eugene, OR).  Smooth muscle cells 
expressing 2mt8CG2 or mt-cpYFP were isolated from intact arteries.  Dissociated smooth 
muscle cells were allowed to adhere to glass coverslips for 15 minutes and then incubated 
with prewarmed (37°C) DMEM/F-12 culture medium supplemented with 
penicillin/streptomycin (1%) containing MitoTracker Orange CMTMRos (100 nM) for 
30 minutes at 37°C in a 74% N2/21% O2/5% CO2 incubator.  Following wash with 
DMEM/F-12 culture medium for 10 minutes at 37°C, cells were fixed with 4% 
paraformaldehyde in phosphate-buffered saline (PBS) for 15 minutes at room 
temperature and imaged using a Zeiss LSM5 Pascal laser-scanning confocal microscope. 
 
 
3.10.2. Imaging protocol 
 
MitoTracker and 2mt8CG2 or mt-cpYFP were imaged using an interleaved image 
acquisition protocol.  Interleaved image acquisition requires sequential collection of 
fluorescence images from the same field for one channel followed immediately for 
another channel.  MitoTracker was excited with 545 nm light and emitted light >560 nm 
was captured.  2mt8CG2 or mt-cpYFP was excited with 488 nm light and emitted light 
505-530 nm captured.  Bandpass emission filter of 505-530 nm collects fluorescence 
emitted within that range, and a long pass emission filter of >510 nm collects all 
fluorescence emitted above 510 nm.  Bandpass emission filter of 505-530 nm was used to 
collect 2mt8CG2 or mt-cpYFP fluorescence to prevent bleedthrough of MitoTracker 
fluorescence (which emits at wavelength >560 nm) into 2mt8CG2 or mt-cpYFP 
emission.  Isolated smooth muscle cells were imaged using a z-resolution of ~1 µm to 
visualize organelle distribution in the cytosol.  
 
 
3.10.3. Analysis of confocal images 
 
Data was analyzed using the Zeiss LSM5 Pascal colocalization module, which 
permits interactive analysis of fluorescence from two channels of an image.  In a smooth 
muscle cell, colocalization would occur when fluorescence of 2mt8CG2 or mt-cpYFP, 
and MitoTracker, a mitochondria-selective indicator are present in the same pixel.  
Therefore, weighted colocalization between 2mt8CG2 or mt-cpYFP and MitoTracker 
was used to quantify mitochondrial targeting of the fluorescent indicator.  Weighted 
colocalization is determined as the sum of intensities of colocalizing pixels in 2mt8CG2 
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or mt-cpYFP channel compared to sum of intensities of all 2mt8CG2 or mt-cpYFP pixels 
above threshold (background).  The values for weighted colocalization range from 0 to 
100%, where 0 indicates no colocalization, and 100 indicates colocalization of all pixels.  
Threshold value was taken from a region in the imaging field where no cells are present. 
 
 
3.11. Imaging 2mt8CG2 in HEK293 Cells  
 
 
3.11.1. Transfection of HEK293 cells with 2mt8CG2 
 
Human Embryonic Kidney 293 (HEK293) cells (ATCC, Manassas, VA) were 
maintained in DMEM culture medium supplemented with 10% fetal bovine serum (FBS) 
(Cellgro, Manassas, VA) and penicillin-streptomycin (1%) under standard tissue culture 
conditions (74% N2/21% O2/5% CO2; 37°C).  HEK293 cells were grown on sterile glass 
coverslips placed in 35 mm petri dishes to achieve 20-50% confluency and transfected 
using the Ca2+ phosphate method.  Briefly, a reaction mixture containing 0.5 µg of 
pMITO-2mt8CG2 and 0.125 M CaCl2 in N,N-bis(2-hydroxyethyl)-2-
aminoethanesulfonic acid (BES)-buffered solution was added dropwise to HEK293 cells 
and placed at 37°C for 16 to 18 hours in a 74% N2/21% O2/5% CO2 incubator.  
Following aspiration of media, cells were washed with sterile PBS and incubated in 
DMEM for 24 hours at 37°C in a 74% N2/21% O2/5% CO2 incubator.   
 
 
3.11.2. Imaging protocol 
 
2mt8CG2 was excited with 488 nm light and emitted light >510 nm captured 
using a Zeiss LSM5 Pascal laser-scanning confocal microscope using a z-resolution of  
~1 µm. 
 
 
3.12. Tetramethylrhodamine, Methyl Ester Imaging for ψm Measurements 
 
 
3.12.1. Principle 
 
ψm was studied using tetramethylrhodamine, methyl ester (TMRM) (Molecular 
Probes, Invitrogen, Eugene, OR), a membrane-permeant fluorescent potentiometric 
indicator (Scaduto, Jr. & Grotyohann, 1999; Cheranov & Jaggar, 2004; Xi et al., 2005).  
Following cell permeation, TMRM is cleaved by intracellular esterases to yield a cationic 
fluorescent probe.  The mitochondrial matrix is negatively charged compared to the 
cytosol, thus enabling the uptake of the cationic TMRM into the mitochondrial matrix 
(Scaduto, Jr. & Grotyohann, 1999).  Mitochondrial depolarization makes the 
mitochondria more positively charged, thereby leading to extrusion of TMRM from the 
mitochondria into the cytosol, and eventually from the cell, leading to a decrease in 
TMRM fluorescence. 
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3.12.2. Procedure 
 
A small volume (100 µl) of Ca2+-free solution containing freshly isolated arterial 
smooth muscle cells was placed on a No. 0 glass coverslip bottom petri dish.  Cells were 
allowed to adhere to the coverslip for 15 minutes.  Cells were subsequently incubated in 
HEPES-buffered PSS containing TMRM (100 nM) for 20 minutes, followed by a 15-
minute wash in HEPES-buffered PSS.  Solutions were perfused through the petri dish at 
room temperature.  Perfusing solutions containing TMRM (1 nM) in addition to the 
stimulus were used to maintain a steady extracellular TMRM concentration.  This was 
found to facilitate TMRM reuptake into the mitochondria when the depolarizing stimulus 
was washed off and when ψm returned to its resting negative value.  At the end of each 
experiment, cell viability was confirmed by application of CCCP, which uncouples the 
ETC and disrupts ψm, leading to a decrease in TMRM fluorescence. 
 
 
3.12.3. Imaging 
 
In a region, every TMRM-loaded smooth muscle cell was chosen as a separate 
zone and fluorescence from every zone was collected.  To measure temporal changes in 
TMRM intensity, smooth muscle cells were excited with 535 nm light, and background 
corrected fluorescence collected every 1 second at 610 nm using a Dage MTI iCCD 
camera and Ionwizard software (Ionoptix, Milton, MA).  Background fluorescence was 
collected from a zone where no smooth muscle cells were present. 
 
 
3.12.4. Analysis 
 
Background-corrected TMRM fluorescence measurements for 2 minutes prior to 
addition of a stimulus were averaged to obtain the control fluorescence.  TMRM 
fluorescence changes in response to stimuli were normalized to the pre-exposure control 
fluorescence. 
 
 
3.13. Dichlorofluorescein Imaging for ROS Measurements 
 
 
3.13.1. Principle 
 
ROS measurements in isolated intact cerebral artery segments (1–2 mm) were 
performed using CM-H2DCFDA (Molecular Probes, Invitrogen, Eugene, OR), a cell-
permeant ROS indicator.  CM-H2DCFDA , which is an acetylated form of 2′,7′-
dichlorofluorescein (DCF) is hydrolyzed by intracellular esterases to remove the acetate 
groups yielding the nonfluorescent derivative dichlorodihydrofluorescein (H2DCF) 
(Jakubowski & Bartosz, 2000).  ROS oxidize the nonfluorescent H2DCF to fluorescent 
DCF (Jakubowski & Bartosz, 2000; Cheranov & Jaggar, 2006).  Amount of DCF 
fluorescence is proportional to the amount of ROS present.  DCF fluorescence changes 
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can therefore be used to measure changes in ROS levels in arterial smooth muscle cells.  
The thiol-reactive chloromethyl group forms covalent bonds with intracellular 
components, permitting retention within the cell (Jakubowski & Bartosz, 2000). 
 
 
3.13.2. Procedure 
 
Cerebral artery segments were cannulated on borosilicate rectangular tubing and 
incubated for 60 minutes at room temperature in HEPES-buffered PSS containing CM-
H2DCFDA (10 µM).  The DCF-loaded arteries were washed with HEPES-buffered PSS 
for 15 minutes at room temperature.  Following wash, the cannulated arteries were placed 
on a No. 0 glass coverslip bottom petri dish and imaged using a confocal microscope. 
 
 
3.13.3. Imaging 
 
DCF was excited with 488 nm light, and emitted light >510 nm was collected 
using a Zeiss LSM5 Pascal laser-scanning confocal microscope using a z-resolution of 
~4.5 µm.  Because the dye is susceptible to photo-oxidation, DCF fluorescence can 
increase spontaneously upon exposure to excitation light (Afzal et al., 2003; Cheranov & 
Jaggar, 2006).  To reduce the laser-induced photo-oxidation, each arterial region was 
scanned only once, and the laser intensity was set to minimize excitation. 
 
 
3.13.4. Analysis 
 
Mean intensity of DCF fluorescence from smooth muscle cells in the imaging 
field was subtracted from background (autofluorescence) to obtain the corrected 
fluorescence in a field.  Autofluorescence was measured in control arteries that were not 
loaded with DCF but underwent the same imaging protocol (laser intensity, detector gain, 
and z-resolution).  Following autofluorescence subtraction, changes in DCF fluorescence 
induced by pharmacological agents were calculated as a % of the initial pre-exposure 
fluorescence.  % changes in DCF fluorescence were then corrected for time-dependent 
photo-oxidation-induced elevation in DCF fluorescence.  Time control measurements 
were obtained in smooth muscle cells of intact DCF-loaded arteries that underwent the 
same imaging protocol, but were not exposed to stimuli. 
 
 
3.14. NAD(P)H Oxidase Inhibitors 
 
gp91phox docking sequence represents the binding site of p47phox subunit of 
NAD(P)H oxidase (Rey et al., 2001).  p47phox translocation to the smooth muscle cell 
membrane and anchoring with gp91phox is required for NAD(P)H oxidase activation (Rey 
et al., 2001).  Therefore, to prevent association of NAD(P)H oxidase subunits and 
activation of NAD(P)H oxidase, peptides were used. 
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gp91ds-tat peptide contains the gp91phox docking sequence (NH2-LQRRIRTSC-
COOH) (Rey et al., 2001) conjugated to the N-terminus of a specific amino acid peptide 
(NH2-RRRQRRKKR-COOH) of HIV viral coats (HIV-tat), which is known to be 
internalized by all cells (Fawell et al., 1994).  gp91scrm-tat contains a scrambled gp91 
peptide (NH2-RSQRTIRLC-COOH) conjugated to N-terminus of HIV-tat (Rey et al., 
2001).  gp91ds-tat and gp91scrm-tat peptides were synthesized by Tufts University Core 
Facility (Boston, MA).   
 
 
3.15. NF-κB Immunofluorescence 
 
 
3.15.1. Principle 
 
NF-κB immunofluorescence was performed to study NF-κB p50 localization in 
the smooth muscle cells of intact arteries.  Following treatment, arteries were incubated 
with anti-p50 antibody and the corresponding fluorophore-conjugated secondary 
antibody.  Nucleus was labeled using a dimeric cyanine nucleic acid stain.  Upon nuclear 
translocation of p50, colocalization of fluorophore (attached to the secondary antibody) 
and nucleic acid stain was anticipated. 
 
 
3.15.2. Procedure 
 
Intact arteries were exposed to pharmacological agents in DMEM/F-12 culture 
medium supplemented with penicillin/streptomycin (1%) and incubated in a 74% N2/21% 
O2/5% CO2 incubator at 37ºC.  Following treatment, arteries were fixed with 4% 
paraformaldehyde in PBS for 1 hour at room temperature, and washed three times for 5 
minutes each with PBS.  Permeabilization of cell membrane to facilitate passage of 
antibodies into cells to bind the protein(s) of interest was done using 0.5% TritonX-100 
dissolved in PBS for 15 minutes at room temperature.  After three washes with PBS, 
arteries were incubated in 5% BSA in PBS for 1 hour at room temperature.  Arteries were 
then incubated with mouse monoclonal anti-NF-κB p50 antibody (1:100 dilution; Santa 
Cruz Biotechnology Inc., Santa Cruz, CA) overnight at 4°C.  The epitope recognized by 
the anti-NF-κB p50 antibody is located in the N-terminus (amino acids 120-239) of NF-
κB p50 of human origin.  After five washes with PBS at room temperature, arteries were 
incubated with Cy3-conjugated goat anti-mouse IgG (1:100 dilution; Jackson 
ImmunoResearch, West Grove, PA) for 1 hour at 37°C.  After ten washes with PBS at 
room temperature, YOYO-1 iodide (1:10,000 dilution; Molecular Probes, Invitrogen, 
Eugene, OR), a fluorescent nucleic acid indicator and Ribonuclease A (RNase A) (250 
µg/ml; Sigma-Aldrich, St.Louis, MO) were added for 30 minutes at 37ºC to counterstain 
smooth muscle cell nuclei.  RNase A was added to destroy cellular RNA and thereby 
prevent YOYO-1 binding to RNA.  A borosilicate rectangular tubing was then placed in 
the lumen of each fixed artery to provide a flat surface for imaging.  The artery was then 
mounted on a glass slide and used for imaging. 
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3.15.3. Imaging 
 
NF-κB localization in smooth muscle cells of intact arteries was examined using a 
Zeiss LSM 5 Pascal laser-scanning confocal microscope using a z-resolution of ~0.8 µm.  
Cy3 was excited with 545 nm light, and emitted light >560 nm was collected.  YOYO-1 
was excited with 488 nm light, and emitted light 505-530 nm was collected.  YOYO-1 
fluorescence was collected using bandpass emission filter (505-530 nm) instead of long 
pass emission filter (>510 nm) to prevent collection of Cy3 fluorescence into the YOYO-
1 channel. 
 
 
3.15.4. Analysis 
 
Data was analyzed using the Zeiss LSM5 Pascal colocalization module.  
Colocalization of p50 and YOYO-1 was determined using weighted colocalization, as 
previously described in section 3.10.3.  Weighted colocalization of p50 pixels with 
YOYO-1 pixels in the field was used to quantify p50 nuclear translocation.  Threshold 
value for each channel was taken from a region in the imaging field outside the artery. 
 
 
3.16. NF-κB-Dependent Luciferase Reporter Gene Activity 
 
 
3.16.1. Vectors encoding luciferase 
 
NF-κB-p-Luc vector contains a luciferase reporter gene under the control of an 
NF-κB promoter (κB sites in the promoter region of the immunoglobulin gene).  Three 
κB sites in the promoter regions are as follows: GGAAATTCCCC (-63 to -53), 
AGGACTTTCC (-225 to -216), and GGGAAACCCC (-319 to -310) (Le Bail et al., 
1993; Arsura et al., 2003; Kaur et al., 2005).  pGL3 Basic control vector (Promega 
Corporation, Madison, WI) which contains the luciferase reporter gene but no promoter 
was used as a control.   
 
 
3.16.2. Principle 
 
NF-κB-dependent transcriptional activity was studied using NF-κB-dependent 
luciferase reporter gene assay.  NF-κB binds to promoter of NF-κB-p-Luc, leading to 
transcription of luciferase reporter gene, resulting in luciferase protein expression and 
fluorescence.  Stimuli which activate NF-κB increase the number of NF-κB proteins 
binding to the κB sites in the promoter.  Transcription of luciferase reporter gene is 
elevated, leading to an increase in luciferase protein expression and fluorescence.  
Therefore, fluorescence obtained from NF-κB-p-Luc is proportional to NF-κB activity. 
 
pGL3 Basic vector contains a luciferase reporter gene but no promoter.  Changes 
in NF-κB activity would therefore not alter the luciferase expression and fluorescence. 
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3.16.3. Procedure 
 
NF-κB-p-Luc or pGL3 Basic vectors were inserted into smooth muscle cells of 
intact arteries using reverse permeabilization.  The arteries were then placed for 3 days at 
37ºC in DMEM/F-12 culture medium supplemented with penicillin/streptomycin (1%) in 
a 74% N2/21% O2/5% CO2 incubator. After 3 days, the arteries were exposed to stimuli 
for an additional 24 hours at 37ºC.  Arterial protein lysates were then isolated and 
quantified (described in detail in section 3.19).  Luciferase activity was determined using 
the Luciferase Assay System (Promega Corporation, Madison, WI).   
 
 
3.16.4. Measuring luciferase activity 
 
Protein lysate (50 µg) was added to Luciferase Assay Reagent (100 µl) and 
luciferase luminescence was measured using a TD-20/20 luminometer (Turner Designs, 
Sunnyvale, CA).  As suggested by the vendor (Promega), the luminometer was 
programmed to perform a 2-second measurement delay followed by a 10-second 
measurement read for luciferase activity.  Luminescence measurements were corrected 
for background luciferase luminescence, which was recorded from lysates of arteries that 
underwent the same reverse permeabilization, culture, and luminescence measurement 
protocol, but were not exposed to NF-κB-p-Luc or pGL3 Basic vectors during the reverse 
permeabilization procedure.  
 
 
3.17. Real-Time PCR 
 
 
3.17.1. RNA isolation  
 
Intact cerebral arteries were either untreated or treated with ET-1 (10 nM) in 
DMEM/F-12 culture medium supplemented with penicillin/streptomycin (1%) in a 74% 
N2/21% O2/5% CO2 incubator for 6 hours at 37ºC.  Following treatment, Trizol 
(Invitrogen, Eugene, OR) was added to arteries, homogenized, and incubated for 5 
minutes at room temperature to completely dissociate cellular nucleoprotein complexes.  
Chloroform was added and centrifuged at 12000  g for 15 minutes at 4°C to separate the 
samples into a DNA-containing phenol, a DNA/protein-containing interphase, and an 
RNA-containing aqueous phase.  RNA in the aqueous phase was precipitated by adding 
isopropyl alcohol and centrifuged at 12000  g for 10 minutes at 4°C.  RNA precipitate 
which forms a gel-like pellet at the bottom of the tube was washed with 75% ethanol and 
reconstituted in RNase-free water. 
 
 
3.17.2. Quantification of RNA 
 
RNA concentration was quantified measuring the absorbance of UV light at 230 
nm (A230), 260 nm (A260), and 280 nm (A280 nm) using a UV spectrophotometer.  
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RNA concentration was calculated from the equation: 
 
RNA concentration (µg/ml) = (A260 – A230) × dilution factor × 40 µg/ml 
 
Nucleic acid purity was estimated from A260/A280 and A260/A230 ratios.  
Ratios between 1.8 and 2.0 generally represent high-quality nucleic acid sample. 
 
 
3.17.3. Reverse transcription 
 
RNA (~250 ng) from arteries for each condition was used in reverse transcription 
to obtain cDNA.  The remaining RNA from each condition was used as template in 
negative control reactions for RT-PCR.  cDNA was reverse transcribed from RNA using 
AffinityScript Multiple Temperature Reverse Transcriptase (Stratagene, Cedar Creek, 
TX).  Briefly, RNA, random primers, and RNase-free water were added to a nuclease-
free centrifuge tube and incubated at 65°C for 5 minutes.  The mixture was slowly cooled 
to room temperature for 10 minutes, to allow annealing of primers to RNA.  DTT (100 
mM), dNTP (100 mM), buffer, and reverse transcriptase were added and the reaction 
incubated at 50°C for 1 hour.  The reaction was stopped by heat inactivating the enzymes 
at 70°C for 15 minutes.  Following reverse transcription, cDNA was used as template for 
RT-PCR. 
 
 
3.17.4. Principle 
 
TaqMan probes are designed to anneal to the DNA region which is amplified by a 
pair of primers.  Probes consist of a fluorophore which is in close proximity to a 
quencher, which inhibits fluorescence from the fluorophore (Holland et al., 1991).  Using 
the DNA template, Taq DNA polymerase synthesizes the nascent strand from the 3’ end 
of the primer.  TaqMan probe that is annealed to the DNA is degraded by the 5' to 3' 
exonuclease activity of the polymerase.  Degradation of the probe releases the 
fluorophore from it, thereby preventing it from being in close proximity to the quencher, 
resulting in elevation of fluorescence.  Presence of more DNA templates causes probe 
binding to more DNA, leading to elevated fluorescence.  Therefore, fluorescence detected 
is directly proportional to the amount of DNA template present in the PCR.  Since the 
DNA template used is reverse-transcribed from mRNA, the fluorescence detected is an 
indication of the cellular mRNA levels and hence, is used to quantify changes in gene 
expression.  
 
 
3.17.5. Primers and probes 
 
RT-PCR assays, hydrolysis probes, and gene specific primers that span long 
introns were designed to distinguish cDNA from genomic DNA using primer design 
online software Universal Probe Library available at 
http://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp.  Primers were ordered 
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from Integrated DNA Techonologies (Coralville, IA).  Hydrolysis probes were ordered 
from Molecular Resource Center, University of Tennessee Health Science Center 
(Memphis, TN).  Primers and probes used for RT-PCR are listed in Table 3-1.  Melting 
temperature of all the primers was between 59 and 60°C.  
 
 
3.17.6. PCR conditions 
 
Quantitative TaqMan PCR reactions were performed using an LC480 light cycler 
(Roche Applied Science, Indianapolis, IN).  Each PCR mixture (10 µl) contained 5 µl of 
Taqman LC480 Master Mix, 0.1 µl of forward primer, 0.1 µl of reverse primer, 0.1 µl of 
hydrolysis probe, 2.7 µl of RNase-free water, and 2 µl of cDNA or mRNA template.  
Reaction was activated at 95ºC for 5 minutes.  Following activation, amplification was  
performed with 40 cycles of denaturation for 10 seconds at 95ºC, and annealing of 
primers for 30 seconds at 60ºC, and 1 cycle of extension for 10 seconds at 72ºC.  
Reaction was cooled to 40°C for 5 minutes.  A negative control using RNA instead of 
cDNA was carried out in each experiment.  Standard curves using four 10-fold dilution 
steps of cDNA samples were run for all probe and primer pairs to determine PCR 
efficiency.  PCR efficiency, determined by the slope of standard curves for all primer and 
probe pairs were between ~1.7 and 2.3. 
 
 
3.17.7. Analysis 
 
CaV1.2 mRNA expression under each condition was calculated from the 
difference between CT values (ΔCT) of CaV1.2 and ribosomal protein subunit 5 (Rps5), 
reference gene.  ΔΔCT was calculated from the difference between the ΔCT values for 
control and ET-1 treatment.  ET-1-induced elevation in CaV1.2 mRNA levels was 
calculated using the formula 100  (2-ΔΔCT) (Livak & Schmittgen, 2001).  All PCR 
reactions including standard curves were performed in triplicate. 
 
 
3.18. Agarose Gel Electrophoresis 
 
 Products of RT-PCR were mixed with Green GoTaq Flexi Buffer (Promega 
Corporation, Madison, WI) and separated by electrophoresis using 2% agarose gel 
containing 0.01% ethidium bromide.  Images of fluorescence from ethidium bromide 
bound to DNA within the gel were collected using the Kodak In-Vivo Imaging System 
(Carestream Health Inc., Woodbridge, CT) and the Kodak Molecular Imaging Software 
v4.5.1 (Carestream Health Inc., Woodbridge, CT). 
 
 
3.19. Protein Quantification and Estimation 
 
Cerebral arteries were homogenized in Laemmli sample buffer (2.5% SDS, 10% 
glycerol, 0.01% bromophenol blue, 5% β-mercaptoethanol, and 100 mM Tris-HCl, pH 
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Table 3-1. Primers and probes used in RT-PCR 
 
 
Gene 
(Accession number) 
 
Forward primer (5’sequence3’) 
(Position) 
Reverse primer (5’sequence3’)  
(Position) 
Hydrolysis probe
(Position) 
 
CaV1.2 
(DQ538522.1) 
 
GAGAGCTTTCCGTGTGCTTC 
(727-746) 
 
GTTCAGGACCACCTGGAGAC 
(777-796) 
 
CTGGAGTC 
(765-772) 
    
Rps5 
(NM_001105722.1) 
GACTGAGAAGCCCGGTTTG 
(70-88) 
CTTGATGTCCGGGGTCTCT 
(134-152) 
CAGCCACA 
(115-122) 
    
HGPRT 
(ENSRNOT00000045153.2) 
TCAACGGGGGACATAAAAGT 
(394-413) 
AGTGTCAATTATATCCAAACCCAAT 
(462-486) 
TGGTGGAG 
(417-424) 
    
Cyclophilin B 
(ENSRNOT00000022828.4) 
ACGTGGTTTTCGGCAAAGT 
(524-542) 
CTTGGTGTTCTCCACCTTCC 
(566-585) 
TGGAAGGC 
(545-552) 
    
β tubulin 
(ENSRNOT00000023452.4) 
CAGAGCCATTCTGGTGGAC 
(239-257) 
GCCAGCACCACTCTGACC 
(333-350) 
GAGCCTGG 
(261-268) 
    
β actin 
(ENSRNOT00000042459.1) 
 
CCCGCGAGTACAACCTTCT 
(17-35) 
CGTCATCCATGGCGAACT 
(71-88) 
CAGCTCCT 
(38-45) 
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6.8).  Tissue debris and nuclear fragments were removed by centrifugation at 6000  g 
for 10 minutes at 4°C.  The whole cell lysate, obtained as a supernatant was transferred to 
a fresh tube and used for protein quantification and Western blotting.  A 5 µl aliquot of 
supernatant was placed on a nitrocellulose membrane, and following amido black 
staining, protein concentration was measured by spectrophotometric quantification at 630 
nm. 
 
 
3.20. Western Blotting 
 
Protein extracts were heated for 3 minutes at 100°C.  Proteins (30 µg per lane) 
were separated by size on 7.5% SDS-PAGE Tris-glycine gels.  Prestained molecular 
weight markers (Bio-Rad, Hercules, CA) were used to monitor progress on the gel.  Gel 
was run in MOPS-SDS Running Buffer (containing SDS and Tris-Glycine) at 200 V until 
the 37 kDa marker reached the bottom of the gel.  Following this, the gel was placed onto 
a PVDF membrane treated with methanol and placed between two sheets of filter paper 
between two sponges, all soaked in Transfer Buffer (Tris base, glycine, and methanol), 
into a binding cassette.  Proteins were transferred for 2 hours at 100 V using a Mini Trans 
Blot Cell (Bio-Rad, Hercules, CA).  The apparatus was placed on ice to manage heat 
exchange during the transfer.  
 
Membranes were blocked in 5% nonfat dry milk in Tris-buffered solution (TBS) 
with 0.1% Tween-20 (TBS-T) for 1 hour at room temperature.  Membranes were then 
incubated with rabbit monoclonal anti-p105/p50 antibody (1:1000 dilution; Abcam Inc., 
Cambridge, MA), mouse monoclonal anti-CaV1.2 antibody (1:200 dilution; UC 
Davis/NINDS/NIMH NeuroMab Facility), or mouse monoclonal anti-actin antibody 
(1:50,000 dilution; Millipore, Billerica, MA) overnight at 4ºC in TBS-T and 5% nonfat 
dry milk.  Anti-CaV1.2 antibody was produced against intracellular C-terminus (amino 
acids 1507-1733) of rabbit CaV1.2.  Epitope recognized by the anti-actin antibody is 
located in the N-terminus (amino acids 50-70) of actin.  Following overnight incubation 
with primary antibodies, membranes were washed three times with TBS-T for 5 minutes 
each, and incubated for 1-2 hours at room temperature with HRP-conjugated secondary 
antibody in TBS-T and 5% nonfat dry milk.  Membranes were then washed three times 
with TBS-T for 5 minutes each, and incubated with enhanced chemiluminiscence 
substrate (Amersham, Arlington heights, IL) for the HRP enzyme conjugated in the 
secondary antibody. 
 
HRP-induced chemiluminescence from bound secondary antibodies was detected 
using a Kodak In-Vivo Imaging System and visualized using the Kodak Molecular 
Imaging Software v4.5.1.  Membranes were developed multiple times using different 
exposure times, to optimize band intensity for densitometric analysis. 
 
The PVDF membranes can be reprobed for other proteins after probing them for 
one.  To achieve this, the membrane was stripped using a Stripping Buffer (Thermo 
Scientific, Rockford, IL) for 15 minutes at room temperature, washed with TBS-T, 
reblocked, and reprobed as explained above. 
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3.21. Densitometric Analysis of Western Blots 
 
Band intensity was quantified using digital densitometry using Quantity One 
software v4.6.9 (Bio-Rad, Hercules, CA).  Briefly, background-subtracted band density 
was calculated by placing rectangular boxes of the same size around bands in each lane.  
Average band density was calculated from all images of the same blot acquired using 
different exposure times.  Averaged band density for a protein was then normalized to the 
band density of actin for the corresponding sample.  Actin was used to normalize data 
because pharmacological treatments used in this study did not alter its expression. 
 
 
3.22. NF-κB p105 Knockdown 
 
 
3.22.1. Principle 
 
siRNA are long double-stranded RNA molecules that have a characteristic two 
nucleotide 3' overhang that allows them to be recognized by the enzymatic machinery of 
RNA interference.  siRNA are separated into single strands which homology-dependently 
bind to target mRNA.  siRNA-mRNA complex is eventually destroyed by the RNA-
induced silencing complex, leading to target mRNA degradation.  siRNA-mediated 
reduction in mRNA levels translate to a decrease in target protein levels. 
 
 
3.22.2. Procedure 
 
Two siRNAs directed against NF-κB p105 subunit (p105siRNA1 and 
p105siRNA2) (10 µg/ml each) (Qiagen, Valencia, CA) were used to inhibit p105 
expression.  p105siRNA1 and p105siRNA2 were directed against target sequences in 
regions 458-478 and 939-959, respectively of p105 sequence (XM_001075876).  
Scrambled siRNA (p105scrm) (20 µg/ml) (Qiagen, Valencia, CA) was used as a control.  
siRNAs were introduced into smooth muscle cells of intact cerebral arteries using reverse 
permeabilization (Lesh et al., 1995; Welsh et al., 2002).  After 3 days in DMEM/F-12 
culture medium supplemented with penicillin/streptomycin (1%) in a 74% N2/21% 
O2/5% CO2 incubator at 37ºC, arteries were exposed to stimuli for an additional 24 hours 
at 37°C.  Artery segments were then either used for pressurized artery diameter 
measurements or protein lysates were isolated, quantified, and used for Western blotting. 
 
 
3.23. Pressurized Artery Diameter Measurements 
 
 
3.23.1. Procedure 
 
Experiments were performed using PSS containing (in mM): 112 NaCl, 4.8 KCl, 
26 NaHCO3, 1.8 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, and 10 glucose (with pH adjusted to 
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7.4 with NaOH).  Prior to use, PSS was oxygenated by bubbling with 74% N2/21% 
O2/5% CO2.  Endothelium-denuded artery segments 1–2 mm in length were cannulated at 
each end in a temperature-controlled perfusion chamber (Living Systems 
Instrumentation, Burlington, VT) containing PSS.  Care was taken to cannulate artery 
segments that did not have a branch or tear in their wall.  The chamber containing the 
cannulated artery was placed on the stage of a Nikon TS100-F microscope.  Intravascular 
pressure was altered using a water-filled reservoir and monitored using a pressure 
transducer.  Arterial wall diameter was measured at 1 Hz using a CCD camera attached to 
the Nikon TS100-F microscope and diameter changes measured in real time using the 
automatic edge-detection function of IonWizard software.  Luminal flow was absent 
during experiments.  Vessels were constantly superfused with PSS alone or containing 
pharmacological agent(s). 
 
At the beginning of each experiment, the artery was allowed to equilibrate for 10 
minutes at an intravascular pressure of ~10 mm Hg.  The artery dilated during this 
equilibration process because of its exposure to warm PSS.  After the arterial diameter at 
10 mm Hg became stable for a period of 5 minutes, the intravascular pressure was 
elevated to ~60 mm Hg.  Elevation of intravascular pressure to 60 mm Hg resulted in 
arterial dilation.  The artery was allowed to sense the elevated intravascular pressure and 
develop pressure-induced vasoconstriction (myogenic tone).  Pharmacological stimuli 
were perfused only after myogenic tone remained steady for a period of 15 minutes.  
After perfusion of the stimulus in PSS, stable diameter achieved for a period of 5 minutes 
was considered as active diameter.  After a stimulus was washed off, time was given for 
the arterial diameter to return to its myogenic tone before addition of the next stimulus.  
Arterial diameter after perfusion of Ca2+-free solution containing EGTA (10 mM) and 
nimodipine (1 µM) was considered as passive diameter.  Endothelial denudation was 
confirmed by the lack of response to carbachol (1 µM), an endothelial-dependent 
vasodilator. 
 
 
3.23.2. Analysis 
 
Experimental traces were analyzed using IonWizard software.  Measurements 
were obtained when the diameter remained stable.  Myogenic tone (%) was calculated as 
100  (1-active diameter/passive diameter). 
 
 
3.24. Reagents and Chemicals 
 
XeC and 17-octadecynoic acid (17-ODYA) were purchased from Cayman 
Chemical Company (Ann Arbor, MI).  Manganese (III) tetrakis (1-methyl-4-pyridyl) 
porphyrin (MnTMPyP) was purchased from AG Scientific Inc.(San Diego, CA).  
Apocynin and Ru360 were purchased from EMD Chemicals (Gibbstown, NJ).  
Recombinant rat TNF-α was purchased from BD Pharmingen (BD Biosciences, San Jose, 
CA).  All other reagents and chemicals were purchased either from Sigma-Aldrich 
Company (St.Louis, MO) or Fisher Scientific (Pittsburgh, PA), unless specified.   
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3.25. Statistical Analysis 
 
OriginLab and GraphPad InStat software were used for statistical analyses.  
Values are expressed as mean±SEM.  Student’s t-test with two-tail p value was used for 
comparing paired and unpaired data from two populations.  Ordinary one-way ANOVA 
followed by Student-Newman-Keuls post-hoc test were used for all multiple data 
comparisons.  For ANOVA, the values were assumed to be sampled from a Gaussian 
distribution.  Repeated measures ANOVA could not be performed since all the conditions 
to be compared were not paired and the sample numbers were not identical.  Adjustments 
for multiple comparisons were made when necessary.  P<0.05 was considered 
statistically significant.   
 
Power analysis was carried out where P>0.05 to verify that sample size was 
sufficient to give a power value of >0.8.  Power value, which is directly proportional to 
the sample size, is the probability of correctly rejecting the null hypothesis that there is no 
significant difference between the groups.  The Type I error probability that the null 
hypothesis was falsely rejected was set to 0.05.  Power analysis was performed using PS 
Power and Sample Size Calculations software (Dupont & Plummer, Jr., 1990). 
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CHAPTER 4. RESULTS* 
 
 
4.1. ET-1 Modifies Local and Global Ca2+ Signals in Cerebral Artery Smooth 
Muscle Cells 
 
The regulation of local and global Ca2+ signals by ET-1, a PLC-coupled receptor 
agonist and vasoconstrictor, was studied in smooth muscle cells of endothelium-denuded 
cerebral artery segments using Noran Oz high-speed laser-scanning confocal imaging and 
fluo-4 AM.  ET-1 elevated mean Ca2+ wave frequency from ~0.34 to 1.42 Hz (~135% of 
control), reduced mean Ca2+ spark frequency from ~1.06 to 0.4 Hz (~32% of control), 
and increased mean global [Ca2+]i from ~193 to 253 nM (~127% of control) (Fig. 4-1).  
Pretreatment with XeC, an IP3R inhibitor (Gafni et al., 1997) did not alter ET-1-induced 
Ca2+ spark inhibition but blocked ET-1-induced Ca2+ wave activation (Fig. 4-1D).  In the 
presence of XeC, ET-1 elevated global [Ca2+]i from ~193 to 225 nM (~113% of control) 
(Fig. 4-1D).  Data indicate that ET-1-induced IP3R activation increases Ca2+ wave 
frequency and contributes to global [Ca2+]i elevation but does not regulate ET-1-induced 
Ca2+ spark inhibition.  
 
 
4.2. ET-1-Induced IP3R-Mediated SR Ca2+ Release Elevates [Ca2+]mito in Cerebral 
Artery Smooth Muscle Cells 
 
To study [Ca2+]mito in arterial smooth muscle cells, complex loading procedures 
have previously been used to enhance mitochondrial loading of synthetic, inorganic Ca2+ 
indicators such as Rhod-2 (Monteith & Blaustein, 1999).  Since inorganic Ca2+ indicators 
cannot be targeted to specific subcellular localizations, non-specific measurements of 
[Ca2+]mito were inevitably obtained (Hajnoczky et al., 1995; Monteith & Blaustein, 1999; 
Kaftan et al., 2000; Trollinger et al., 2000; Collins et al., 2001; Gerasimenko & Tepikin, 
2005).  To specifically measure [Ca2+]mito, genetically-encoded, targetable Ca2+ indicators 
have been developed (Griesbeck et al., 2001; Filippin et al., 2005).  Regulation of 
[Ca2+]mito by ET-1-induced Ca2+ signals was measured in smooth muscle cells of intact 
arteries using 2mt8CG2, a genetically-encoded, mitochondria-targeted, fluorescent Ca2+ 
indicator (Griesbeck et al., 2001; Filippin et al., 2005). 
 
 
 
 
 
 
 
 
 
* Portions of this chapter adapted with permission. Narayanan D, Xi Q, Pfeffer LM, & 
Jaggar JH (2010). Mitochondria control functional CaV1.2 expression in smooth muscle 
cells of cerebral arteries. Circ Res 107, 631-641. 
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Figure 4-1. ET-1 regulates local and global Ca2+ signals in arterial smooth muscle 
cells 
 
Notes:  A, Confocal images illustrating average fluo-4 fluorescence in smooth muscle 
cells in the same artery in control and after ET-1 (10 nM).  White boxes illustrate 
locations where Ca2+ sparks occurred during 10 seconds of imaging.  Colored boxes 
illustrate locations from where normalized fluorescence (F/F0) over time traces shown in 
C were obtained.  B, Two representative Ca2+ sparks that occurred at locations labeled in 
A for each condition.  C, F/F0 over time traces illustrate that ET-1 elevates Ca2+ wave 
frequency.  D, Mean data (n=7 for each condition).  Values are expressed as mean±SEM.   
* indicates P<0.05 compared to control.  # indicates P<0.05 compared to ET-1. 
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4.2.1. Mitochondrial localization of 2mt8CG2 
 
 
4.2.1.1. HEK293 cells 
 
2mt8CG2 expression in HeLa cells produces punctuate fluorescence when 
localized to mitochondria (Filippin et al., 2005).  Here, transfection of HEK293 cells with 
the pMITO-2mt8CG2 vector by using Ca2+ phosphate, reproduced the punctuate 
fluorescence pattern when visualized using a Zeiss LSM 5 Pascal laser-scanning confocal 
microscope, suggesting mitochondrial localization of 2mt8CG2 (Fig. 4-2A). 
 
 
4.2.1.2. Cerebral artery smooth muscle cells 
 
pMITO-2mt8CG2 vector was inserted into smooth muscle cells of intact cerebral 
arteries using reverse permeabilization (Lesh et al., 1995; Welsh et al., 2002).  Confocal 
imaging revealed punctate staining in smooth muscle cells, indicating mitochondrial 
localization of 2mt8CG2 (Fig. 4-2B).  To confirm mitochondrial targeting of 2mt8CG2, 
colocalization studies were performed using MitoTracker Orange.  2mt8CG2 
fluorescence exhibited ~95% pixel colocalization with MitoTracker Orange, confirming 
mitochondrial localization (Fig. 4-2C). 
 
 
4.2.2. [Ca2+]mito measurements using 2mt8CG2 
 
In smooth muscle cells of intact arteries, ET-1 increased mean 2mt8CG2 
fluorescence to ~140% of control, and this elevation was blocked by thapsigargin and 
XeC (Fig. 4-3A,B), suggesting that ET-1 elevates [Ca2+]mito due to IP3R-mediated SR 
Ca2+ release.  Thapsigargin was applied 15 minutes prior to ET-1, a time course sufficient 
to deplete SR Ca2+ load (Xi et al., 2008).  Ionomycin, a Ca2+ ionophore (Liu & Hermann, 
1978), elevated mean 2mt8CG2 fluorescence to ~137% of control in smooth muscle cells 
of intact arteries (Fig. 4-3B), consistent with the fluorescence range of this indicator 
(Filippin et al., 2003; Filippin et al., 2005).  Ru360, a MCU blocker (Matlib et al., 1998), 
also blocked the ET-1-induced elevation in 2mt8CG2 fluorescence (Fig. 4-3B), 
indicating that ET-1-induced mitochondrial Ca2+ uptake occurs through the MCU.  
Thapsigargin, XeC, or Ru360 alone did not alter 2mt8CG2 fluorescence (Fig. 4-3B).  
Membrane depolarization (60 mM K+), which elevates global [Ca2+]i, did not alter 
2mt8CG2 fluorescence (Fig. 4-3B), suggesting that [Ca2+]mito elevation occurs due to 
local Ca2+ signals and not due to global [Ca2+]i elevation.  CCCP, a protonophore that 
disrupts ψm by permeabilizing the inner mitochondrial membrane to H+ (Goldsby & 
Heytler, 1963; Heytler, 1963) and abolishes the driving force for mitochondrial Ca2+ 
uptake (McCarron & Muir, 1999), reduced 2mt8CG2 fluorescence to ~63% of control 
(Fig. 4-3B).  Results with Ru360 and CCCP confirm the mitochondrial localization of 
2mt8CG2.  These data indicate that ET-1-induced IP3R-mediated SR Ca2+ release 
elevates [Ca2+]mito in arterial smooth muscle cells. 
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Figure 4-2. Mitochondrial localization of 2mt8CG2 in HEK293 cells and cerebral 
artery smooth muscle cells 
 
Notes:  A, Confocal image illustrates punctate fluorescence of 2mt8CG2 in HEK293 
cells.  B, Confocal image of smooth muscle cells dissociated from arteries reverse 
permeabilized with pMITO-2mt8CG2.  Punctate pattern of fluorescence suggests 
mitochondrial targeting of 2mt8CG2.  C, Colocalization of punctate 2mt8CG2 
fluorescence with MitoTracker Orange in a smooth muscle cell.  Colocalization 
quantified using weighted colocalization was 94.8±0.8% (n=10, p<0.001).  Scale bar=10 
µm. 
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Figure 4-3. ET-1-induced IP3R-mediated SR Ca2+ release elevates [Ca2+]mito in arterial 
smooth muscle cells 
 
Notes:  A, Confocal images of 2mt8CG2 fluorescence in smooth muscle cells in the same 
area of a cerebral artery in control and ET-1.  Scale bar=10 µm.  B, Average changes in 
2mt8CG2 fluorescence for ionomycin (10 µM, n=7), ET-1 (n=8), thapsigargin (100 nM, 
n=5), ET-1+thapsigargin (n=6), XeC (20 µM, n=5), ET-1+XeC (n=6), Ru360 (10 µM, 
n=4), ET-1+Ru360 (n=4), CCCP (10 µM, n=4), and 60 mM K+ (n=6).  ET-1 
concentration was 100 nM in all experiments.  Values are expressed as mean±SEM.   
* indicates P<0.05 compared to control.  # indicates P<0.05 compared to ET-1. 
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4.3. ET-1-Induced IP3R-Mediated SR Ca2+ Release Depolarizes Mitochondria in 
Cerebral Artery Smooth Muscle Cells 
 
Regulation of mitochondria potential ET-1 was studied in isolated smooth muscle 
cells using TMRM.  ET-1 (30 nM) reversibly reduced TMRM fluorescence intensity to 
~67% of control (Fig. 4-4A-C).  A second application of ET-1 (30 nM) produced a 
similar amplitude change in TMRM fluorescence (~69% of control), indicating that the 
first ET-1 application did not desensitize the ET-1 receptors (Fig. 4-4A,B).  ET-1 caused 
concentration-dependent reduction in TMRM fluorescence with an EC50 of 29 nM (Fig. 
4-4B).  Thapsigargin and XeC abolished the ET-1-induced reduction in TMRM 
fluorescence, but did not alter TMRM fluorescence when applied alone (Fig. 4-4C).  
CCCP reduced TMRM fluorescence intensity to ~34% of control, whereas 60 mM K+ did 
not alter TMRM fluorescence (Fig. 4-4C).  These data indicate that ET-1-induced IP3R-
mediated SR Ca2+ release depolarizes mitochondria in arterial smooth muscle cells.  In 
contrast, a global [Ca2+]i elevation does not alter ψm. 
 
 
4.4. ET-1-Induced IP3R-Mediated SR Ca2+ Release and [Ca2+]mito Elevation 
Stimulates MitoROS Generation 
 
 
4.4.1. MitoROS measurements using mt-cpYFP 
 
To examine physiological functions of [Ca2+]mito, we tested the hypothesis that an 
elevation in [Ca2+]mito may alter mitoROS generation.  MitoROS was measured using mt-
cpYFP, a genetically-encoded mitochondria-targeted fluorescent O2-· indicator (Wang et 
al., 2008a).   
 
 
4.4.1.1. Mitochondrial localization of mt-cpYFP 
 
Mitochondrial targeting of mt-cpYFP was studied by performing colocalization 
studies using MitoTracker Orange.  mt-cpYFP fluorescence exhibited ~95% pixel 
colocalization with MitoTracker Orange, indicating mitochondrial localization (Fig. 4-5). 
 
 
4.4.1.2. ET-1 elevates mitoROS production 
 
In smooth muscle cells of intact arteries, ET-1 elevated mt-cpYFP fluorescence to 
~199% of control, and this was blocked by XeC, Ru360, rotenone, a mitochondrial ETC 
complex I inhibitor (Fukami et al., 1967), and micromolar CCCP (Fig. 4-6A,B).  When 
applied alone, rotenone and micromolar CCCP reduced mt-cpYFP fluorescence to ~54 
and 64% of control, respectively (Fig. 4-6B).  In contrast, Ru360, XeC, and 60 mM K+ 
did not alter mt-cpYFP fluorescence (Fig. 4-6B).  In cerebral artery smooth muscle cells, 
1 nM CCCP reduced TMRM fluorescence to ~87% of control, and elevated DCF 
fluorescence to ~140% of control, suggesting that a low concentration of CCCP induces a  
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Figure 4-4. ET-1-induced IP3R-mediated SR Ca2+ release depolarizes mitochondria in 
arterial smooth muscle cells 
 
Notes:  A, ET-1 caused reproducible mitochondrial depolarization in cerebral artery 
smooth muscle cells.  ET-1-induced mitochondrial depolarization was blocked by 
pretreatment with XeC (20 µM).  B, Concentration-dependent mitochondrial 
depolarization by ET-1 (n=4-7).  C, Average changes in TMRM fluorescence for ET-1 
(n=37), second ET-1 application (n=12), thapsigargin (100 nM, n=18), ET-
1+thapsigargin (n=18), XeC (20 µM, n=12), ET-1+XeC (n=12), 60 mM K+ (n=10), and 
CCCP (10 µM, n=65).  ET-1 concentration was 30 nM in all experiments.  Values are 
expressed as mean±SEM.  * indicates P<0.05 compared to control.  # indicates P<0.05 
compared to ET-1. 
61 
 
 
62 
 
 
 
 
Figure 4-5. Mitochondrial localization of mt-cpYFP in cerebral artery smooth muscle 
cells 
 
Notes:  Confocal images illustrate colocalization of punctate mt-cpYFP fluorescence with 
MitoTracker Orange in a smooth muscle cell.  Colocalization quantified using weighted 
colocalization was 94.7±1.2% (n=10, p<0.001).  Scale bar=10 µm. 
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Figure 4-6. ET-1-induced IP3R-mediated SR Ca2+ release and mitochondrial Ca2+ 
uptake elevates mitoROS generation in arterial smooth muscle cells 
 
Notes:  A, Original images illustrating ET-1-induced elevation in mt-cpYFP fluorescence 
in smooth muscle cells of an intact artery.  Scale bar=20 µm.  B, Average mt-cpYFP 
fluorescence changes in smooth muscle cells of intact arteries.  ET-1, XeC (20 µM), ET-
1+XeC, Ru360 (10 µM), ET-1+Ru360, rotenone (10 µM), ET-1+rotenone, CCCP (10 
µM), ET-1+CCCP, CCCP (1 nM), and 60 mM K+.  ET-1 concentration was 100 nM in 
all experiments.  n=5 for each condition.  Values are expressed as mean±SEM.                
* indicates P<0.05 compared to control.  # indicates P<0.05 compared to ET-1. 
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small mitochondrial depolarization and increases mitoROS generation (Xi et al., 2005).  
Similarly, here 1 nM CCCP elevated mt-cpYFP fluorescence to ~124% of control (Fig. 
4-6B).  These data indicate that mitochondria generate ROS in the absence of ET-1, and 
that ET-1-induced IP3R-mediated SR Ca2+ release and [Ca2+]mito elevation stimulate 
mitoROS generation.  Results with Ru360, rotenone, and micromolar CCCP confirm the 
mitochondrial localization of mt-cpYFP. 
 
 
4.4.2. ET-1-induced mitoROS generation elevates cytosolic ROS levels 
 
Cytosolic ROS was measured using HyPer-CYTO, a genetically-encoded 
fluorescent cytosolic H2O2 indicator (Fig. 3-1) (Belousov et al., 2006).  Exogenous H2O2 
elevated HyPer-CYTO fluorescence to ~234% of control (Fig. 4-7A).  ET-1 similarly 
increased HyPer-CYTO fluorescence in smooth muscle cells of endothelium-intact and -
denuded arteries to ~158 and 168% of control, respectively (Fig. 4-7B,C).  When applied 
alone, rotenone and MnTMPyP, a SOD and catalase mimetic (Faulkner et al., 1994), 
reduced HyPer-CYTO fluorescence ~75 and 80% of control, respectively (Fig. 4-7C).  
Rotenone and MnTMPyP blocked the ET-1-induced elevations in HyPer-CYTO 
fluorescence (Fig. 4-7C).  These data indicate that mitoROS production contributes to 
cytosolic ROS levels in the absence of ET-1 and that ET-1-induced mitoROS elevation 
leads to an increase in cytosolic ROS in cerebral artery smooth muscle cells. 
 
 
4.4.3. ROS measurements using DCF 
 
 
4.4.3.1. ET-1 stimulates ROS generation 
 
To confirm measurements obtained using mt-cpYFP and HyPer-CYTO, ROS 
levels were studied in smooth muscle cells of cerebral arteries using CM-H2DCFDA, an 
inorganic fluorescent ROS indicator.  ET-1 increased mean DCF fluorescence in smooth 
muscle cells of endothelium-intact and -denuded arteries to ~154 and 151% of control, 
respectively (Fig. 4-8A,B).  Exogenous H2O2 application elevated mean DCF 
fluorescence intensity to ~219% of control (Fig. 4-8B).  ET-1-induced DCF fluorescence 
elevations were blocked by thapsigargin, XeC, and MnTMPyP (Fig. 4-8B).  When 
applied alone, thapsigargin and XeC did not alter, but MnTMPyP reduced DCF 
fluorescence to ~74% of control (Fig. 4-8B).  60 mM K+, which leads to global [Ca2+]i 
elevation did not alter DCF fluorescence (Fig. 4-8B).  These data confirm the finding that 
ET-1-induced IP3R-mediated SR Ca2+ release stimulates ROS generation. 
 
 
4.4.3.2. Source of ET-1-induced ROS elevation is mitochondria 
 
ET-1-induced DCF fluorescence elevations were blocked by CCCP and rotenone 
(Fig. 4-9A).  In the presence of oxypurinol, a xanthine oxidase inhibitor (Elion et al., 
1968) and 17-ODYA, a cytochrome P450 blocker (Zou et al., 1994), ET-1 elevated DCF  
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Figure 4-7. ET-1-induced IP3R-mediated SR Ca2+ release elevates cytosolic ROS in 
arterial smooth muscle cells 
 
Notes:  A,B,  Confocal images illustrating that exogenous H2O2 (A) and ET-1 (B) 
elevates HyPer-CYTO fluorescence in arterial smooth muscle cells.  C, Average changes 
in HyPer-CYTO fluorescence for H2O2 (100 µM), ET-1 (endothelium-intact), ET-1 
(endothelium-denuded), rotenone (10 µM), ET-1+rotenone, MnTMPyP (10 µM), and 
ET-1+MnTMPyP.  ET-1 concentration was 100 nM in all experiments.  n=5 for each 
condition.  Values are expressed as mean±SEM.  * indicates P<0.05 compared to control.   
# indicates P<0.05 compared to ET-1. 
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Figure 4-8. ET-1-induced IP3R-mediated SR Ca2+ release elevates DCF fluorescence 
in arterial smooth muscle cells 
 
Notes:  A, Confocal images of DCF fluorescence in smooth muscle cells of the same 
cerebral artery in control and ET-1.  Scale bar=20 µm.  B, Mean DCF fluorescence 
changes in arterial smooth muscle cells.  H2O2 (100 µM, n=6), ET-1 (endothelium-intact, 
n=10), ET-1 (endothelium-denuded, n=6), thapsigargin (100 nM, n=5), ET-
1+thapsigargin (n=10), XeC (20 µM, n=5), ET-1+XeC (n=6), MnTMPyP (10 µM, n=5), 
ET-1+MnTMPyP (n=6), and 60 mM K+ (n=6).  Values are expressed as mean±SEM.          
* indicates P<0.05 compared to control.  # indicates P<0.05 compared to ET-1. 
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Figure 4-9. ET-1-induced mitoROS generation elevates DCF fluorescence in arterial 
smooth muscle cells 
 
Notes:  A, Mean DCF fluorescence change for ET-1 (endothelium-intact, n=10), rotenone 
(10 µM, n=5), ET-1+rotenone (n=10), CCCP (10 µM, n=5), ET-1+CCCP (n=10), 
gp91ds-tat (50 µM, n=5), ET-1+gp91ds-tat (n=5), oxypurinol (10 µM, n=5), ET-
1+oxypurinol (n=6), 17-octadecynoic acid (10 µM, n=5), and ET-1+17-octadecynoic acid 
(n=6).  B, Mean DCF fluorescence change for TNF-α (100 ng/ml, n=5), ET-1 
(endothelium-intact, n=10), gp91scrm-tat (50 µM, n=5), TNF-α+gp91scrm-tat (n=5), ET-
1+gp91scrm-tat (n=5), gp91ds-tat (50 µM, n=5), TNF-α+gp91ds-tat (n=5), and ET-
1+gp91ds-tat (n=5).  ET-1 concentration was 100 nM in all experiments.  * indicates 
P<0.05 compared to control.  Values are expressed as mean±SEM.  # indicates P<0.05 
compared to ET-1.  § indicates P<0.05 compared to TNF-α. 
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fluorescence to ~153 and 146% of control, respectively (Fig. 4-9A).  Oxypurinol and 17-
ODYA did not alter baseline DCF fluorescence, whereas CCCP and rotenone alone 
decreased baseline DCF fluorescence to ~62 and 72% of control, respectively (Fig.  
4-9A). 
 
TNF-α, which stimulates NAD(P)H oxidase-derived ROS in cerebral artery 
smooth muscle cells (Cheranov & Jaggar, 2006), elevated DCF fluorescence to ~190% of 
control (Fig. 4-9B).  gp91ds-tat did not alter baseline DCF fluorescence, whereas blocked 
DCF fluorescence elevations induced by TNF-α, suggesting that gp91ds-tat inhibits  
NAD(P)H oxidase (Fig. 4-9B).  In the presence of gp91ds-tat, ET-1 increased DCF 
fluorescence to ~143% of control (Fig. 4-9B).  Scrambled gp91-tat did not alter baseline 
DCF fluorescence, or ET-1- or TNF-α-induced DCF fluorescence elevations (Fig. 4-9B). 
 
Data obtained using DCF confirm ROS measurements obtained using mt-cpYFP 
and HyPer-CYTO, that mitochondria generate ROS in the absence of ET-1, and that ET-
1-induced IP3R-mediated SR Ca2+ release and [Ca2+]mito elevation stimulate mitoROS 
generation, leading to an increase in cytosolic ROS in cerebral artery smooth muscle 
cells. 
 
 
4.5. ET-1-Induced IP3R-Mediated MitoROS Elevation Stimulates NF-κB 
 
 
4.5.1. ET-1 stimulates nuclear translocation of NF-κB p50 
 
To examine physiological functions of an IP3R-mediated mitoROS elevation, we 
tested the hypothesis that mitochondria regulate the expression of genes that modulate 
smooth muscle cell contractility.  Therefore, immunofluorescence was performed to 
study cellular localization of the p50 subunit of NF-κB, a ROS-sensitive transcription 
factor (Lee et al., 2008), in arterial smooth muscle cells.  ET-1 increased mean pixel 
colocalization of p50 with YOYO-1 from ~12 to 22% (Fig. 4-10A-C), suggesting that 
ET-1 stimulates nuclear translocation of p50. 
 
 
4.5.2. ET-1 elevates NF-κB-dependent transcriptional activity 
 
To investigate the regulation of NF-κB-dependent transcriptional activity, assays 
were performed using vectors that express firefly luciferase under the control of an NF-
κB promoter.  As a control, regulation of luciferase activity by TNF-α, which activates 
NF-κB (Li et al., 1999) was measured.  TNF-α increased mean luciferase activity to 
~547% of control (Fig. 4-11).  ET-1 increased luciferase activity to ~372% of control, 
and this was blocked by thapsigargin and XeC (Fig. 4-11).  Rotenone and MnTMPyP 
reduced the ET-1-induced elevation in luciferase activity to ~152 and 109% of control, 
respectively (Fig. 4-11).  Exogenous H2O2 elevated luciferase activity to ~252% of 
control, and this effect was not altered by rotenone, indicating that rotenone did not cause 
general inhibition of luciferase expression (Fig. 4-11).  When applied alone, thapsigargin,  
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Figure 4-10. ET-1 stimulates p50 nuclear translocation in arterial smooth muscle cells 
 
Notes:  A, Immunofluorescence images of smooth muscle cells in arteries illustrating 
YOYO-1 (nuclear stain, green), p50 (red), overlay, and DIC (lumenally-inserted 
rectangular glass cannula can be seen).  B, Enlarged images indicated by boxes in A 
illustrate ET-1-induced elevation in p50 and YOYO-1 pixel colocalization (purple).  
Scale bars=20 µm.  C, Mean data for weighted pixel colocalization (n=10 for each).  
Values are expressed as mean±SEM.  * indicates P<0.05 compared to control. 
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Figure 4-11. ET-1 stimulates NF-κB-dependent transcription through IP3R-mediated 
SR Ca2+ release and mitoROS elevation in arterial smooth muscle cells 
 
Notes:  Average NF-κB-p-Luc luciferase activity with TNF-α (100 ng/ml, n=4), ET-1 
(n=5), thapsigargin (100 nM, n=5), ET-1+thapsigargin (n=5), XeC (20 µM, n=5), ET-
1+XeC (n=5), rotenone (1 µM, n=5), ET-1+rotenone (n=5), MnTMPyP (10 µM, n=4), 
ET-1+MnTMPyP (n=4), H2O2 (100 µM, n=4), and H2O2+rotenone (n=4).  ET-1 
concentration was 100 nM in all experiments.  Values are expressed as mean±SEM.            
* indicates P<0.05 compared to control.  # indicates P<0.05 compared to ET-1.                
§ indicates P<0.05 compared to rotenone or MnTMPyP. 
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XeC, rotenone, and MnTMPyP reduced luciferase activity to ~84, 78, 77, and 80% of 
control, respectively (Fig. 4-11).  TNF-α, ET-1, thapsigargin, XeC, rotenone, MnTMPyP, 
and H2O2 did not alter luciferase activity in arteries in which a promoter-deficient control 
vector was inserted (Fig. 4-12).  These data indicate that IP3R-mediated SR Ca2+ release 
stimulates NF-κB primarily by elevating mitoROS generation, but also via a secondary 
mitochondria- and ROS-independent pathway in arterial smooth muscle cells. 
 
 
4.5.3. ROS measurements corresponding to transcriptional studies 
 
For transcriptional studies performed using luciferase reporter assays, arteries 
were exposed to stimuli for 24 hours.  To determine if the inhibitors used, blocked the 
ET-1-induced ROS elevations which corresponded to the time points used in the above 
transcriptional studies, ROS levels were measured using DCF.  After a 24-hour 
incubation in control, ET-1 elevated DCF fluorescence to ~145% of control (Fig. 4-13).  
ET-1-induced DCF fluorescence elevations were blocked by 24-hour incubation in 
thapsigargin, XeC, or rotenone (Fig. 4-13).  These data indicate that the inhibitors used 
for a period of time in transcriptional studies blocked the ET-1-induced ROS elevations. 
 
 
4.6. ET-1-Induced IP3R-Mediated SR Ca2+ Release Stimulates CaV1.2 Expression 
by MitoROS Elevation and NF-κB Activation 
 
We sought to examine the functional significance of IP3R-mediated, 
mitochondrial-dependent NF-κB activation.  CaV1.2 channels are the principal Ca2+ 
influx pathway in smooth muscle cells of resistance-size arteries and are essential for 
contractility regulation by a wide variety of stimuli, including intravascular pressure and 
membrane potential (Cheng et al., 2007).  However, mechanisms that regulate 
CACNA1C transcription in arterial smooth muscle cells are unclear.  Three NF-κB 
binding motifs are located immediately upstream of the human Cav1.2 promoter (Shi et 
al., 2005).  Therefore, we tested the hypothesis that ET-1-induced IP3R-mediated, 
mitoROS-dependent NF-κB activation regulates CaV1.2 expression in cerebral arteries. 
 
 
4.6.1. ET-1 stimulates CaV1.2 gene transcription 
 
To study ET-1 regulation of gene expression we performed RT-PCR.  We sought 
to identify a reference gene whose transcription is not affected by ET-1 (6 hours).  RT-
PCR reactions were performed for five genes, namely beta (β) actin, beta (β) tubulin, 
cyclophilin B, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), and Rps5.  
CT values for the reference genes in control and ET-1 are shown in Table 4-1.  Rps5 
which had the least difference in average CT values between control and ET-1 treatment 
groups was chosen as the reference gene.   
 
RT-PCR data indicated that in cerebral arteries, ET-1 increased CaV1.2 channel 
mRNA expression to ~244% of control, after normalization to Rps5 (Fig. 4-14D). 
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Figure 4-12. Mean changes in promoter-deficient (pGL3 Basic) luciferase activity 
 
Notes:  Mean data.  TNF-α (100 ng/ml, n=4), ET-1 (n=5), thapsigargin (100 nM, n=4), 
ET-1+thapsigargin (n=4), XeC (20 µM, n=3), ET-1+XeC (n=3), rotenone (1 µM, n=4), 
ET-1+rotenone (n=4), MnTMPyP (10 µM, n=3), ET-1+MnTMPyP (n=3), H2O2 (100 
µM, n=3), and H2O2+rotenone (n=3).  ET-1 concentration was 100 nM in all 
experiments.  Values are expressed as mean±SEM. 
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Figure 4-13. ROS measurements at time points used for transcriptional studies 
 
Notes:  Average change in DCF fluorescence with ET-1 (100 nM, n=5) after a 24 hour 
incubation in control, in the presence of thapsigargin (100 nM, n=3), XeC (20 µM, n=3), 
or rotenone (1 µM, n=5).  Values are expressed as mean±SEM.  * indicates P<0.05 
compared to control.  # indicates P<0.05 compared to ET-1. 
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Table 4-1. Identification of reference gene for RT-PCR 
 
 
Gene 
 
CTcontrol CTET-1 CTcontrol - CTET-1 
 
Rps5 
 
25.43 
 
24.83 
 
0.60 
    
HGPRT 31.90 31.21 0.69 
    
Cyclophilin B  27.39 26.71 0.68 
    
β tubulin 32.81 32.12 0.69 
    
β actin 
 
22.5 21.53 0.97 
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Figure 4-14. ET-1 stimulates CaV1.2 gene transcription in cerebral arteries 
 
Notes:  A,B, Representative amplification curves generated with probes and RT-PCR 
primers specific for CaV1.2 (A) and Rps5 (B) genes in control (blue) and ET-1(10 nM)-
treated (red) arteries.  The data points for the amplification curves shown were obtained 
by calculating the average of data points from triplicates for each condition.  C, 
Application of ET-1 (10 nM) for 6 hours elevated mean CaV1.2 mRNA in cerebral 
arteries compared to control arteries (n=7 for each condition).  Values are expressed as 
mean±SEM.  * indicates P<0.05 compared to control.  D, Agarose gel illustrating 
transcripts amplified using RT-PCR primers for CaV1.2 (70 bp) and Rps5 (83 bp) from 
cerebral arteries in control and ET-1 (10 nM).  NC, negative control using cerebral artery 
mRNA. 
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4.6.2. ET-1-induced IP3R activation and mitoROS elevation stimulate CaV1.2 
expression  
 
Western blotting indicated that ET-1 (24 hrs) increased CaV1.2 channel (190 and 
240 kD bands) protein to ~141% of control (Fig. 4-15A,B).  XeC, rotenone, and 
MnTMPyP alone reduced basal CaV1.2 expression to ~87, 89, and 80% of control, 
respectively (Fig. 4-15A,B).  XeC blocked the ET-1-induced elevation in CaV1.2 
expression (Fig. 4-15A,B).  Rotenone and MnTMPyP reduced the ET-1-induced 
elevation in CaV1.2 expression to ~113 and 90% of control, respectively (Fig. 4-15B).  
Exogenous H2O2 increased CaV1.2 expression to ~128% of control, and this elevation 
was not altered by rotenone, indicating that rotenone did not induce non-specific 
inhibition of CaV1.2 expression (Fig. 4-15B).  These data indicate that ET-1-induced 
IP3R-mediated SR Ca2+ release and mitoROS elevation stimulate CaV1.2 expression in 
cerebral arteries. 
 
 
4.6.3. ET-1-induced NF-κB activation elevates CaV1.2 expression 
 
Two different siRNAs were used to knockdown expression of p105, the p50 
precursor (Baeuerle & Baltimore, 1996).  p105siRNA1, p105siRNA2, and a combination 
of both siRNAs (p105siRNAs) reduced mean p105 protein to ~73, 80, and 57%, 
respectively, of that in arteries treated with scrambled siRNA (p105scrm) (Fig. 4-16A,B).  
 
p105siRNAs reduced CaV1.2 expression to ~64% of p105scrm (Fig. 4-17A,B), 
indicating that NF-κB controls basal CaV1.2 expression.  In p105scrm-treated arteries, 
ET-1 increased CaV1.2 protein to ~136% of p105scrm (Fig. 4-17A,B).  In p105siRNAs-
treated arteries, ET-1 increased CaV1.2 protein from ~64 to 74% of p105scrm (~117% of 
p105siRNAs) (Fig. 4-17A,B).  These data indicate that IP3R-mediated SR Ca2+ release 
stimulates CaV1.2 expression via mitochondria-dependent NF-κB activation. 
 
 
4.7. ET-1-Induced IP3R-Mediated SR Ca2+ Release Also Stimulates p105 
Expression 
 
The p105 gene promoter contains an NF-κB-binding sequence, and p50 activation 
can elevate p105 expression (Ten et al., 1992).  Therefore, mechanisms that regulate NF-
κB subunit expression in cerebral arteries were investigated.  Inhibiting IP3R-mediated 
SR Ca2+ release using XeC reduced basal p105 and p50 expression to ~87 and 90% of 
control, respectively (Fig. 4-18A,B).  Inhibiting mitoROS production using rotenone or 
dismutating cellular ROS using MnTMPyP, did not alter basal p105 or p50 expression 
(Fig. 4-18B).  ET-1 elevated p105 and p50 expression to ~127 and 119% of control, 
respectively and XeC blocked this effect (Fig. 4-18B). In contrast, rotenone or 
MnTMPyP had no effect on the ET-1-induced elevation in p105 and p50 subunit 
expression (Fig. 4-18B).  Exogenous H2O2 applied alone or in the presence of rotenone 
did not change p105 and p50 expression (Fig. 4-18B). 
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Figure 4-15. ET-1-induced IP3R-mediated SR Ca2+ release and mitoROS elevation 
stimulate CaV1.2 protein expression in cerebral arteries 
 
Notes:  A, Western blot indicating that ET-1(10 nM) application for 24 hours elevated 
CaV1.2 protein expression and XeC (20 µM) blocked the ET-1-induced elevation in 
CaV1.2 expression.  B, Mean data for ET-1 (n=12), XeC (20 µM, n=7), ET-1+XeC (n=7), 
rotenone (1 µM, n=6), ET-1+rotenone (n=6), MnTMPyP (10 µM, n=5), ET-
1+MnTMPyP (n=5), H2O2 (100 µM, n=5), and H2O2+rotenone (n=5).  ET-1 
concentration was 10 nM in all experiments.  Values are expressed as mean±SEM.              
* indicates P<0.05 compared to control.  # indicates P<0.05 compared to ET-1.                
§ indicates P<0.05 compared to rotenone or MnTMPyP. 
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Figure 4-16. p105 knockdown in cerebral arteries 
 
Notes:  A, Western blot illustrating that p105siRNA1, p105siRNA2, and p105siRNA1+2 
reduce p105 expression in cerebral arteries.  B, Mean data.  n=5 for each.  Values are 
expressed as mean±SEM.  * indicates P<0.05 compared to arteries reverse permeabilized 
with p105scrm. 
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Figure 4-17. NF-κB controls basal and ET-1-induced elevation in functional CaV1.2 
expression in cerebral arteries 
 
Notes:  A, Western blot illustrating effects of p105siRNAs (10 µg/ml each) on basal and 
ET-1-induced CaV1.2 expression.  B, Mean data.  n=5 for each.  Values are expressed as 
mean±SEM.  * indicates P<0.05 compared to arteries reverse permeabilized with 
p105scrm.  # indicates P<0.05 compared to arteries reverse permeabilized with 
p105siRNAs. 
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Figure 4-18. ET-1-induced IP3R-mediated SR Ca2+ release elevates p105/p50 
expression via a mitochondria-, and ROS-independent mechanism in cerebral arteries 
 
Notes:  A, Western blots indicating that XeC (20 µM) blocked an ET-1-induced elevation 
in p105 and p50 expression.  B, Mean data for p105 (black) and p50 (red).  p105 and p50 
data were measured in the same blots, and thus experimental number is identical for each 
protein.  ET-1 (n=8), XeC (20 µM, n=6), ET-1+XeC (n=6), rotenone (1 µM, n=5), ET-
1+rotenone (n=5), MnTMPyP (10 µM, n=5), ET-1+MnTMPyP (n=5), H2O2 (100 µM, 
n=6), and H2O2+rotenone (n=6).  Values are expressed as mean±SEM.  * indicates 
P<0.05 compared to control.  # indicates P<0.05 compared to ET-1.  § indicates P<0.05 
compared to rotenone or MnTMPyP. 
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4.8. ET-1-Induced NF-κB Activation Does Not Stimulate p105 Expression 
 
p105siRNAs reduced p105 and p50 expression to ~57 and 53% of p105scrm (Fig. 
4-19A,B).  ET-1 increased p105 expression in p105scrm-treated arteries to ~123% of 
p105scrm, and in p105siRNAs-treated arteries from ~57 to 67% of p105scrm (~121% of 
p105siRNAs) (Fig. 4-19A,B).  Similarly, ET-1 increased p50 expression in p105scrm-
treated arteries to ~118% of p105scrm, and in p105siRNAs-treated arteries from ~53 to 
65% of p105scrm (~124% of p105siRNAs) (Fig. 4-19A,B).  These data indicate that 
p105siRNAs did not alter the ET-1-induced relative increase in p105 and p50 expression 
(Fig. 4-19A,B).   
 
Collectively, these data indicate that IP3R-mediated SR Ca2+ release activates 
p105/p50 expression via a mitochondria-, ROS-, and NF-κB-independent pathway.  Data  
also indicate that rotenone, MnTMPyP, and p105siRNAs do not cause general inhibition 
of gene transcription. 
 
 
4.9. NF-κB Stimulates Functional CaV1.2 Expression in Cerebral Artery Smooth 
Muscle Cells 
 
To investigate NF-κB regulation of functional CaV1.2 expression, diameter 
regulation of pressurized (60 mmHg) endothelium-denuded arteries was studied. 
 
 
4.9.1. Myogenic tone development in arteries 
 
In resistance-size cerebral arteries, an elevation of intravascular pressure from 10 
to 60 mmHg stretches the smooth muscle cells of the arterial wall, leading to activation of 
mechanosensitive ion channels (Hill et al., 2001).  Stimulation of stretch-activated cation 
channels induces a graded membrane depolarization of smooth muscle cells from ~-60 to 
-40 mV (Jaggar, 2001), which increases the steady-state open probability of CaV1.2 
channels on smooth muscle cells (Knot & Nelson, 1998).  This leads to increased Ca2+ 
influx through CaV1.2 channels to elevate steady-state arterial wall [Ca2+]i.  Increased 
arterial wall [Ca2+]i activates myosin light chain kinase, which leads to maintained 
constriction (‘myogenic tone’) (Fig. 4-20). 
 
 
4.9.2. ET-1-stimulates functional CaV1.2 expression via NF-κB activation 
 
Arteries were treated with either p105scrm or p105siRNAs and then exposed to 
either no further treatment or to ET-1 for 24 hours.  At 60 mm Hg, control arteries 
(p105scrm) developed ~21% myogenic tone and membrane depolarization with 60 mM 
K+ elevated tone to ~45%.  p105 knockdown (p105siRNAs) reduced myogenic tone and 
depolarization-induced vasoconstriction to ~14 and 31%, respectively (Fig. 4-21A,B).  A 
24-hour exposure to ET-1 elevated mean myogenic tone and depolarization-induced tone 
in control arteries to ~32 and 55%, respectively (Fig. 4-21A,B).  p105siRNAs attenuated  
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Figure 4-19. ET-1 elevates p105/p50 expression via an NF-κB-independent pathway in 
cerebral arteries 
 
Notes:  A, Western blot illustrating effects of p105siRNAs (10 µg/ml each) on p105 and 
p50 expression and regulation by ET-1.  B, Mean data for p105 (black) (n=5 for each) 
and p50 (red) expression (n=4 for each).  ET-1 concentration was 10 nM in all 
experiments.  Values are expressed as mean±SEM.  * indicates P<0.05 compared to 
arteries reverse permeabilized with p105scrm.  # indicates P<0.05 compared to arteries 
reverse permeabilized with p105siRNAs. 
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Figure 4-20. Myogenic tone development in cerebral arteries 
 
Notes:  Respresentative trace illustrating that an elevation of intravascular pressure from 
10 to 60 mm Hg induces nimodipine-sensitive myogenic tone in a cerebral artery.  
Addition of 60 mM K+ causes massive depolarization leading to further vasoconstriction.  
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Figure 4-21. p105 knockdown reduces myogenic tone and attenuates ET-1-induced 
elevation in myogenic tone in cerebral arteries 
 
Notes:  A, Representative traces illustrating diameter in arteries pressurized to 60 mm Hg 
(6 mM K+).  Nimodipine (1 µM) fully dilated p105scrm- and p105siRNAs-treated 
arteries.  B, Mean myogenic tone at 60 mm Hg (p105scrm, n=5, p105scrm + ET-1, n=6, 
p105siRNAs, n=6, p105siRNAs + ET-1, n=6), in 60 mM K+ at 60 mm Hg (p105scrm, 
n=5, p105scrm + ET-1, n=5, p105siRNAs, n=5, p105siRNAs + ET-1, n=5), or 
nimodipine (1 µM) at 60 mm Hg (p105scrm, n=5, p105scrm + ET-1, n=6, p105siRNAs, 
n=5, p105siRNAs + ET-1, n=5).  Values are expressed as mean±SEM.  * indicates 
P<0.05 compared to arteries reverse permeabilized with p105scrm.  # indicates P<0.05 
compared to arteries reverse permeabilized with p105siRNAs.  
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the ET-1-induced elevation in myogenic tone and depolarization-induced 
vasoconstriction to ~17 and 39%, respectively (Fig. 4-21A,B).  Nimodipine fully dilated 
arteries regardless of treatment, indicating that vasoconstriction occurred due to CaV1.2 
channel activation (Fig. 4-21A,B).  These data indicate that NF-κB is essential for 
functional basal CaV1.2 expression in cerebral artery smooth muscle cells and that ET-1-
induced NF-κB activation elevates CaV1.2 expression and vasoconstriction. 
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CHAPTER 5. DISCUSSION* 
 
 
5.1. Summary of Findings 
 
Here, we investigated physiological signaling mechanisms that regulate [Ca2+]mito, 
functional consequences of changes in [Ca2+]mito, and mitochondrial regulation of ion 
channel gene expression in arterial smooth muscle cells.  This study was performed using 
small, resistance-size cerebral arteries that regulate blood pressure and regional blood 
flow to the brain.  In this study, we have used state-of-art techniques, including 
genetically-encoded fluorescent indicators and laser-scanning confocal microscopy to 
measure [Ca2+]mito and ROS, fluorescence imaging and luciferase reporter gene assays to 
examine NF-κB activity, molecular biology and biochemical techniques to examine 
CaV1.2 expression, and pressurized artery diameter measurements to study the functional 
significance of elevated CaV1.2 channel expression. 
 
A schematic diagram summarizing major findings of this study is provided in 
Figs. 5-1 and 5-2.  Under resting conditions, basal levels of IP3 activate IP3R, leading to 
SR Ca2+ release.  IP3R-mediated SR Ca2+ release and constitutively produced mitoROS 
activate NF-κB.  NF-κB controls basal CaV1.2 expression in cerebral artery smooth 
muscle cells and NF-κB knockdown leads to vasodilation.  
 
ET-1-induced IP3R-mediated SR Ca2+ release generates Ca2+ waves, elevates 
[Ca2+]mito, and depolarizes mitochondria, leading to an increase in mitoROS generation.  
ET-1-induced IP3R-mediated mitoROS elevate cytosolic ROS that increase NF-κB 
nuclear translocation and transcriptional activity.  ET-1-induced NF-κB activation 
stimulates CaV1.2 expression, leading to an elevation in CaV1.2-dependent pressure- and 
depolarization-induced vasoconstriction.  ET-1-induced IP3R-mediated SR Ca2+ release 
also elevates NF-κB p105/p50 subunit expression via a mitochondria-, ROS-, and NF-
κB-independent pathway.  Collectively, these data indicate that IP3R-mediated SR Ca2+ 
release elevates [Ca2+]mito, stimulating mitoROS which activate NF-κB-dependent CaV1.2 
channel expression.  Thus, mitochondria sense IP3R-mediated SR Ca2+ release to control 
functional CaV1.2 channel transcription in arterial smooth muscle cells, thereby 
regulating arterial contractility. 
 
 
5.2. Ca2+ Signaling in Vascular Smooth Muscle Cells by PLC-Coupled Agonists 
 
Several vasoconstrictors, including UTP, Ang II, and ET-1 activate PLC 
(Rosendorff, 1997; Ralevic & Burnstock, 1998; Touyz & Schiffrin, 2000; Zhang et al., 
2003), leading to PIP2 hydrolysis and the generation of IP3 and DAG.  IP3 stimulates  
 
 
* Portions of this chapter adapted with permission. Narayanan D, Xi Q, Pfeffer LM, & 
Jaggar JH (2010). Mitochondria control functional CaV1.2 expression in smooth muscle 
cells of cerebral arteries. Circ Res 107, 631-641.
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Figure 5-1. Proposed signaling pathways that control basal CaV1.2 expression in smooth muscle cells of cerebral arteries 
 
Notes:  Basal levels of IP3R-mediated SR Ca2+ release and constitutively produced mitoROS activate NF-κB leading to CaV1.2 
expression.  IP3 indicates inositol 1,4,5-trisphosphate, ETC indicates mitochondrial electron transport chain, and ψm indicates 
mitochondrial membrane potential.  
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Figure 5-2. Proposed signaling pathways that control ET-1-induced CaV1.2 expression in smooth muscle cells of cerebral arteries 
 
Notes:  ET-1-induced IP3R-mediated SR Ca2+ release activates NF-κB: (a) primarily by stimulating a mitochondrial ROS elevation 
and (b) via a secondary mitochondria-independent pathway, leading to CaV1.2 expression.  IP3 indicates inositol 1,4,5-trisphosphate, 
ETC indicates mitochondrial electron transport chain, and ψm indicates mitochondrial membrane potential. 
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IP3Rs, and DAG activates PKC.  Activation of IP3R1, the major isoform expressed in 
smooth muscle cells of resistance-size cerebral arteries stimulates SR Ca2+ release in the 
form of Ca2+ waves, which contribute to global [Ca2+]i elevation (Jaggar & Nelson, 2000; 
Zhao et al., 2008).  IP3R1 activation also induces physical coupling of the N-terminus of 
IP3R1 and the C-terminus of plasma membrane TRPC3 channel, leading to ICat activation.  
IP3R-dependent ICat activation produces membrane depolarization, CaV1.2 channel 
activation, a global [Ca2+]i elevation, and vasoconstriction (Xi et al., 2008; Zhao et al., 
2008; Adebiyi et al., 2010).  Therefore, vasoconstrictor-induced IP3R activation elevates 
[Ca2+]i in cerebral artery smooth muscle cells via SR Ca2+ release-dependent and -
independent mechanisms.  In contrast, vasoconstrictor-activated PKC inhibits Ca2+ 
sparks, which leads to membrane depolarization, CaV1.2 channel activation, and a global 
[Ca2+]i elevation (Jaggar & Nelson, 2000).   
 
 
5.3. Regulation of [Ca2+]mito  by Cytosolic Ca2+ Signals 
 
The regulation of arterial smooth muscle cell [Ca2+]mito by vasoconstrictor-
induced intracellular Ca2+ signals is unclear.  Electron microscopy studies indicate that 
mitochondria can be located in close proximity (~20 nm) to the SR membrane in many 
cell types, including cultured arterial smooth muscle cells (Rizzuto et al., 1999; Duchen, 
2000b; Szado et al., 2003; Pacher et al., 2008).  Such localization should place 
mitochondria within the vicinity of SR Ca2+ release channels that generate micromolar 
cytosolic Ca2+ elevations.  Given that the MCU is sensitive to Ca2+ only within the 
micromolar concentration range (Gunter & Pfeiffer, 1990), such structural orientation 
allows local signaling between SR Ca2+ release channels and mitochondria.  In cultured 
vascular smooth muscle cells, SR Ca2+ release elicited a [Ca2+]mito elevation (Pacher et 
al., 2008) and a delayed [Ca2+]mito elevation occurred when [Ca2+]i increased >1 µM, but 
not when the [Ca2+]i elevation was <500 nM (Monteith & Blaustein, 1999).  Ca2+ influx 
via the plasma membrane Na+/Ca2+ exchanger also elevated [Ca2+]mito in cultured 
vascular smooth muscle cells (Poburko et al., 2009).  In non-cultured, voltage-clamped 
colonic smooth muscle cells, uncaging IP3 leads to mitochondrial Ca2+ uptake that feeds 
back to regulate IP3R activity (Olson et al., 2010).   
 
Previous studies have used inorganic Ca2+ indicators to measure [Ca2+]mito in 
cultured arterial smooth muscle cells (Monteith & Blaustein, 1999; Pacher et al., 2008; 
Poburko et al., 2009).  These fluorophores are not designed to target to specific cellular 
locations, which inevitably leads to non-specific Ca2+ measurements.  To our knowledge, 
our study is the first to use a genetically-encoded, mitochondria-targeted, fluorescent 
indicator to measure [Ca2+]mito in contractile arterial smooth muscle cells.  Furthermore, 
we studied cerebral artery smooth muscle cells in their native, contractile phenotype, 
while previous studies primarily used cultured, proliferating vascular smooth muscle 
cells.  In vitro cultivation of vascular smooth muscle cells results in phenotypic 
alterations, characterized by changes in cell morphology, receptor expression, and 
contractile-cytoskeletal protein profiles, and switches arterial smooth muscle cell 
phenotype from a contractile state to an invasive, proliferative state (Absher et al., 1989; 
Campbell et al., 1989; Eguchi et al., 1994).  Therefore, it is highly likely that 
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physiological functions of mitochondria differ in these different cell phenotypes, 
particularly since spatial proximity to Ca2+ channels and transporters are critical for 
mitochondrial Ca2+ uptake. 
 
Our data indicate that in contractile cerebral artery smooth muscle cells, 
thapsigargin, XeC, and Ru360 did not alter resting [Ca2+]mito, ψm, or mitoROS.  In 
contrast, mitochondrial inhibitors reduced basal [Ca2+]mito, depolarized mitochondria, and 
reduced mitoROS levels.  These data indicate that in resting arterial smooth muscle cells, 
mitochondria contain Ca2+ and generate low levels of ROS through mechanisms that are 
independent of IP3R-mediated SR Ca2+ release.  Therefore, basal mitochondrial Ca2+ 
levels appear to be maintained by Ca2+ uptake through transporters other than the MCU, 
which is sensitive to micromolar Ca2+ as that produced by SR Ca2+ release (Gunter & 
Pfeiffer, 1990).  Apart from the MCU, several mitochondrial pumps and exchangers, 
including RaM (Gunter et al., 2000) and reversal mode of mNCX (Griffiths et al., 1998) 
have been speculated to be responsible for mitochondrial Ca2+ uptake and the 
maintenance of resting [Ca2+]mito levels (Gunter et al., 2000). 
 
ET-1-induced IP3R-mediated SR Ca2+ release stimulated Ca2+ waves and elevated 
[Ca2+]mito, leading to mitochondrial depolarization and mitoROS generation.  Here, 
thapsigargin and XeC blocked the ET-1-induced [Ca2+]mito elevation, mitochondrial 
depolarization, and mitoROS generation.  In contrast, membrane depolarization, which 
elevates global [Ca2+]i, did not alter [Ca2+]mito, ψm, or mitoROS generation.  These data 
are consistent with the hypothesis that IP3R-mediated SR Ca2+ release stimulates 
mitochondrial Ca2+ uptake, leading to a [Ca2+]mito elevation, mitochondrial depolarization, 
and mitoROS generation. 
 
 
5.4. Ca2+ Waves May Be the Cytosolic Ca2+ Signal Regulating Mitochondrial 
Events 
 
Consistent with imaging data indicating that vasoconstrictor-induced Ca2+ waves 
occur due to IP3R activation in smooth muscle cells (Zhao et al., 2008), our data suggest 
that Ca2+ waves specifically regulate [Ca2+]mito and mitoROS generation in arterial 
smooth muscle cells.  Given that Ca2+ waves are propagating Ca2+ signals, [Ca2+]mito and 
mitoROS may also oscillate.  Here, [Ca2+]mito and mitoROS was measured within 
multiple smooth muscle cells in the arterial wall.  [Ca2+]mito and mitoROS within 
individual mitochondria may oscillate.  In our experiments, 2mt8CG2 and mt-cpYFP 
fluorescence in each field was measured from mitochondria within ~25 smooth muscle 
cells within the arterial wall.  Therefore, any asynchronous [Ca2+]mito or mitoROS 
oscillations within individual mitochondria would have been averaged out by the imaging 
protocol.  This protocol was necessary to measure sufficient 2mt8CG2 or mt-cpYFP 
fluorescence and to reduce the effects of indicator bleaching on measurements in cerebral 
artery smooth muscle cells.  It would be interesting to study spatial and temporal 
relationships between ET-1-induced Ca2+ waves and [Ca2+]mito or mitoROS changes 
within individual mitochondria in arterial smooth muscle cells.  However, such an 
examination of millisecond changes in [Ca2+]mito or mitoROS is more suitable for a future 
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investigation, and may require the use of a different mitochondria-targeted Ca2+ or ROS 
indicator that better suits the type of experiment.  Future studies should be designed to 
examine spatial and temporal relationships between Ca2+ waves and [Ca2+]mito or 
mitoROS signals within individual mitochondria in arterial smooth muscle cells. 
 
 
5.5. Regulation of MitoROS Generation by [Ca2+]mito and Mitochondrial 
Potential 
 
ET-1-induced mitoROS elevation was blocked by XeC, Ru360, rotenone, and 
CCCP, indicating that IP3R-mediated SR Ca2+ release, mitochondrial Ca2+ uptake, and 
mitochondrial depolarization stimulate mitoROS generation.  The mechanism by which 
mitochondrial Ca2+ uptake induces mitochondrial depolarization and elevates ETC-
generated mitoROS was not determined.  A [Ca2+]mito elevation may stimulate mitoROS 
generation at complexes I, III, and via QH· generation through multiple mechanisms 
(Brookes et al., 2004): 1) stimulation of the tricarboxylic acid cycle enhancing electron 
flow through the ETC complexes; 2) inhibition of complex I; 3) dissociation and release 
cytochrome c from inner mitochondrial membrane; and 4) mPTP opening (Brookes et al., 
2004). 
 
Mitochondrial depolarization has been demonstrated to increase or decrease ROS 
in a variety of different cell types, including smooth muscle cells of anatomically diverse 
blood vessels (Brookes et al., 2004; Xi et al., 2005; Belousov et al., 2006; Wang et al., 
2008a).  ψm is another important regulator of mPTP opening.  Mitochondrial 
depolarization can induce mPTP opening by shifting the threshold potential to higher 
levels (Petronilli et al., 1993; Bernardi, 1999).  mPTP opening can in turn depolarize the 
mitochondria further, thereby enhancing the mitochondrial Ca2+ uptake-induced 
depolarization (Brookes et al., 2004; Wang et al., 2008a).  Therefore, as suggested by a 
previous study, mitochondrial Ca2+ uptake may depolarize mitochondria due to (a) flow 
of Ca2+ ions into the mitochondrial matrix, and (b) mPTP opening (Duchen, 2004).   
 
mPTP opening also elevates mitoROS generation via several pathways, including 
dissipation of chemical gradients across the mitochondrial membrane, and by changing 
the fluidity and rigidity of the inner mitochondrial membrane, leading to diversion of 
electrons in the ETC to mitoROS generation (Wang et al., 2008a).  Therefore, a [Ca2+]mito 
elevation and mitochondrial depolarization may stimulate mitoROS generation by 
opening the mPTP. 
 
In the present study, a small mitochondrial depolarization increased mitoROS 
generation, whereas a large mitochondrial depolarization inhibited mitoROS production, 
consistent with an earlier report in cerebral artery smooth muscle cells (Xi et al., 2005).  
A small mitochondrial depolarization induced by nanomolar CCCP may increase 
mitoROS generation by shifting the mPTP threshold potential to higher levels (Petronilli 
et al., 1993; Bernardi, 1999).  Micromolar CCCP, which causes massive uncoupling of 
ETC, and disrupts the regulation of ψm, may severely affect electron transfer through the 
ETC complexes, resulting in a reduction in mitoROS generation.  ETC uncoupling has 
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been shown to decrease mitoROS generation in many cell types, including vascular 
smooth muscle cells (Okuda et al., 1992; Negre-Salvayre et al., 1997; Xi et al., 2005).   
 
MitoROS production is also regulated by additional factors, including redox 
status of respiratory substrates, permeability of the inner mitochondrial membrane, and 
proton pumping by ETC complexes (Starkov & Fiskum, 2003).  Future investigations 
should examine the mechanisms by which a vasoconstrictor-induced [Ca2+]mito elevation 
and mitochondrial depolarization stimulate mitoROS generation. 
 
 
5.6. Characterization of ET-1-Induced ROS Elevation 
 
Endothelial denudation did not alter the ET-1-induced HyPer-CYTO and DCF 
fluorescence elevations, indicating that ROS were generated within smooth muscle cells 
and not by endothelial cells.  This is in agreement with a previous study in pulmonary 
arteries suggesting that ET-1 elevates ROS in the arterial smooth muscle cells and not 
endothelial cells (Wedgwood et al., 2001).  Our data with mt-cpYFP suggest that ET-1 
elevates mitochondrial O2-· production in arterial smooth muscle cells.  Rotenone blocked 
the ET-1-induced elevations in mt-cpYFP and HyPer-CYTO fluorescence suggesting that 
ET-1-induced mitoROS elevation leads to an increase in cytosolic H2O2 levels.  
Dismutation of O2-· to H2O2 may occur both in the mitochondrial matrix and in the 
intermembrane space by mitochondrial SOD (Turrens, 2003; Li et al., 2005; Archer et 
al., 2010).  Therefore, ET-1 elevates generation of mitochondrial O2-· and cytosolic 
H2O2.  However, ET-1-induced elevations in O2-· and H2O2 may also result in generation 
of OH·, NO, and ONOO· through various pathways, including Fenton reaction (Turrens, 
2003).  ROS regulation of cellular signaling depends on the reactivity, and stability of the 
species.  H2O2 which is more stable than O2-·, can diffuse for a longer distance allowing it 
to serve as a signaling molecule (Archer et al., 2010).  H2O2 modulates the activity of 
several ROS-sensitive transcription factors such as HIF-1α (Huang et al., 1996) and NF-
κB (Takada et al., 2003; Oliveira-Marques et al., 2009). 
 
 
5.7. ROS–Dependent and –Independent Pathways Which Activate NF-κB 
 
Physiological functions and mechanisms of regulation of NF-κB in contractile 
arterial smooth muscle cells are poorly understood.  Our data indicate that thapsigargin, 
XeC, rotenone, and MnTMPyP reduced basal NF-κB-dependent luciferase activity. 
Therefore, under basal conditions, NF-κB activation is regulated by both IP3R-mediated 
SR Ca2+ release and constitutively produced mitoROS.  This is consistent with studies in 
neurons, indicating that Ca2+ influx through VDCCs and IP3R-mediated Ca2+ release are 
responsible for the basal NF-κB activity (Lilienbaum & Israel, 2003). 
 
ET-1-induced NF-κB activation was blocked by XeC, and inhibited by rotenone 
and MnTMPyP.  This indicates that ET-1-induced NF-κB activation occurs primarily via 
IP3R-mediated mitoROS generation in cerebral artery smooth muscle cells.  MitoROS 
activate NF-κB in several cell types, including in cultured vascular smooth muscle cells 
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(Lee et al., 2008).  However, alternate ROS-mediated mechanisms have also been 
demonstrated to activate NF-κB in arterial smooth muscle cells.  For example, following 
arterial balloon injury, ROS derived from NO and NAD(P)H oxidase are primarily 
responsible for the elevated NF-κB activity in arterial smooth muscle cells (Souza et al., 
2000; Ialenti et al., 2001).  The mechanisms by which ROS activate NF-κB are unclear, 
with reports suggesting that ROS stimulate IKK, leading to serine phosphorylation and 
proteasomal degradation of IκB (Gloire et al., 2006).  Studies also indicate that ROS 
activate other kinases, such as tyrosine kinase to cause IκB tyrosine phosphorylation 
rather than the classical serine phosphorylation (Takada et al., 2003; Brzoska & Szumiel, 
2009).  Additional studies will be necessary to identify the specific mechanisms by which 
ROS activate NF-κB in contractile arterial smooth muscle cells. 
 
Rotenone and MnTMPyP abolished the ET-1-induced mitoROS elevation, but did 
not completely block ET-1-induced NF-κB activation.  Therefore, ET-1-induced IP3R-
mediated SR Ca2+ release may activate NF-κB via a secondary mitoROS-independent 
pathway.  Ca2+-dependent, redox-independent NF-κB activation mechanisms may be 
mediated by calcineurin, PI3K/Akt, and/or PKC, as demonstrated in neurons (Lilienbaum 
& Israel, 2003).  Calcineurin activation occurs due to Ca2+ binding to CaM, leading to the 
dissociation of the two proteins, allowing the catalytic site of calcineurin to become 
accessible (Lilienbaum & Israel, 2003).  In addition to CaM, Ca2+ activate NF-κB via 
Ca2+-sensitive PKC isoforms, including PKCα and PKCβ1, and PI3K/Akt (Lilienbaum & 
Israel, 2003).  Supporting bi-modal activation, ER Ca2+ release activates NF-κB through 
both calcineurin- and redox-dependent mechanisms in U937 cells (Shatrov et al., 1997).  
In addition to ET-1, Ang II, another PLC-coupled receptor agonist activates transcription 
factors, including NF-κB through ROS-dependent and -independent mechanisms 
(Iadecola & Gorelick, 2004).  Binding of Ang II to AT1 receptors leads to PLC 
activation, [Ca2+]i elevation, and PKC activation (Iadecola & Gorelick, 2004).  PKC-
mediated phosphorylation of p47phox stimulates ROS generation via NAD(P)H oxidase 
(Iadecola & Gorelick, 2004).  Activated PKC could also stimulate cellular effectors in a 
ROS-independent manner (Iadecola & Gorelick, 2004). 
 
In whole artery immunofluorescence experiments to study NF-κB localization, it 
is interesting to note that p50 nuclear translocation occurred in nuclei of some smooth 
muscle cells but not others.  These experiments were performed on fixed arteries after 1 
hour of ET-1 treatment, therefore, representing a snapshot of the cellular events occurring 
in the arterial smooth muscle cells at that time point.  NF-κB activation and nuclear 
translocation may not occur at the same time in all smooth muscle cells of the artery due 
to a variety of reasons.  The time taken for ET-1 to reach individual smooth muscle cells 
and stimulate its receptors will depend upon the location of the smooth muscle cell in the 
arterial wall.  ET-1 will stimulate receptors of smooth muscle cells located on the 
periphery of the arterial wall prior to activating those cells in deeper layers.  In some 
cells, ET-1 may have stimulated SR Ca2+ release but there may not be mitochondria in 
close proximity to the SR to stimulate mitoROS elevation and NF-κB activation.  It is 
also possible that NF-κB nuclear translocation and activation of transcription may have 
already taken place and NF-κB may have recycled back to the cytosol within 1 hour.  
Nevertheless, our data suggests that ET-1 increases p50 nuclear translocation, thereby 
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activating NF-κB in cerebral artery smooth muscle cells.  Transcriptional studies 
performed using NF-κB-dependent luciferase constructs confirm the finding that ET-1 
activates NF-κB. 
 
 
5.8. Regulation of Basal and ET-1-Induced Elevation in CaV1.2 Expression 
 
CaV1.2 channels are the principal functional Ca2+ influx pathway in smooth 
muscle cells of resistance-size arteries (Jaggar et al., 2000; Jaggar, 2001; Cheng et al., 
2007).  CaV1.2 channels regulate multiple physiological functions in arterial smooth 
muscle cells, including contractility and gene expression, but signaling mechanisms and 
transcription factors that regulate their expression in these cells are unclear. 
 
Our data indicate that IP3R-mediated NF-κB activity controls basal CaV1.2 
expression through both mitoROS generation and via a mitochondria-independent 
pathway.  XeC, rotenone, and MnTMPyP slightly reduced basal CaV1.2 expression.  In 
the absence of PLC-coupled receptor ligands, [IP3]i and thus, IP3R activity should be low.  
However, in the intact artery preparation studied here, basal release of receptor ligands, 
including ET-1, by endothelial cells may generate low levels of [IP3]i in smooth muscle 
cells.  Even though this basal IP3R-mediated SR Ca2+ release was insufficient to elevate 
[Ca2+]mito, depolarize mitochondria, or stimulate mitoROS and cytosolic ROS, it was 
sufficient to activate NF-κB and stimulate CaV1.2 expression.  IP3R-independent basal 
mitoROS generation also activates NF-κB, leading to stimulation of basal CaV1.2 
expression.  Thus, IP3Rs contribute to basal CaV1.2 expression through mitochondria- 
dependent and -independent NF-κB activation.  In our experiments, the degree of p105 
knockdown and the reduction in basal CaV1.2 expression were similar, indicating that 
NF-κB is a major transcriptional factor regulating CaV1.2 gene expression in arterial 
smooth muscle cells. 
 
Data indicate that ET-1-induced IP3R-mediated Ca2+ release stimulates CaV1.2 
expression by causing a [Ca2+]mito elevation, leading to mitoROS generation that activate 
NF-κB.  Consistent with effects on NF-κB transcriptional activity, rotenone and 
MnTMPyP did not fully block the ET-1-induced elevation in CaV1.2 expression.  Thus, 
IP3R activation may also stimulate CaV1.2 expression via a secondary mitochondria- and 
ROS-independent pathway that also involves NF-κB.  Therefore, ET-1-induced IP3R 
activation stimulates NF-κB-dependent elevation in CaV1.2 expression primarily via a 
mitoROS-dependent pathway and through a secondary mitochondria- and ROS-
independent pathway.  Consistent with our finding that NF-κB controls CaV1.2 
expression, TNF-α-induced NF-κB activation elevated L-type Ca2+ current in cultured rat 
hippocampal neurons (Furukawa & Mattson, 1998).  In contrast, in human colonic 
smooth muscle cells NF-κB p50 and p65 subunit activation reduced CaV1.2 channel 
expression (Shi et al., 2005).  Opposing regulation of CaV1.2 transcription by NF-κB in 
these different smooth muscle cell types may occur through interaction with different κB 
binding motifs, of which there are several upstream of the CaV1.2 gene (Shi et al., 2005).  
Furthermore, the presence or absence of additional transcriptional activators and/or 
repressors may explain differential regulation of CaV1.2 expression by NF-κB.   
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Ang II, a vasoconstrictor caused an endothelium-dependent increase in CaV1.2 
expression in primary culture of rat mesenteric artery smooth muscle cells although it is 
unclear if depolarization of the smooth muscle cells is involved in this upregulation 
(Wang et al., 2008b).  Ang II has been shown to stimulate endothelial cells and induces 
ET-1 gene expression and secretion (Dohi et al., 1992; Morey et al., 1998).  Therefore, 
the Ang II-induced ET-1 elevation may stimulate the pathway described here, resulting in 
an elevation in CaV1.2 expression in mesenteric artery smooth muscle cells.  In cultured 
ventricular myocytes, global [Ca2+]i elevation stimulated transcription of CaV1.2 α1 
subunit (Davidoff et al., 1997).  In rat renal arteries, membrane depolarization which 
elevates global [Ca2+]i, increased CaV1.2 protein (Pesic et al., 2004).  Here, IP3R-
mediated SR Ca2+ release stimulated CaV1.2 expression.  Data from these studies raise 
several possibilities, including that local and global Ca2+ signals regulate CaV1.2 
expression by different mechanisms in cerebral and renal artery smooth muscle cells and 
ventricular myocytes.  Conceivably, this could occur at many levels in the pathway 
described here, including that global [Ca2+]i may elevate [Ca2+]mito in renal artery smooth 
muscle cells and ventricular myocytes, leading to mitoROS generation and NF-κB 
activation. 
 
 
5.9. Regulation of p105/p50 Expression by IP3R-Mediated SR Ca2+ Release 
 
Factors that regulate p105 gene expression in arterial smooth muscle cells are 
poorly understood.  Our data indicate that XeC reduced the basal p105/p50 expression 
and blocked the ET-1-induced elevation in p105/p50 expression.  However, rotenone and 
MnTMPyP did not affect the basal and ET-1-induced elevation in p105/p50 expression.  
In addition, p105 knockdown did not alter the ET-1-induced relative increase in p105/p50 
expression.  These data indicate that ET-1-induced IP3R-mediated SR Ca2+ release 
stimulated p105/p50 subunit expression via a mitochondria-, ROS-, and p105/p50-
independent pathway.  This is in contrast to the mitoROS- and p105/p50-dependence of 
CaV1.2 expression.  Thus, ET-1-induced IP3R-mediated SR Ca2+ release regulates CaV1.2 
and NF-κB subunit expression through mitoROS- and p105/p50-dependent and -
independent pathways, respectively. 
 
The p105 promoter has binding sites for several transcription factors, including 
NF-κB, Sp1, Egr-1, and PEA3 (Cogswell et al., 1993).  In our study, using siRNA we 
specifically suppressed expression of only one NF-κB protein, namely p105, and its 
product p50.  Expression of other NF-κB proteins, including p100/p52, p65, RelB, and c-
Rel were not studied.  Our data indicate that IP3R-mediated SR Ca2+ release regulates 
p105 expression through a p105/p50-independent pathway.  p105 gene transcription 
could be regulated by other members of the NF-κB family, as previously shown 
(Cogswell et al., 1993).  In addition, other Ca2+-activated transcription factors, including 
Sp1 (Santini et al., 2001) and Egr-1 (Thiel et al., 2010) may also regulate p105 
expression in the cerebral artery smooth muscle cells. 
 
ET-1-induced IP3R-mediated SR Ca2+ release activates NF-κB and also elevates 
NF-κB subunit expression.  It is interesting to determine the relative contribution of each 
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of these signaling events in the ET-1-induced NF-κB-dependent elevation in CaV1.2 
expression.  Our data indicate that rotenone and MnTMPyP reduced the ET-1-induced 
elevation in NF-κB-dependent luciferase activity and CaV1.2 expression but did not affect 
the ET-1-induced elevation in p105/p50 expression.  This suggests that ET-1 regulation 
of CaV1.2 expression is dependent on NF-κB activation and not an elevation in p105 
expression.  However, the ET-1-induced elevation in NF-κB subunit expression may 
amplify the elevation in NF-κB-dependent CaV1.2 transcription. 
 
 
5.10. ET-1 and Vascular Function 
 
ET-1 belongs to the endothelin (ET) peptide family, which have three more 
isoforms (Masaki, 2004).  ET synthesis begins with production of preproET, which is 
cleaved by peptidases to yield big-ET, a biologically inactive intermediate (Masaki, 
2004).  Big-ET undergoes further cleavage by ET converting enzymes to produce ET 
(Masaki, 2004).  Endothelial cell is the major source of ET-1 produced.  In addition to 
endothelial cells, ET-1 is also produced by airway epithelial cells, macrophages, 
fibroblasts, cardiomyocytes, and neurons (Kedzierski & Yanagisawa, 2001).  ET-1 
released from the endothelial cells acts in a paracrine and autocrine manner by interacting 
with receptors on vascular smooth muscle cells and endothelial cells, respectively, and 
thereby modifying vascular contractility, growth, and proliferation (Kedzierski & 
Yanagisawa, 2001).  Arterial smooth muscle cells express ETA and ETB2 receptors 
(Masaki, 2004; Dammanahalli & Sun, 2008a), and endothelial cells express ETB1 
receptors (Dammanahalli & Sun, 2008a).  Stimulation of ETA and ETB2 receptor 
activation stimulates Ca2+ waves, increases global [Ca2+]i, and vasoconstriction.  ETB1 
receptor activation leads to endothelial release of NO and prostaglandins, resulting in 
arterial vasodilation (Dammanahalli & Sun, 2008b). 
 
ET-1 was used in this study to elicit local and global Ca2+ signals in cerebral 
artery smooth muscle cells.  ET-1 plasma levels in rats and normal human subjects is ~20 
pg/ml (8 pM) and 3.6 pg/ml (1.44 pM), respectively (Loffler et al., 1993; Parlapiano et 
al., 1999).  Circulating levels of ET-1 in the plasma represent merely the "spillover" by 
endothelial cells (Zhu et al., 1994; Maeda et al., 1998).  Vascular smooth muscle cells are 
exposed to ET-1 concentrations which are much higher than its plasma level (Zhu et al., 
1994; Maeda et al., 1998).  In this study, concentrations of ET-1 used for different 
experiments ranged from 10-100 nM based on the experimental preparations and 
conditions.  Experiments designed to study mRNA and protein levels, required exposure 
of arteries to ET-1 over a long period of time.  In these experiments, smooth muscle cell 
ET-1 receptors were intact and using higher concentrations over a long period of time 
could have desensitized the receptors.  Therefore, a low concentration of ET-1 (10 nM) 
was used.  ψm measurements were performed using isolated smooth muscle cells.  The 
enzymes and trituration procedure used during the dissociation process could also result 
in damaging a few ET-1 receptors on the surface of arterial smooth muscle cells, 
resulting in a reduction of healthy ET-1 receptors.  Therefore, a moderately high 
concentration of ET-1 (30 nM) was used.  [Ca2+]mito, mitoROS, and cytosolic ROS 
measurements were obtained using moderately expressed amounts of genetically-encoded 
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fluorescent indicators.  Therefore, a higher concentration of ET-1 (100 nM) was used for 
these experiments to elicit fluorescence changes from these indicators.  ψm measurements 
using TMRM suggested that the different concentrations of ET-1 (10, 30, and 100 nM) 
used are within the slope of the sigmoidal curve.  This indicates that the ET-1 
concentrations used in this study neither understimulated nor saturated the receptors. 
 
 
5.11. Regulation of Gene Expression by Ca2+ Signals 
 
Vasoconstrictors, including purinergic and adrenergic receptor agonists modulate 
local and global Ca2+ signals similarly to ET-1 in smooth muscle cells of cerebral and 
systemic resistance-size arteries (Jaggar & Nelson, 2000; Mauban et al., 2001).  
Therefore, IP3R regulation of Ca2+ waves, [Ca2+]mito, and mitoROS generation may be a 
common mechanism by which vasoconstrictors regulate smooth muscle cell NF-κB 
activity, and thus control functional CaV1.2 expression and arterial contractility.  
Identification of this transcriptional pathway expands knowledge of Ca2+ signaling 
mechanisms regulating ion channel expression in vascular smooth muscle cells.  Local 
and global Ca2+ signals have been shown to activate transcription factors and regulate ion 
channel gene expression in arterial smooth muscle cells.  IP3R-mediated SR Ca2+ release 
and local Ca2+ influx through CaV1.2 channels also stimulates calcineurin-dependent 
nuclear translocation of NFATc3 in cerebral artery smooth muscle cells (Gomez et al., 
2002; Nieves-Cintron et al., 2008).  However, Ca2+ sparks suppress calcineurin-
dependent NFATc3 activation (Gomez et al., 2002).  NFATc3 activation downregulates 
expression of the KCa channel β1 subunit and Kv2.1, leading to hypertension (Amberg et 
al., 2004; Nieves-Cintron et al., 2007).  In arterial smooth muscle cells, voltage-
dependent Ca2+ influx and Ca2+ spark inhibition activate CREB leading to an increase in 
c-fos expression (Cartin et al., 2000).  Our data not only demonstrate that mitochondria 
are essential for mediating Ca2+-dependent gene expression in arterial smooth muscle 
cells, but indicate that these organelles do so by sensing IP3R-mediated Ca2+ release.  
 
 
5.12. Conclusion 
 
In native cerebral artery smooth muscle cells, SR Ca2+ release through IP3R-gated 
Ca2+ channels elevates [Ca2+]mito, leading to mitochondrial depolarization and mitoROS 
generation.  An IP3R-mediated elevation in mitoROS generation activates NF-κB, leading 
to an elevation in CaV1.2 expression and vasoconstriction.  In summary, this study 
indicates that mitochondria sense IP3R-mediated SR Ca2+ release to control NF-κB 
activity, and thereby, functional CaV1.2 expression in cerebral artery smooth muscle 
cells. 
 
A previous study has shown that mitochondria are involved in acute regulation of 
arterial contractility by activating Ca2+ sparks (Xi et al., 2005).  This study identifies 
another physiological function for mitochondria in arterial smooth muscle cells and 
shows that mitochondria can control ion channel gene expression and regulate arterial 
contractility on a more long-term basis.  This study also highlights an important signaling 
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cascade wherein intracellular local Ca2+ signals modulate functional expression of plasma 
membrane Ca2+ channels and thereby regulate Ca2+ influx and arterial contractility. 
 
 
5.13. Restoration of Homeostasis – Possible Negative Feedback Mechanisms  
 
The pathway studied here begins with ET-1 binding to its receptors on arterial 
smooth muscle cells, and eventually results in elevated CaV1.2 expression and enhanced 
arterial contractility.  Under normal conditions, various negative feedback mechanisms 
could regulate individual signaling events in the pathway described here leading to 
restoration of homeostasis.  1) ET-1 binding to endothelial ETB receptors decreases the 
circulating ET-1 available to bind smooth muscle cell receptors thereby buffering the 
circulating ET-1 levels (Sanchez et al., 2002), preventing overstimulation of smooth 
muscle cell receptors.  2) Increased ET-1 secretion can exert a negative feedback on ET-1 
gene transcription in endothelial cells, through activation of ETB receptors and 
internalization of the ET-1/ETB receptor complex, as previously demonstrated in cultured 
porcine aortic endothelial cells (Sanchez et al., 2002).  Inhibition of ET-1 gene 
transcription would result in decreased ET-1 synthesis and therefore, result in a reduction 
in ET-1 secretion.  3) ET-1-induced [IP3]i elevation stimulates IP3R-mediated SR Ca2+ 
release.  IP3 and Ca2+ have been suggested to inhibit IP3R (Hajnoczky & Thomas, 1994), 
thereby maintaining cytosolic IP3R-mediated Ca2+ elevations.  4) Mitochondrial 
depolarization which occurs due to [Ca2+]mito elevation, reduces the driving force for 
further mitochondrial Ca2+ uptake (Gunter et al., 2000) and therefore could limit 
[Ca2+]mito and mitoROS elevation.  5) NF-κB activation leads to nuclear translocation and 
stimulation of gene transcription.  One of the mechanisms by which NF-κB autoregulates 
its activity is by stimulating transcription of IκBα, which causes cytosolic retention of 
NF-κB and reduces its activation (Chen & Greene, 2004).  6) As previously reported in 
cultured neurons, an elevation in [Ca2+]i, can internalize CaV1.2 channels reducing Ca2+ 
influx and [Ca2+]i elevation. 
 
Presence of these negative feedback loops may be essential for normal vascular 
physiology.  Deregulation of these regulatory mechanisms could contribute to the 
development and maintenance of cardiovascular diseases. 
 
 
5.14. Clinical Significance 
 
Functional integrity of the endothelium is responsible for Ca2+ channel 
availability in vascular smooth muscle cells (Simard & Li, 2000).  Dysfunctional 
endothelium is associated with a variety of diseases including hypertension and 
atherosclerosis (Ogita & Liao, 2004; Ray & Shah, 2005).  Cardiovascular diseases, 
including systemic (Shichiri et al., 1990) and pulmonary hypertension (Stewart et al., 
1991b) are associated with an elevation in circulating vasoconstrictors, including ET-1 
(Ishikawa et al., 1995; Abdel-Sayed et al., 2003).  Hypertension is also associated with 
an increase in vascular ROS, NF-κB activity, CaV1.2 protein, and Ca2+ currents (Wang et 
al., 2006; Sawada et al., 2007; Touyz & Schiffrin, 2008).  These disease-associated 
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alterations may occur through activation of the IP3R/mitoROS/NF-κB/CaV1.2 pathway.   
 
Apart from hypertension, circulating plasma levels of ET-1 are elevated in other 
cardiovascular diseases, including cardiogenic shock (Cernacek & Stewart, 1989), 
myocardial infarction (Stewart et al., 1991a), atherosclerosis (Luscher & Barton, 2000), 
and ischemic stroke (Estrada et al., 1994).  In addition, TNF-α, interferon-γ, Ang II, and 
thrombin increase ET-1 release from endothelial cells (Delerive et al., 1999).  Elevated 
levels of ET-1 receptors on arterial smooth muscle cells are observed in cardiovascular 
diseases, including pulmonary hypertension (Masaki, 2004), ischemic heart disease 
(Wackenfors et al., 2004), and atherosclerosis (Pernow et al., 2000).  Enhancement of the 
ET-1-induced signaling pathways in arterial smooth muscle cells may occur due to 
endothelial injury resulting in increased ET-1 secretion, elevated ET-1 plasma levels, 
and/or enhanced ET-1 receptor expression levels.  Pathological changes related to 
increased activation of ET-1 receptors may occur due to triggering of the 
IP3R/mitoROS/NF-κB activation pathway.  Therefore, targeting this pathway may 
provide a better understanding of the disease-related pathological changes and could be 
beneficial in developing therapeutic strategies to treat cardiovascular diseases. 
 
 
5.15. Future Directions 
 
This study shows that mitochondria control functional ion channel expression in 
native contractile cerebral artery smooth muscle cells.  Future studies could be performed 
in several parts of the proposed signaling cascade to better characterize the individual 
events in the pathway.  Potential investigations could be designed to explore: 
 
1. The spatial and temporal relationships between Ca2+ waves and [Ca2+]mito or mitoROS 
signals within individual mitochondria in arterial smooth muscle cells to determine if 
[Ca2+]mito and mitoROS oscillate within individual mitochondria.  It would also be 
interesting to examine whether propagation of Ca2+ waves induces waves of [Ca2+]mito 
and mitoROS originating from mitochondria located along the path of propagation of 
the Ca2+ wave. 
 
2. The precise mechanisms by which a [Ca2+]mito elevation and mitochondrial 
depolarization stimulate mitoROS generation.  
 
3. The pathways by which mitoROS and IP3R-mediated SR Ca2+ release activate NF-κB 
in arterial smooth muscle cells. 
 
4. The involvement of other members of the NF-κB family, including p52, p65, c-Rel, 
and RelB in regulating CaV1.2 expression. 
 
5. The role(s) played by additional ROS-sensitive transcription factors, including AP-1, 
CREB, and Kruppel-like factor transcription factor(s) in the regulation of CaV1.2 
gene expression. 
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6. If the proposed pathway is common to most Gq-protein coupled receptor agonists, 
including UTP and Ang II.  
 
7. The regulation of expression of α2δ, β, and γ subunits of CaV1.2, and other NF-κB 
proteins, including p52, p65, c-Rel, and RelB by IP3R-mediated SR Ca2+ release, 
mitoROS, and NF-κB. 
 
8. The importance and relevance of this pathway in the maintenance of hypertension by 
administration of pharmacological inhibitors of NF-κB and smooth muscle cell ET-1 
receptors to hypertensive rodent models, followed by monitoring the blood pressure. 
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